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Abstract. 
Background: Adherence to antiretroviral therapy (ART) is critical: only 70% achieve 
viral suppression at a year. Current adherence methodologies, with slow reaction to 
missed dosing, inadequately predict virological outcomes. Ideal adherence methods 
would be cheap, easy to use, and allow rapid response to missed doses to improve 
outcomes. We explored ideal adherence monitoring methodology for a large public-
sector ART clinic in Cape Town.  
Methods: We designed a randomised controlled study for ART-naïve individuals to 
determine whether text messaging after a missed dose would improve adherence 
recorded by an electronic adherence monitoring device (EAMD), reduce treatment 
interruptions or impact on virological outcome (using regression modelling). Five 
other measures of adherence were captured prospectively during the study: self-
recall (SR), clinic-based pill count (CPC), pharmacy refill data (PR-average or PR-gaps) 
and efavirenz concentration. The predictive value of each adherence methodology 
on virological and HIV-1 resistance outcomes was compared by calculating the area 
under the receiver operating characteristic curve, from logistic regression models. 
The impact of efavirenz concentration and CYP2B6 metaboliser genotype data on 
failure was examined using Cox proportion hazard modelling; and the most 
predictive lower limit for EFV concentration was determined. Antiretroviral cohort 
and pharmacy refill data were compared, using simple statistics, to determine which 
provided the best method of determining those retained in care. 
Results: 230 participants were randomised 1:1 to control and intervention arms. 
Text messaging significantly reduced the number of treatment interruptions of >3 
days but did not improve adherence or virological outcomes. Median (IQR) 
adherence at week 48 was: EAMD 86 (59-94)%, SR 100 (100-100)%, TR 100 (95-
107)%; PR-average 103 (95-105)% and PR-gaps 100% (95-100). Efavirenz 
concentration was 2.1 (1.5-3.4)mg/L. Pharmacy refill and EAMD data best predicted 
virological and resistance outcomes. Pharmacy refill data was more efficient at 
identifying individuals continuing on ART than cohort data. Efavirenz concentrations 
were predictive of virological outcome, but CYP2B6 metaboliser genotype was not. 
The most predictive lower threshold was 0.7mg/L.  
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Conclusion: Our study did not show that reminders after a missed dose improved 
adherence, but did show that treatment interruptions were minimised, a benefit 
that might have had more impact had a non-naïve population been selected. More 
research is needed on the use of the Wisepill in identifying those with poor 
adherence and initiating intervention beyond text-messaging in real time. Pharmacy 
refill data is underutilised: electronic dispensing systems exist at most clinics and 
with programmatic support could be used for adherence monitoring and 
programme evaluation. Low EFV concentrations can predict poor virological 
outcomes in a naïve population; but the currently recommended therapeutic range 
for EFV is too high. When directly comparing six adherence measures, EAMD and 
pharmacy refill best predicted clinical outcomes and programmatic use of these 
methods should be explored.  
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1.  Introduction. 
1.1. Background - placing the importance of adherence to ART in context. 
Adherence definition and nomenclature. 
The human immunodeficiency virus (HIV) is a sexually transmitted virus which 
results in a chronic progressive illness. The HIV causes damage through 
inflammation and progressive decline in the CD4+ T lymphocytes, eventually 
resulting in death through the development of malignancies or opportunistic 
infections. Over the past two decades antiretroviral therapy (ART) has changed this 
almost uniformly fatal infectious disease into a manageable illness with a near 
normal anticipated lifespan, even in a resource-poor setting. (1, 2)  
This increase in life years is contingent on a successful response to ART. (1) Taking 
ART requires daily or twice daily medication dosing of syrup, tablets or capsules, at 
regular times, for the rest of the HIV-infected individual’s life. Adherence to ART, 
namely the correct following of such prescribed medication instructions, involves a 
number of processes, including initiation of the correct medication/s, at the correct 
dose, and at the correct time of day, and continuing this without interruption in 
treatment while being retained in care over the entire prescription period. (3)  
Adherence nomenclature has changed over time, and remains under debate. Vrijens 
et al have recently suggested that the following terms are used:  
 Initiation: whether people commence ART. These people are not seen in ART 
studies as they do not begin ART. Lack of trust in the health care system or 
negative beliefs relating to HIV and ART might be influential in initiation 
choices. 
 Implementation: problems with carrying out the instructions given by the 
health care provider. Issues here might evolve from alcohol or drug use, 
depression or the inability to form a habit; and can result in missing single 
doses, interruptions in treatment (missing multiple sequential doses) or 
taking extra doses. 
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 Discontinuation: Many people do not persist in taking ART and discontinue 
treatment over time. Drug side-effects or a poor health provider relationship 
can increase these losses to care. (3, 4) 
Where an individual is in their treatment process, either at initiation, implementing 
or discontinuing, will influence their needs. While adherence is not the only factor 
impacting on treatment outcomes, it is one which can be altered.(5) This thesis will 
largely focus on adherence implementation. 
A large number of people require daily ART.  
South Africa is home to the single largest number of individuals living with HIV. 
Recent estimates suggest that 6.2 to 6.8 million South Africans live with HIV, with 
prevalence of 12 to 18%, and a current incidence of 1.22% per annum. (6-8) Over 
20% of reproductively active women are infected. (7) After an initial lag in response, 
from 2004 onwards antiretroviral treatment programmes have delivered ART to the 
general South African population through public sector clinics. In 2012, nearly a third 
of those living with HIV had accessed ART; in 2015 this this may be as many as 3.1 
million people. (6, 9)  
Over time, the vast majority of those living with HIV will require ART to survive. At 
the start of 2015, the CD4 cell count required to access treatment in the public 
sector increased from 350 cells/mm3 to 500 cells/mm3. (10) In mid-2015, the START 
and TEMPRANO study results were released, recommending treatment at any CD4 
count. (11, 12) While South Africa has not yet shifted its guidelines to include ART 
for all, it is widely anticipated that this will happen in the near future. Treatment 
expansion will improve the health of individual living with HIV, but it will also have 
impact at clinic level by increasing the numbers of individuals accessing care in the 
short term, adding to already congested HIV services. (11, 13) In addition, data show 
that those who start treatment in the earlier stages of the disease, while still 
benefitting clinically, are more frequently lost to follow-up. (14, 15) Thus, the 
intention to provide broader access to care may have an unanticipated negative 
effect by bringing people into care who are not yet ready to commit to lifelong ART, 
while being unable to provide adequate support for them.  
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The consequence of poor adherence is drug resistance. 
To achieve viral suppression, the concentration of each antiretroviral medication in 
the plasma should remain above the inhibitory concentration (IC) required to 
prevent 90% of the HIV (IC90) from replicating. Adequate plasma concentrations are 
maintained by good implementation of dosing instructions, i.e. regular daily or twice 
daily dosing, depending on the medication being taken.  
If doses are missed, drug concentrations drop below the IC90, allowing the HIV to 
replicate in the presence of the medication. During replication, the viral reverse 
transcriptase enzyme makes errors while copying the RNA gene, with the resulting 
mutated virus differing structurally or functionally from the parent virus. These 
changes often result in development of viral resistance to an antiretroviral 
medication, thus giving that particular virus a survival advantage in the presence of 
that medication in the future.  
The HIV can develop resistance to some antiretroviral medications with only a single 
mutation; these drug have a low genetic barrier to resistance. This applies to all 
three first-line medications: tenofovir, emtricitabine and efavirenz. Other 
medications are more robust, with a high genetic barrier to resistance, requiring the 
virus to accumulate multiple mutations before the drug stops working. Combination 
ART, i.e. giving three medications at once, reduces the likelihood of resistance 
occurring. 
Older ART regimens required >95% adherence, equivalent to missing fewer than 
three doses a month during twice a day dosing, to minimise the development of 
resistance. (16) Newer regimens, including medications with a longer plasma or 
intracellular half-life, may be more forgiving of a single missed dose, but three or 
more sequential missed doses, or a treatment interruption, may still result in the 
development of drug resistance. (17) Current first line treatment includes tenofovir, 
emtricitabine and efavirenz.(10) The plasma half-life (T½) of tenofovir is 17 hours, 
emtricitabine 10 hours and that of efavirenz a much longer 52 to 76 hours. This 
difference in T½ results in tenofovir and emtricitabine being eliminated from the 
plasma before efavirenz leaving efavirenz unprotected as monotherapy [Figure 
1.1].Active metabolites of some drugs, such as tenofovir diphosphate, may have 
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longer intracellular half-lives, rendering this picture more complex. However, 
missing three or more sequential doses when taking an efavirenz-containing 
regimen increases the risk of viral replication and the development of drug 
resistance.(17) This growth of resistant virus, would be followed by a reduction in 
CD4 cell count and progression of HIV disease despite the individual taking ART. A 
new regimen, often with more complex dosing, such as current second-line therapy, 
would then be required [Figure 1.2]. (18)  
 
In multiple sites across sub-Saharan Africa, more than 90% of individuals who fail 
first-line ART have two drug class resistance, usually including resistance to 
lamivudine/emtricitabine and the chosen non-nucleoside reverse transcriptase 
inhibitor (NNRTI), either efavirenz or nevirapine.(19-22) Much of this resistance is 
likely to occur due to viral replication occurring in the presence of sub-optimal 
concentrations of ART.  
In sub-Saharan Africa, viral loads are a limited resource, due to their high cost. In the 
South African private sector viral load monitoring is suggested every 3 to 6 
months.(23) In the public sector, viral loads are only available annually.(10) In a 
South African public-sector cohort where viral load monitoring was more tightly 
monitored, HIV resistance was much less frequent and complex than seen in 
standard ART clinics. (19, 24) This author has shown that an intensive adherence 
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intervention results in 67% of those who have a first viral load >1000 copies/ml 
becoming re-suppressed at the subsequent viral load.(25) Tight control of adherence 
with early intervention thus is likely to reduce the time that virus is exposed to sub-
therapeutic drug levels and thereby reduce development of drug resistance.  
Not taking ART and failing to remain in care results in earlier mortality.  
The expected lifespan of an individual with HIV is estimated to be 10 years shorter 
than that of someone who does not live with HIV. While the decrease in life 
expectancy due to HIV is greatly mitigated by the use of ART, there is still a deficit in 
life years due to living with the HIV. (2) In addition to this deficit, Johnson et al 
report a 15-20% decrease in life expectancy in individuals who fail to remain in care 
for 24 months. (1) Remaining in care is thus also key to reducing loss of life years 
due to HIV infection. Early identification of those who leave care remains a 
challenge. 
Maintaining people on first-line ART is critical.  
ART options are limited in resource-poor settings, due the public health approach 
required to supply large numbers of people with treatment and the cost of 
purchasing and delivering it. First-line ART, usually containing a NNRTI and two 
nucleoside reverse transcriptase inhibitors (NRTIs), is three times cheaper than 
second-line ART (at R95 a month vs. R338 a month). The ART in first line regimens is 
selected primarily due to better tolerability and low cost; despite all three drugs 
having a low genetic barrier to resistance. As fixed dose single tablet combinations 
are available for first-line ART, this regimen is easier to supply logistically, as well as 
to take and to adhere to, than second line treatment.(10, 26) 
Current second-line ART in South Africa comprises another two NRTIs as well as a 
protease inhibitor. This regimen has an increased number of both tablets and dosing 
times, making it more difficult for an individual to maintain adherence (Figure 1.2), 
and for the supply chain to maintain stock. (26) Although the regimen is more 
robust, with a high genetic barrier to resistance, the protease inhibitor is also less 
well tolerated. Keeping an individual on first-line is therefore programmatically 
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simpler and cheaper, as well as easier and safer to take for the person involved, but 
lapses in adherence are more likely to result in resistance.  
 
Current methods of monitoring adherence are inadequate. 
In the early years of the expansion of ART to resource- poor settings in Africa, 2004-
2007, adherence as measured by self-report, tablet returns and pharmacy refill 
appeared excellent in many reported cohorts, yet despite this the number of those 
experiencing virological failure and requiring a switch to second-line has continued 
to increase (27-32). Existing sub-Saharan ART programmes also have high rates of 
treatment discontinuation (33-35), so more recently, the impact of treatment 
retention and minimising treatment interruptions on virological outcomes has been 
explored in these populations. (17, 36-39) Many people cycle in and out of care, with 
each interruption increasing their risk of developing resistant HIV and thus reducing 
their potential years of healthy life.(37, 38) 
Data from the Desmond Tutu HIV Centre (DTHC) clearly illustrates the discrepancy 
between adherence measures and rates of failure. This author, with other staff from 
the DTHC, has monitored two large antiretroviral cohorts for more than a decade. 
Patients taking ART at the Hannan Crusaid Treatment Centre (HCTC), a large public 
sector antiretroviral roll out site, in Gugulethu, Cape Town, South Africa, have been 
monitored since September 2002, and those at Masiphumelele clinic, South 
Peninsula, since 2004. Currently over 8000 individuals are being treated at both 
sites, with more than 1300 (16%) on second-line therapy. Over 20% of individuals 
page 22 
 
who start first-line ART at the HCTC fail first line therapy by the end of five years. 
(40)  
Adherence is monitored at each visit by counting the number of tablets returned 
unused since the previous clinic visit. A study by this author showed that adherence 
by tablet return was excellent (≥95%) among those who suppressed virologically 
(median 97.8%). However, it was also excellent for those who failed (median 96.6%). 
(38) Some of those who failed did so through poor adherence (<95%), but a 
substantial subset (19%) failed despite apparently having adequate adherence 
[Table 1.1].  
Table 1.1: Virological outcome at week 48 by adherence category. Adherence was 
measured by tablet returns. (n=211). 
At week 48 on first-line ART* Viral load ≤50 copies/ml Viral load >50 copies/ml 
Cumulative adherence ≥ 95% Expected viral suppression 
n=124 (59%) 
Unexpected non-suppression 
n=41 (19%) 
Cumulative adherence <95% Unexpected viral suppression 
n=28 (13%) 
Expected non-suppression 
n=18 (7%) 
*Tablet count adherence data from HCTC cohort as described by Ncaca et al. (38) 
Some of the “unexpected non-suppression” may be explained by overestimation of 
adherence or treatment interruptions, as discussed below. “Unexpected 
suppression”, may be due to increased drug concentrations: in sub-Saharan Africa, 
genetic variants of the cytochrome p450 2B6 enzyme result in slowing of efavirenz 
metabolism in a proportion of the population (see Therapeutic Drug Monitoring, 
page 30). Higher concentrations may be more forgiving of missed ART doses.(41).  
Many methods of quantifying adherence overestimate the number of doses taken. A 
study by this author explored different adherence measures in the paediatric cohort 
of the HCTC. Tablet and syrup returns overestimated adherence by 8% compared to 
Medical Electronic Monitoring System (MEMS) data. (42)  
Interruptions or gaps in treatment may also contribute to treatment outcomes not 
matching adherence data. Despite excellent adherence (>95%) when in possession 
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of ART, a single treatment interruption of 28 days or more increased the odds of 
failure by 5.65 (CI 1.40-22.85). (38) Other groups have noted similar losses of 
suppression with interruptions in treatment. (17, 39, 43) Parienti et al showed that 
missing more than three consecutive doses while on a NNRTI-based regimen had 
impact on virological outcome. Each consecutive dose missed beyond two days 
increased the risk of virological breakthrough.(17) Treatment interruptions in our 
setting are frequent and often not identified until the individual is back in care. (37, 
38) 
In addition, these local cohorts also experience high rates of treatment 
discontinuation. More than 20% of the Gugulethu cohort is considered lost to follow 
up by 3 years and 40% by year 7.(33, 40) Data from the National Health Laboratory 
Service (NHLS) indicates a 40% loss to care by 3 years in the South African ART 
programme (Ian Sanne, personal communication, 2015). 
Current systems of monitoring patients in treatment cohorts are useful for monthly 
reporting and public health measures, but are often too unwieldy to be useful to 
most individuals. It is not helpful, in the face of adherence implementation 
problems, such as increased treatment interruptions and failure rates, to be using 
methods of monitoring adherence that are inadequate and overestimate treatment 
success. Similarly, it is difficult to retain individuals in care, when current systems 
cannot identify short treatment interruptions and only identify those lost to care 
more than 12 weeks after their last clinic visit. (33)  
Benefits of improved adherence measurement. 
While adherence is not the only factor impacting on treatment outcomes, it is one 
which can be altered.(5) Multiple interventions to date have been shown to 
improve adherence (see Literature review, page 42). Accurate and timely adherence 
assessments are thus critical.  
Any discontinuation begins with a few missed doses. A robust system of monitoring 
adherence to allow for early identification of these missed doses or treatment 
interruptions would allow intervention to improve adherence before viral rebound 
and the development of resistance. A system that could incorporate a cheap, 
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automated and acceptable intervention at the same time as monitoring adherence 
could potentially address early missed doses, without intensive staff input. Tight 
control of adherence with an early intervention would reduce both treatment failure 
and losses to care.  
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1.2. Methods of monitoring adherence. 
If currently used methods of measuring adherence in our cohorts are inadequate, 
then better methods need to be identified. Since 2000 we have known that it is 
critical to maintain high levels of adherence in individuals being treated with 
HIV.(16) In the last decade, a variety of ART adherence measures have been used to 
determine the outcome of adherence interventions, however, to date there is still 
no clear gold standard for quantitating adherence [Figure 1.3]. Measures used in a 
clinical setting might differ from those best used for research purposes. Commonly 
used measures, with some advantages and disadvantages of each, are described 
here. 
 
Self report. 
Self-report is a subjective measure of reporting adherence which implies that a 
person taking ART is asked by a clinician or an interviewer to recall the number of 
doses they have taken or missed over a specified period of time, usually between 3 
and 30 days.(44) Shorter periods of recall, e.g. 3 days or a week, are likely to give 
more accurate results than longer periods.(45, 46)  
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Many self-reported questionnaires are based on the Adult AIDS Clinical Trials Group 
3-day recall instrument where a patient is asked to remember if they took a dose 
that day, the day before and then day before that (a count-based measure). (47, 48) 
Adherence would be reported as the number of doses taken over doses possible e.g. 
4 of 6 possible doses were taken (66.7%). In others estimated recall methods are 
used e.g. a visual analogue scale can be used for a patient to mark their estimated 
adherence over the specified time period [Figure 1.4].(47) 
 
The use of self-reported adherence measures to monitor adherence is common, as 
these measures are easy to perform and have no added cost. (44, 49) A number of 
adherence studies have relied on this measure. (50-53) In most cases self-report 
overestimates adherence, due to recall bias and the social desire to please.(54) If 
asked, most people will report that they take their tablet regularly and note few 
missed doses. Their perception is one of good adherence, while in reality those few 
missed doses are significant, making this measure unreliable for research purposes.  
In few cases is a subjective, self-reported adherence measure predictive of 
virological outcome when used alone. However, a report of incomplete adherence 
can be clinically useful in triggering adherence intervention. (55, 56) Prediction of 
virological failure is more likely when used together with an objective measure e.g. 
tablet return or electronic monitoring of adherence. (55, 56) Despite these 
limitations, recent guidelines on monitoring adherence recommend “self-reported 
adherence should be obtained routinely in all patients”.(5)  
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Tablet returns. 
Tablet return is a more objective measure of ART adherence that has been 
commonly used. (44) In recent years the regular use of tablet returns has fallen out 
of favour due to the time required by clinic staff to complete the count and the 
complexity of the calculation required in the clinic. Tablets need to be returned, and 
then counted. Thereafter, adherence must be calculated based on prior dispensing 
dates.(38) There is again a risk of over-estimation of adherence through patients 
being able to deliberately modify their response e.g. altering their returns by pill-
dumping so adjusting the tablets brought back to match the doses that should have 
been taken. (3, 5, 38, 44, 54) 
A typical tablet return calculation requires four pieces of informations: a count of the 
days between the last dispensing date and the current date, knowledge of the 
number of tablets dispensed at the last dispensing date, number of tablets taken per 
day and a count of tablets returned at the current visit.(38) 
So, percentage adherence is equal to:   (tablets dispensed – tablets returned) x 100
                    (tablets/day x count of days)  
While some studies have shown reasonable correlation of tablet return data with 
virological outcomes, recent comprehensive adherence guidelines suggest counts of 
tablet returns should not be recommended routinely.(5) 
Pharmacy refill. 
Data from collection of medication from the pharmacy can provide information 
related to continuity of ART supply. Some pharmacy refill methods simply count the 
number of times medication was collected over a fixed time period e.g. four out of 
six months; and others use dispensing dates and volume given to examine 
medication free days i.e. days on which the patient would have had no medication 
available. (57, 58)  
As pick-up of medication does not guarantee actual swallowing of the tablets, and 
there may be more tablets in a pack than days between clinic visits e.g. 30 days of 
efavirenz dispensed with a 28 day next clinic date, pharmacy refill measures also 
overestimate adherence. The advantage of pharmacy refill measures is that all 
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missed or late pick-ups are noted. In common with tablet return, pharmacy refill 
measures do not give any information relating to timing of dosing, and also require 
systems in place to maintain either paper or electronic pharmacy records.(3, 54)  
However, both short and longer term methods based on pharmacy refill data have 
been used to predict virological failure and mortality, and this method is 
recommended as a routine means of monitoring adherence.(57-59) Electronic 
dispensing systems, available in many resource- poor settings, make this method 
even more attractive.  
Electronic devices. 
Electronic monitoring of adherence has most frequently included the use of devices 
such as Medication Event Monitoring System (MEMS) caps. These are lids that can 
be placed on a tablet or syrup bottle and which record the date of time of each 
opening for download at the next clinic visit [Figure 1.5].(42, 44) More recently, the 
Wisepill® device, an electronic pill box with a SIM card that sends a real-time signal 
via the cell-phone system once the box is opened has been developed in South 
Africa and is being used quite widely [Figure 1.5]. (60-62)  
It is thought that these methods might underestimate adherence as multiple tablets 
can be removed from a bottle / box with only one opening, however adherence 
measured electronically is more consistently associated with virological outcomes 
than any other measure. (3, 5, 44, 54) Despite this, Thompson et al did not 
recommend the routine use of such monitoring as devices are expensive and often 
not practical to use.(5)  
The unique advantage of using electronic monitoring over all the above measures is 
that the timing of the dose is also captured, allowing for the possibility of acting 
immediately or within a few days of missed dosing, creating real-time interventions 
to improve adherence.(3, 63).  
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Therapeutic drug monitoring. 
Therapeutic drug monitoring is not recommended as a routine approach to 
measuring ART adherence (5, 64, 65), despite recent literature from HIV prevention 
studies showing that adherence to product is linked to concentration of drug in the 
blood, which is in turn linked with effectiveness.(66, 67) When using ART as 
treatment, reviews on the use of therapeutic drug monitoring show that therapeutic 
drug levels do not always correlate well with virological outcomes.(64, 65, 68) This 
inconsistency may be due to the lack of information on tablet-taking behaviour in 
many studies or possible inconsistencies between measured adherence and drug 
levels e.g. patients can modify outcome by dosing immediately prior to clinic visit 
thus having adequate drug concentration despite poor adherence. Poor adherence 
over time may also result in viral resistance, altering the relationship between drug 
concentration and viral suppression. In addition, these methods require a blood 
draw and laboratory capabilities.(54) 
Efavirenz metabolism differs in the sub-Saharan African population. Metaboliser 
status (ultra-slow, slow, intermediate or rapid) due to genetic variants in the 
cytochrome 2B6 enzyme, results in differences in drug exposure. (41).Efavirenz 
metabolism is slower in a subset of this population, resulting in increased EFV levels. 
(69, 70) The impact of metaboliser status on the consequence of missed doses has 
not been fully explored: slower decline of EFV concentration might result in a more 
forgiving regimen, safely allowing a few doses to be missed and reducing the impact 
of treatment interruptions, or conversely, the higher concentrations might result in 
increased toxicity and lead to reduced adherence (65, 71) These genetic factors may 
thus also impact on the discrepancy between recorded adherence and virological 
outcomes. 
Hair concentrations. 
Measuring ART concentrations in hair is a novel method of quantitating longer-term 
adherence, and has been shown to be a strong predictor of virological response. (72-
74) Hair levels correlate well with plasma ART levels measuring frequently used ART 
and reflect adherence over the duration of hair growth e.g. 4 to 6 weeks, in a similar 
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manner that glycated haemoglobin or HbA1C reflects longer-term glucose levels in a 
diabetic population.(75)  
Hair samples are relatively easy to collect, store and transport. Forty to fifty hair 
strands from different parts of the head need to be cut off close to the scalp and 
stuck onto the collection form with the scalp end identified. These can be placed in 
an envelope and kept dry until analysis. Although, in our context, many men have 
shaved heads and women with braids are often reluctant to allow sampling, this 
non-invasive method could be a useful additional tool for predicting ART outcomes. 
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1.3. Problem statement and rationale for developing this thesis. 
Both through review of the literature, and through taking an interest in patient 
adherence behaviour while working in the South African public sector ART service 
over the past decade, I have noted that as the ART service has expanded, so our 
quality of care has reduced. This is evidenced by increasing rates of virological failure 
and reduced retention in care, and is clearly described in a number of our 
publications. (14, 40, 76, 77) 
Treatment discontinuation can be thought of as a natural extension and 
consequence of initial poor tablet taking behaviour, either poor overall adherence 
execution or treatment interruptions. Losses are amplified by inadequate methods 
currently used to monitor individuals while they are in care, usually self-report and 
tablet returns, with slow or no reaction to missed dosing. Current cohort monitoring 
systems also do not allow immediate reaction to missed visits. Improving adherence 
is however time consuming and costly, usually requiring intensive intervention. (25, 
78) So, at the same time as requiring more immediately reactive systems to note 
and act early on missed doses, there is little room within the public-sector clinic 
system for expansion of services either in terms of physical space or staff capacity. 
An ideal adherence monitoring method for a large public-sector clinic would be 
cheap, easy to use, and allow rapid response to missed doses or gaps in treatment. A 
system which incorporated an adherence improvement intervention, immediately 
linked to missed doses and requiring no additional staff input would be even better.  
Some questions that I hoped to answer within the studies designed for this PhD 
were: 
 Is there a technology that could improve adherence and retention without 
requiring extra resources, such as staff time? Immediate or real-time monitoring 
might allow us to build the habit of adherence early into treatment. Eighty 
percent of those who have a viral load drawn at a year into ART are suppressed. 
Could real-time monitoring allow us to identify those more likely to fail and focus 
the use of expensive viral load there?  
page 33 
 
 Is it possible to maximise the use of systems that are in place already, such as the 
pharmacy dispensing system, which might more simply and efficiently identify 
those in care and those who miss visits, than current methods? 
 The connection between adherence and virological outcomes should be found in 
drug concentrations, as noted in the HIV-prevention literature, though not in the 
treatment literature [Figure 1.6]. (5, 64-68) 
 
Is this due to a lack of adherence information or less than ideal methods of 
estimation of adherence in these studies? Few of these studies examine EFV TDM 
in a resource- poor setting.(64, 65) Does the genetic difference in EFV metaboliser 
genotype in sub-Saharan Africans make a difference to treatment outcomes?(69, 
76) Slow metabolisers with higher drug concentrations might be protected from 
the effect of poor adherence. Perhaps efavirenz drug concentrations can predict 
outcomes in a naive population, with knowledge of metaboliser status? 
 Few studies directly compare adherence methodologies.(54, 61, 79) Will a 
comparison of multiple methods of monitoring adherence in our resource- poor 
setting, identify the optimal methodology?  
In summary: while we can improve adherence, in order to do so, we need to be 
able to assess adherence as accurately as possible. The significance of poor 
adherence may be affected by the characteristics of the ART used and the 
metaboliser status of the individual. The desired outcome is to improve 
virological suppression and reduce development of HIV resistance to first-line 
antiretroviral therapy.   
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1.4. Objectives. 
The aim of this PhD was to focus on adherence implementation, through exploring 
newer adherence methodologies, including electronic adherence monitoring, iDART 
pharmacy dispensing technology and drug concentrations, using locally available and 
developed resources, in order to determine which of these might improve the 
monitoring of adherence and either more accurately predict virological or resistance 
outcomes or allow more real-time reaction to missed doses or missed visits. This 
included the assessment of whether the use of text message reminders soon after a 
missed ART dose could improve adherence, reduce treatment interruptions and 
decrease loss to care.  
We hypothesised that the use of real-time adherence monitoring would reduce the 
overestimation of adherence seen with other methods, including self-report, pill 
count, and pharmacy refill data. With the addition of a reminder sent by text 
message in the randomised arm should dosing be late, we hypothesised that 
electronic adherence monitoring would improve adherence, reduce treatment 
interruptions and subsequently reduce first-line ART failure rate. In addition we 
hypothesised that EFV dug concentrations would predict virological outcome in an 
ART-naïve population, with knowledge of cytochrome 2B6 metaboliser status.  
More specifically the objectives of this PhD were:  
1. To determine whether a locally developed real time electronic adherence 
monitoring device (Wisepill®) with an immediate cell phone test message 
feedback intervention can improve adherence, reduce treatment interruptions 
and increase retention in care in an ART-naïve South African population. 
2. To determine whether an existing locally developed pharmacy database, 
Intelligent Dispensing of Antiretroviral Therapy (iDART), can be used to more 
accurately and rapidly monitor adherence and retention in care for local ART 
cohorts. 
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3. To determine whether knowledge of pharmacogenetic data and mid-dose 
efavirenz concentrations can predict treatment outcome in a sub-Saharan 
African population.  
4. To compare multiple different methods of quantifying adherence within one 
cohort and to determine whether electronic adherence monitoring using 
Wisepill® better  predicts virological and resistance outcomes than standard 
adherence measures, including self-report, tablet returns, iDART pharmacy refill 
data and spot EFV concentrations.  
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1.5. Data sources. 
Observational data 
The Desmond Tutu HIV Foundation (DTHF) has been involved in monitoring and 
evaluation of two large community antiretroviral services since 2002. The two clinics 
are Masiphumelele in the South Peninsula and the Hannan Crusaid Treatment 
Centre (HCTC) in Gugulethu. Over 14 000 patients have entered care at these two 
sites over the last 13 years. As of May 2015, over 8000 remain in care. Both cohorts 
are managed according to the South African National ART Guidelines and have been 
well described in the literature. (25, 37, 40, 80, 81). Both sites donate data annually 
to the IeDEA-Southern Africa collaboration.(82, 83) 
At entry, the demographics and clinical status of each patient is recorded: date of 
birth, gender, WHO clinical stage, baseline CD4 cell count and viral load (where 
available).  
All ART drug dispensing data is captured from the electronic pharmacy dispensing 
system at both sites (iDART). From 2007 iDART data was downloaded directly into 
the HCTC database, and from the end of 2012 was incorporated into the 
Masiphumelele database. iDART was developed locally by Professor Robin Wood 
and Cell-Life (UCT Department of Engineering). (84) 
Laboratory data, including viral load and CD4 cell count results, from the National 
Health Laboratory Service (NHLS), are downloaded into both databases monthly.  
Tablet returns are counted at each clinic visit and an adherence percentage 
calculated and recorded in the folder. 
All patients who are more than a month late for a clinic visit (i.e. 12 weeks since 
their last visit to clinic, blood draw or collection of ART) are traced and an outcome 
ascertained. Outcomes include: remaining in care, death, transfer to another clinic 
or loss to follow up (if tracing was unsuccessful). The database has monthly quality 
checks and is validated frequently.  
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Contribution of cohort data to the thesis: 
These cohorts are well-established and contain data from a large number of patients 
on ART over more than a decade. In 2012, the iDART data from the Masiphumelele 
site was compared to the cohort data (without iDART), to determine whether the 
pharmacy database could monitor retention in care more accurately and efficiently 
than the standard cohort methodology (Chapter 4). Data from iDART was also 
incorporated into the randomised controlled study data (see below) after 
completion in July 2014 (Chapter 3). Viral loads and tablet return data for the 
randomised study were also retrieved from the cohort databases throughout 2012-
2014 (Chapters 3 and 6). 
Ethics Approvals:  
The Desmond Tutu HIV Centre has had approval from the University of Cape Town 
Research Ethics Committee to collect routine clinical data on all individuals included 
in the HCTC and Masiphumelele databases since 2002 and 2004 respectively. This is 
renewed annually. The approval for 2015 is attached in Appendix 1.  
Randomised controlled trial 
The answers to many of the questions posed in the objectives could not be gleaned 
directly from the observational cohorts described above, and so I designed a 48-
week randomised controlled trial (RCT). 
The TAP study: A randomised controlled Trial to explore Adherence-failure 
relationships in a South African antiretroviral delivery site using an electronic 
adherence device and sparse Pharmacokinetic sampling, ran from July 2012 to July 
2014 at the HCTC site. Protocol development was completed in early 2012, and staff 
(study coordinator, quality manager and 3 research assistants) were recruited in 
March 2012. The TAP study protocol is presented in Appendix 2. Participant 
recruitment began in July 2012 and was completed in March 2013. The final end of 
study visit occurred on the 4th July 2014.  
This study explored the acceptability and impact of a locally produced, novel, 
wireless, electronic device, the Wisepill® [Figure 1.7], on adherence behaviour in 
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ART-naïve individuals commencing first-line ART at the HCTC. We hypothesised that 
the use of real-time electronic monitoring would reduce the overestimation of 
adherence seen with current methods. With the addition of a reminder sent by text 
message sent when dosing was late in the randomised arm, we hypothesised that 
the use of the Wisepill® would improve adherence, reduce treatment interruptions 
and subsequently reduce first-line ART failure rate. In 2010, up to 92% of South 
Africans carried cell phones, so the use of reminder text messages was considered 
feasible in our population. (85) 
Adherence was also quantified at each study visit (weeks 16, 32 and 48 into 
treatment) using multiple methodologies including clinic based tablet return data, 3-
day recall self-report and from the pharmacy refill data as imported to the cohort 
database from iDART.  
Timed pharmacokinetic samples and samples for cytochrome 2B6 enzyme 
pharmacogenetic analyses were collected from all individuals who give consent.  
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The study was funded by the European and Developing Countries Clinical Trials 
Partnership (EDCTP) through the mechanism of a Senior Fellowship, awarded in 
December 2011.  
Contribution of the RCT data to the thesis: 
The randomised data from this study was used to examine whether text messages 
sent soon after a missed ART dose could improve adherence and reduce treatment 
interruptions (Chapter 3). The six adherence measures collected from the individuals 
in the RCT were compared to determine which best predicted virological failure and 
the development of HIV-1 resistance (Chapter 6). EFV concentration and cytochrome 
2B6 metaboliser status was used together with electronic adherence data to 
examine whether the utility of drug concentrations in predicting virological 
outcomes improves with knowledge of genotype and adherence status (Chapter 5). 
EFV concentrations were completed at the Division of Clinical Pharmacology 
laboratory, our collaborating partner for this project. 
Ethics Approvals:  
The TAP study received approval from the University of Cape Town Research Ethics 
Committee in May 2013 and had annual re-approval until July 2015, when the study 
was closed, on submission of the primary publication. Approvals are presented in 
Appendix 1.  
Conflict of interest: 
Although Wisepill® is a commercial business, the author declares no financial conflict 
of interest. 
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1.6. Overview and structure of the thesis. 
The thesis includes an introduction (above) which places the importance of 
monitoring and improving antiretroviral adherence in context and describes the 
objectives of the thesis, which were conceptualised in 2012.  
This is followed by a literature review, chapter 2, broken into two sections:  
1. A systematic review of all studies with comparator arms and adherence as an 
outcome published from a resource –limited setting as completed by this author 
in early 2012. This was a sub-section of a larger review commissioned by the 
International Association of Physicians in AIDS Care (IAPAC): Guidelines for 
Improving Entry Into and Retention in Care and Antiretroviral Adherence for 
Persons with HIV - Evidence-Based Recommendations, published in mid-2012.(5) 
This review helped to guide and clarify objectives and intervention methodology 
for this thesis.  
2. A systematic review of all studies in resource-poor setting using electronic 
methods, such as text messaging or automated voice messages to improve 
adherence. This review was conducted initially to inform the design of the 
intervention for this thesis in 2012 and has been updated regularly (last review 
July 2015). 
Table 1-1: Link between thesis objectives, data sources and results chapters. 
 Objective Data source Chapter 
1 To explore the impact of real time electronic 
adherence monitoring device (Wisepill®) 
reminders on adherence, retention and 
virological outcome. 
RCT 
Cohort data 
(Gugulethu) 
3 
2 To examine whether Intelligent Dispensing of 
Antiretroviral Therapy (iDART) can successfully 
monitor adherence and retention in care. 
RCT 
Cohort data 
(Masiphumelele) 
4, 6 
3 To determine whether 2B6 pharmacogenetic 
data and efavirenz pharmacokinetics can predict 
treatment outcome. 
RCT 5 
4 To compare multiple different methods of 
quantifying adherence. 
RCT 6 
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Four publications, either published or submitted for publication, are presented as 
results chapters (Table 1.2): 
 Chapter 3, the published results of the RCT to determine whether text messaging 
when dosing is late can improve adherence and reduce treatment interruptions, 
addresses Objective 1. 
 Chapter 4 presents a published brief report using cohort data which describes 
how the iDART system can be used to determine retention in care more easily 
than the current cohort monitoring system and, together with pharmacy refill 
data predicting virological and resistance outcomes from Chapter 6, fulfils 
Objective 2.  
 The submitted manuscript presented as Chapter 5 uses data from the RCT to 
show that EFV levels, together with metaboliser genotype status data can predict 
virological outcomes, and determines an EFV predictive cut-off concentration. 
These data addresses Objective 3. 
 Chapter 6 is a published paper comparing the predictive value of each of the 
adherence measures used to monitor the cohort during the RCT and completes 
Objective 4. 
A final discussion to synthesise key messages from the thesis is presented in Chapter 
seven. Recommendation for future research and policy changes are made here. The 
conclusion summarises the novel contribution of the thesis. 
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2.  Literature review. 
2.1. Overview.  
This literature review is in two parts. The objective of the first part is to discuss the 
published literature on methods to improve adherence to antiretroviral therapy in 
resource-poor settings. In 2012, when this review was completed, there was a 
relative paucity of well-structured randomised studies or studies with a comparator 
arm examining this topic. (27, 28) An update, based on recent reviews, have been 
included at the end of section 2.2 to bring this data up to date. 
This first review allowed the author to consider which adherence interventions had 
been shown to be successful and to conceptualise the use of the Wisepill® electronic 
adherence monitoring device in the development of the randomised controlled 
study described above, as well as to elucidate objectives for this thesis.  
The objective of the second part of the literature review was to examine in more 
detail the literature related to using automated electronic systems to monitor and 
improve adherence in a resource-poor setting. This review has been updated 
annually since 2012, with the last review of the literature completed in July 2015. 
2.2. Part one - In a resource poor setting, which adherence interventions 
have proven to be successful? 
Background 
This review was undertaken in 2012 as part of a larger review of studies examining 
methods to improve adherence world-wide. Due to the few studies conducted in 
resource poor settings, the review did not differentiate between resource-rich and -
poor settings. Studies were instead grouped by type of intervention. The data from 
resource-poor settings alone is presented for the first time here.(5) 
Note: this systematic review described below was completed by the IAPAC review 
team. Once manuscripts were extracted, all those related to resource-poor setting 
were sent to this author for review and recommendation. 
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Search methodology 
A systematic search for studies examining interventions to improve antiretroviral 
adherence and monitoring was performed. To be included, the study had to 
evaluate an intervention to improve adherence through either a randomised 
controlled design or through the use of a comparator arm. Either an adherence 
measure or a biological measure related to HIV, namely CD4 cell count or HIV-1 viral 
load, had to be used as the primary outcome measure. Observational data without 
comparator arms were not included. In addition, for studies to be forwarded to this 
author, the term “resource poor” or resource limited” was included in the key 
words. Countries that were considered “resource-poor” were those defined by the 
World Bank as having low or middle income economies, also known as “developing” 
economies.(86)  
The following journal databases were searched: MEDLINE, EMBASE, CINAHL, as well 
as the Centers for Disease Control (CDC) and Prevention Research Synthesis 
database. Cochrane, Clinical Trials.gov and the Pan-African Clinical Trials Registry 
clinical trials databases were also searched. All searches included data from the 
commencement of each database up to the end of 2011. Conference abstracts from 
the Conference of Retroviral and Opportunistic infections, IAPAC adherence 
conferences, International AIDS Society conferences on HIV pathogenesis, 
Treatment and Prevention, were also searched from 2009 to 2011. For abstracts 
that have been published subsequently, the final manuscript was reviewed. Two 
reviewers employed by the CDC and funded by IAPAC extracted and coded the data 
for each study. 
This search was updated in July 2015, with a search for recent reviews covering 
interventions to improve adherence to antiretroviral therapy in resource-poor 
setting. The search was completed using on-line electronic databases (PubMed and 
GoogleScholar) including the terms “HIV/human immunodeficiency virus – MeSH 
term” AND “Antiretroviral therapy/ART/HAART – MeSH term” AND 
“Adherence/adherent/compliant/non-compliance/non-adherence/treatment 
failure/treatment success/ viral suppression (non-compliance/compliance) – MeSH 
term”. We limited the search to review articles published in English after 2011.  
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Results of the 2012 review 
Of 325 studies which met the above criteria in late 2011, only 24 (7.4%) were from 
resource-poor settings. This in itself was unexpectedly few, considering how, in 
many low- and middle-income countries, particularly in sub-Saharan Africa, the 
management of HIV, including delivery of ART is a key public health issue. 
Considering further, that ART options are limited in such settings, due to the cost of 
drug and the large numbers of people requiring treatment, this lack of well-
structured data on improvement of adherence could be having critical impact on 
ART programme outcomes. 
The interventions in these 24 studies could be broadly categorised into six groups as 
per Table 2.1: directly observed therapy, education or counseling programmes, peer 
treatment supporters, food supplementation packages, programme structure (which 
included task-shifting) and electronic reminders.  
Some studies included more than one intervention, for example, the study by 
Muñoz, et al used three combined interventions, published as two separate 
manuscripts. Within each group, while there was some consistency in methods of 
measuring outcomes, the interventions differed quite widely. This was particularly 
notable for the peer support and education/counseling interventions. The major 
findings for each group will be discussed below.  
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Table 2.1: adherence studies with comparator arms. Abbreviations are listed below the table.  
Category 1 Category 2 Authors Year Country Study Design n Intervention Outcome 
Directly 
observed 
therapy 
  Idoko, et al. 
(87) 
2007 Nigeria Non-randomised 
cohort study 
175 DOT vs. SoC CD4, VL 
Directly 
observed 
therapy 
  Muñoz, et al. 
(88) 
2010 Peru Cohort, matched 
comparison 
120 DOT vs. SoC SR, CD4, VL 
Directly 
observed 
therapy 
Peer support Nachega, et 
al. (89) 
2010 South Africa RCT 274 DOT vs. SoC TR, CD4, VL 
Directly 
observed 
therapy 
  Pearson, et al. 
(90) 
2007 Mozambique RCT 350 DOT vs. SoC SR, CD4 
Directly 
observed 
therapy 
  Sarna, et al. 
(91) 
2008 Kenya RCT 234 DOT vs. SoC SR, TR, VL 
Education / 
counseling 
  Mansoor, et 
al. (92) 
2006 South Africa RCT 120 Complex or simple patient 
information leaflet vs. SoC 
SR, TR 
Education / 
counseling 
  Oligbu, et al. 
(93) 
2009 Nigeria RCT 420 10 education modules vs. 
SoC 
Retention, 
mortality 
Education / 
counseling 
  Sampaio-Sa, 
et al. (94) 
2008 Brazil RCT 107 Group educational 
sessions vs. SoC 
SR, PR, CD4, VL 
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Category 1 Category 2 Authors Year Country Study Design n Intervention Outcome 
Education / 
counseling 
  van 
Loggenerberg, 
et al. (95) 
2010 South Africa RCT 297 Motivational interviewing 
vs. SoC 
VL 
Peer support   Chang, et al. 
(96) 
2010 Uganda RCT (clinics) 1336 Peer support (clinic and 
home-based) vs. SoC 
TR, CD4, VL 
Peer support  Muñoz, et al. 
(97) 
2011 Peru Cohort, matched 
comparison 
120 Community-based care =/- 
microfinance vs. SoC 
SR, CD4, VL 
Peer support Directly 
observed 
therapy 
Mugusi, et al. 
(98) 
2009 Tanzania RCT 621 Dosing diary or peer 
support or DOT vs. SoC 
SR, CD4, retention 
Peer support Directly 
observed 
therapy 
Taiwo, et al. 
(99) 
2009 Nigeria RCT 499 Patient-selected 
treatment partner vs. SoC 
PR, CD4, VL 
Programme 
structure 
  Batavia, et al. 
(100) 
2010 India Cross-sectional 
study (4 arms) 
635 Cost recovery programme 
vs. SoC 
SR 
Programme 
structure 
Peer support Kipp, et al. 
(101) 
2010 Uganda Non-randomised 
cohort study 
385 Community based vs. 
hospital care 
TR, CD4, VL 
Programme 
structure 
  Matovu, et al. 
(102) 
2011 Uganda RCT 92 Nurse-peer vs. doctor-
counsellor care 
TR, CD4, VL 
Programme 
structure 
  Sanne et al. 
(81) 
2010 South Africa RCT 806 Nurse vs. doctor care VL, retention 
Programme 
structure 
  Zachariah, et 
al. (103) 
2007 Malawi Within district 
cohort 
comparison 
1634 Community support vs. 
none 
PR, retention 
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Category 1 Category 2 Authors Year Country Study Design n Intervention Outcome 
Food 
supplementati
on 
  Cantrell, et al. 
(104) 
2007 Zambia Cohort (stepped 
intervention by 
clinic) 
636 Monthly food rations vs. 
SoC 
PR, retention 
Food 
supplementati
on 
  Serrano, et al. 
(105) 
2010 Niger Cohort, with 
comparator arm 
180 Monthly food rations vs. 
SoC 
TR, CD4 
Electronic 
reminders 
Education / 
counseling 
Chung, et al. 
(106) 
2011 Kenya 
RCT 400 Education or alarm device 
or both vs. SoC 
TR, VL 
Electronic 
reminders 
  Lester, et al. 
(50) 
2010 Kenya RCT 538 Weekly SMS vs. SoC SR, VL 
Electronic 
reminders 
  Pop-Eleches, 
et al. (107) 
2011 Kenya RCT 431 SMS reminders vs. SoC MEMS, TI 
Electronic 
reminders 
  Sabin, et al. 
(62)  
2009 China RCT 68 Counseling if adherence 
drops vs SoC 
MEMS, CD4 
Electronic 
reminders 
  Uzma, et al. 
(108) 
2011 Pakistan RCT 76 Weekly phone call 
reminders vs. SoC 
SR, CD4, VL 
CD4: CD4 cell count; DOT: Directly observed therapy; MEMS: Medical Electronic Monitoring System; PR: pharmacy refill; RCT: Randomised 
controlled trial; SMS: Short messages or text messages; SoC: Standard of Care; SR: self-report, TI: Treatment interruption; TR: tablet return; 
VL: viral load. 
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Directly observed therapy (DOT):  
DOT refers to the observation of treatment doses by someone other than the patient. Five 
randomised studies and two cohort studies exploring the use of directly observed therapy in 
the context of ART in resource-poor settings had been published by 2012. (87-91, 98, 99) All, 
except one from Peru, were conducted in sub-Saharan Africa, and all included an ART-naïve 
adult population.  
Not all DOT is equal, and in these studies it differed by cadre of observer, proportion of 
doses observed and duration of the observations. Idoko et al compared self-administered 
therapy to three versions of DOT: daily, twice weekly or weekly in a non-randomised cohort 
study over 48 weeks. The participants were observed by a treatment partner they had 
selected and who had received some training on adherence at the study clinic. (87) Muñoz 
et al, employed a DOT community team to observe every dose over a 12-month period. 
Those receiving DOT were matched by age and CD4 cell count to others in another study of 
community support, not using DOT. (88, 97).  
The remaining five studies were RCT. Pearson et al randomised ART naïve adults to receive 
DOT on every daytime week day dose for six weeks, observed at home by lay staff employed 
by the clinic, compared to standard of care. Night-time doses and weekend doses were self-
administered. (90) Nachega et al compared partial DOT (at least one daily dose) delivered by 
a patient-selected treatment partner, who received a short training session at the clinic, to 
others self-administering therapy over 24 months. (89) Taiwo et al also used patient-chosen 
treatment partners, who lived near to the participant, to observe dosing at home at least 
once a day for 48 weeks. They were compared to others receiving care at the same clinic 
without DOT. (99) Sarna et al used nurse-observed DOT twice a week at the clinic, with 
tracing for those who did not attend, compared to self-administered therapy. (91) Mugusi et 
al’s study comprised three interventions: either morning dose DOT at the clinic for a month 
or peer support or a dosing diary, compared to standard of care. (98) 
All of these studies used biological markers as a measure of outcome (CD4 cell count or viral 
load). One of the cohort studies did not use an adherence measure (87), and the others 
presented adherence data quantitated by either self-report (88, 90, 98), tablet return (89) 
or both (91). Taiwo used pharmacy refill data. (99) 
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All five of the RCTs and one of the cohort studies showed no benefit of DOT on increasing 
CD4 cell count or improving viral suppression over the full study duration [Figure 2.1]. (89-
91, 98) DOT also did not have an impact on retention in most cases; though one RCT (90) 
showed some improvement in people remaining in care. Sarna and Taiwo et al both showed 
some improvement in adherence by self-report and tablet return, or pharmacy refill 
respectively. (91, 99) In Nachega’s study, the intervention arm had reduced mortality 
compared to standard of care, possibly due to early benefits in increasing CD4 cell count, 
but this did not impact on virological response or CD4 improvement at 12 or 24 months. (89) 
The one cohort study that did show an improvement in adherence and viral suppression 
rates with DOT (Muñoz et al) had a number of limitations: the control group was less 
impoverished and the intervention enrolled more ill people. It was also difficult to tease out 
the impact of DOT compared with that of the community group intervention, which 
included microfinance support and food packages. (88) 
 
Despite showing a few benefits, the overall impression of DOT is that it does not improve 
virological outcomes, thus does not achieve improvement in the main goal of ART. As three 
studies combined DOT with an aspect of peer support, it is also difficult to assign benefit to 
the observing of doses alone.(88, 89, 99) This is reflected in the recommendation not to use 
DOT in the IAPC review: “directly administered ART is not recommended for routine clinical 
care settings”.(5) DOT would be a complex and potentially expensive intervention to utilise 
on a large scale in resource-poor settings.   
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Education/Counseling: 
Five randomised controlled studies included interventions linked to pre-treatment 
antiretroviral education or counselling. Again, all included ART-naïve adults as their study 
population. Two of these studies were South African, and the others were from Nigeria, 
Kenya and Brazil, see Table 2.2. (92-95, 106) 
Three studies focused their education intervention on improving treatment literacy. Pre-
treatment education was one component of the RCT intervention published by Chung et al. 
in Kenya.(106) The use of an alarm device was the other intervention, as described in the 
Electronic Reminder section above. The educational component included three group 
sessions of 30-45 minutes delivered by counselors; two delivered prior to ART 
commencement and one a month after starting. Content was practical, and included 
information on HIV, AIDS and ART, and explored personal barriers to adherence in the first 
month on therapy. Standard of care was a 15-minute explanation on ART dosing and 
potential side effects by the pharmacist as ART was dispensed. (106) The Brazilian RCT from 
Sampaio-Sa held small group education sessions (four sessions of 2-3 hours each) with 
similar content over two months around time of ART commencement, but they were staffed 
by a psychologist or social worked, rather than by a lay counselor. The control group were 
shown four short educational videos over a matching two-month period. (94) Oligbu, in an 
as yet unpublished RCT from Nigeria, compared 10 structured teaching modules, again 
covering information on HIV and ART and addressing possible adherence related issues, to 
casual teaching by nurses in the ward. All participants were hospitalised. (93)  
The remaining two studies were more diverse: van Loggerenberg added an individualised 
intensive motivational interviewing intervention to the standard three treatment literacy 
sessions used in South Africa.(10) The sessions were client-centred and tailored to that 
participant. (95) The last RCT, published in 2006, randomised participant to receive either a 
complex or a simple patient-information leaflet to improve adherence to cotrimoxazole vs. 
no leaflet, after a short interview explaining the use of cotrimoxazole. (92)  
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Table 2.2: Outcomes of education-based studies. SoC as per South African ART guidelines. 
Author Intervention Control Outcome 
 Type Duration Staff Type Duration Staff  
Chung 
(106) 
Treatment 
literacy, 
group 
30-45 
minutes x 
3 
Counsellor Dispensing 
process 
15minute x 
1 
Pharma-
cist 
Improve TR, 
VL  
Oligbu 
(93) 
Treatment 
literacy, 
group 
?duration 
x 10 
Not 
specified 
Casual Not 
specified 
Nurse Improve (↓ 
mortality) 
Sampaio-
Sa (94) 
Treatment 
literacy, 
group 
2-3 hours x 
4 
Psychologi
st or social 
worker 
Educational 
video 
8-10 
minutes x 
4 
None NS change 
(TR, PR or 
VL) 
Van 
Logger-
enberg 
(95) 
Treatment 
literacy, 
group 
PLUS 
individual 
motivational 
interviewing 
session 
30-45 
minutes x 
3 
PLUS 1  
Counsellor Treatment 
literacy, 
group 
30-45 
minutes x 
3 
Counsel-
lor 
NS change 
(VL) 
Mansoor 
(92) 
Simple PIL, 
short 
information 
leaflet 
15 minutes Nurses No leaflet, 
short 
information 
session 
15 minutes Nurses Improved 
(TR, SR) 
Mansoor 
(92) 
Complex PIL, 
short 
information 
session 
15 minutes Nurses No leaflet, 
short 
information 
session 
15 minutes Nurses NS change  
(TR, SR) 
 
 
Adherence was measured in three of the studies Chung, Mansoor and Sampaio-Sa, by either 
tablet return alone (106), tablet return and self-report (92) or tablet return and pharmacy 
refill data (94) respectively. Sampaio-Sa and Chung included both an adherence and a 
biological measure (VL) and van Loggerenberg only reported viral load outcomes. (94, 95, 
106) Oligbu presented hospital stay and mortality data only. 
Of the three studies focused on improving treatment literacy, two reported improved 
outcomes. Chung et al showed that the three education sessions improved adherence by 
Standard of care (SoC) More than SoC Less than SoC 
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tablet returns by 6% at 18 months, as well as a reduced the chance of virological failure 
[Table 2,3].(106) Although not presenting an adherence measure, Oligbu found the 10 
education sessions reduced hospital stay, readmission and mortality. (93) In contrast, 
Sampaio-Sa found no difference in adherence, CD4 or viral load outcomes between their 
four adherence group sessions and the short educational videos (94) Mansoor’s study 
showed that simple patient information leaflets improved self-reported and tablet return 
adherence in the short term, but complex leaflets did not. (92) The study from van 
Loggerenberg, using individual motivational interviewing did not have an impact of viral load 
outcomes at 9 months.(95) 
Although the interventions in these studies are diverse, the benefit of some pre-treatment 
education comes through. Chung and Oligbu compared structured education to minimal 
input and showed improvements in adherence, virological or mortality outcomes. (93, 106) 
Sampaio-Sa compared two difference methods of education, and saw no difference 
between the two. (94) Efforts to improve adherence beyond that gained from treatment 
literacy, by adding motivational interviewing did not prove successful [Table 2.3]. (95) 
There are multiple recommendations related to education in the IAPAC review, and 
although the composite message is that education is beneficial, the evidence to support this 
recommendation is still not of the best quality. (5) Pre-treatment education is standard of 
care in South Africa. (10) In most resource-poor areas, the epidemic remains in the 
heterosexual adult population, not a marginalised population. The majority achieve viral 
suppression at a year. It seems likely that preparing people for ART is enough adherence 
input for this majority. More specialist adherence interventions, such as motivational 
interviewing, may prove to be of more benefit when focused on those noted to struggle 
with adherence later on.   
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Peer support:  
For the sake of this review, a peer supporter is defined as an unpaid volunteer chosen by 
either the clinic, community or the study participant. Four RCTs and 2 cohort studies, all in 
ART-naïve adults, examined the impact of peer support on adherence. (89, 96-99, 101) All, 
except one from Peru, were from sub-Saharan Africa.  
Three studies included some combined form of DOT and peer support as a single 
intervention [Figure 2.2]. (89, 97, 99). In Nachega’s RCT, peer treatment supporters who 
were aware of the participant’s HIV diagnosis were selected by the participant and attended 
initial clinic-based adherence and DOT training, which was reinforced every 3 months. In the 
self-administered arm, participants also selected someone for peer support, but with 
training on adherence only at ART commencement.(89) Participants in Taiwo’s RCT also 
selected their own peer supporter, who received the same single training session that all 
study participants received as standard of care. The peer supporter was asked to observe 
dosing once a day and remind the participant when to pick up medication. (99) In Muñoz’s 
complex cohort study, peer supporters were part of a team providing DOT, but the 
intervention also included microfinance loans and food baskets.(97) 
The remaining three 
RCTs used peer support alone [Figure 2.2]. Kipp et al offered community-based care to HIV-
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positive individuals in a local sub-district and compared outcomes to those who attended 
the local hospital in a non-randomised cohort study. The community selected volunteer 
peer supporters to attend a two-day training on HIV ART, adherence and adverse effects. 
The peer supporters then visited each participant on ART in the sub-district weekly to count 
tablet returns and provide on-treatment support. In addition, each participant selected a 
family member for daily support. Peers could collect ART at the hospital for a participant if 
required. (101) Chang trained HIV-positive individuals to support others living with HIV, by 
providing ART counseling, and collecting self-report and tablet return adherence data at the 
participant’s home every second week. Clinics in the health district were either randomised 
to utilise this peer support system or not.(96) One intervention arm of Mugusi’s RCT 
included the use of patient-selected peer supporters who attended adherence counselling 
with the patient and then supported them at home. The other interventions were DOT (as 
described above), vs. standard of care. (98) 
All studies used a biological measure as an outcome, ether CD4 cell count or viral load. They 
also all used an adherence measure: either self-report (97, 98), or tablet return (89, 96, 101) 
or pharmacy refill. (99) 
The 4 RCTs showed no improvement in CD4 count or HIV-1 RNA suppression at 1 year with 
the use of peer support. (89, 96, 98, 99) Taiwo’s study showed an improved in adherence in 
those receiving adherence support which extended to 48 weeks.(99) However, in other the 
three studies peer support showed no improvement in adherence at 1 year compared to 
standard of care. (89, 96, 98) Kipp et al showed no difference in virological outcomes using 
peer supported community care compared to hospital-based care, perhaps more 
importantly showcasing a successful community model for treatment delivery, than the 
impact of peer support.(101) The only study which showed improvement in viral load and 
CD4 cell count was the complex cohort study by Muñoz, with multiple interventions that 
were difficult to disentangle.  
While peer support is another attractive option for resource-poor settings, through the use 
of volunteers who can be incorporated into standard treatment literacy sessions rather than 
paid health care workers, there is little hard evidence to date that peer support results in 
improved outcomes on ART over time. The IAPAC review states: “peer support may be 
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considered”, but notes that the combination of the use of peer support together with other 
adherence interventions has resulted in limited evidence for benefit. (5)  
  
page 56 
 
Programme structure:  
The five studies examining the improvements in adherence through altering the system of 
delivery of ART fall into two categories: task-shifting and cost recovery programmes. While 
neither would be considered a classic adherence interventions, these studies included 
adherence benefit as an outcome and so are included here. The one study on cost recovery 
originated in India (100), and the four describing the use of alternate cadres of health staff 
originated in sub-Saharan Africa. (81, 101-103) Support in the community by any staff 
employed by the care-system was considered task-shifting, as compared to volunteers 
chosen by the patient, defined as peer-support.  
Batavia et al explored a system of cost-recovery at a large Indian hospital-based ART service. 
All patients attending the ART service were assigned to contribute 0, 50, 75 or 100% of 
medication costs according to their declared socio-economic status. (100) Two task-shifting 
RCTs compared nursing care with physician-based care for patients initiating ART. The first 
compared a nurse-peer model to the traditional doctor-counselor model over 12 months in 
an Ugandan hospital maternity unit.(102) The second study, from Sanne et al, randomised 
participants commencing ART to receive care from a nurse or a medical officer over 96 
weeks in resource-poor communities in South Africa.(81)  
The remaining two studies were cohort studies with various comparator arms. Kipp et al. 
describe rural community-based delivery of ART by community elected peer supporters who 
visited participants weekly and who could also collect ART for them. The district used was 
selected as it was some distance from the hospital and had traditionally limited ART access. 
Outcomes from the community were compared to those or participants receiving care at 
the hospital site.(101) Zachariah et al describes outcomes with a system of community 
support in some health districts of Malawi, compared to other districts without this support. 
Community activities were implemented by community nurses and volunteers who visited 
patients at home, and included identification of ill patients for referral, adherence support, 
HIV and ART education and income generations activities. (103) 
Batavia et al. unfortunately used self-reported adherence alone to assess the impact of the 
cost recovery programme.(100) Sanne and Matovu presented results using CD4 and viral 
load outcomes. In addition Matovu used tablet returns to assess impact on adherence, 
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whereas Sanne did not note adherence outcome. (81, 102) Kipp et al also compared 
virological outcomes, but only collected tablet return adherence data for the community 
cohort.(101) Zachariah used pharmacy refill data to determine retention in care. (103) 
 
Batavia noted an improvement in adherence by self-report in those whose medication was 
completely funded: a 13% increase in those reporting adherence >95%. (100) Both Sanne 
and Matovu noted no significant difference (non-inferiority) in the proportion of those with 
viral load suppression by type of care delivery, and, for Matovu, no difference in adherence 
by tablet return by arm [Figure 2.3].(81, 102) Kipp showed excellent adherence in the 
community cohort, and similar viral load outcomes between the hospital and community 
cohorts.(101) Zachariah showed a 20% improvement in adherence in those with community 
support, together with a reduction in mortality and losses to care. (103) 
It is important in a resource-poor setting that down referral of care was at least non-inferior, 
if not an improvement on standard medical-based care in all these studies. The IAPAC 
review incorporates this as a recommendation: “using nurse or community counselor based 
care has adherence and biological outcomes similar to those of doctor or clinic-based 
counselor care and is recommended in under-resourced settings”.(5) Innovative models of 
care are becoming more important as the number of individuals receiving ART in resource 
limited setting increase. New systems are required not only to relieve burden on medical 
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officers who are in short supply, but also to decongest clinics and provide alternative models 
of care for those who initiate ART with higher CD4 cells counts while clinically well.   
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Food supplementation: 
Two studies from sub-Saharan African countries, Niger and Zambia, explored the use of 
monthly food supplementation packages on adherence to ART. Again, while the 
intervention here improves social welfare more directly than health, the outcome of these 
studies was adherence to ART and so these studies were included in the review. In both 
studies, adults who were ART-naïve and attending local government clinics were included. 
(104, 105) 
These adult populations did differ: Serrano et al, from Niger, presented a cohort study with 
a comparator arm. All adults commencing ART as well as those pre-ART, were included in 
the cohort. Those with late stage HIV-disease (WHO clinical stage 3 or 4 and/or a CD4 cell 
count of <200 cells/mm3), or a body mass index of <18.5 kg/m2 were eligible for six months 
of family nutritional support. This included cereals, legumes and vitamin A-enriched 
vegetable oils. (105) Cantrell’s cohort study, in Zambia, included only adults with 
documented food insecurity. As the food supplementation programme roll-out across the 
health district was staggered, this allowed for comparison between people with 
documented food insecurity at clinics with the supplementation and those at clinics 
without. Participants again received six months of cereal, legumes and oil for six 
people.(104) Food rations were dispensed monthly in both studies. 
Both studies showed substantial improvement in adherence by objective adherence 
measures: a 21% improvement in tablet returns over 6 months in those received 
supplementation in Niger (105) and a 22% improvement in medication possession as 
calculated from pharmacy refill data at 12 months in Zambia (104).The latter, Cantrell, did 
not note an improvement in CD4 cell count response, whereas Serrano noted a 1.7 times 
increase in CD4 cell count over the six months of the food supplementation programme.  
The data from these two cohort studies were considered compelling enough to warrant a 
recommendation in the IAPAC review: “Interventions providing… resources to address food 
insecurity… are recommended”. (5) Although such programmes are attractive in resource-
poor settings, both studies were completed with donor food supplies from the World Food 
Programme. Without such donations, this is likely to be a costly intervention, and require 
some complex administration.  
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Electronic reminders:  
In early 2012, there were five published randomised studies which used electronic 
monitoring or reminders to improve adherence, see Table 2.3. All studies were in HIV-1 
positive adults new to ART, taking first-line non-nucleoside reverse transcriptase inhibitor-
based treatment regimens. All three African studies were completed in Kenya, and two 
studies were from Pakistan and China. (50, 106-109) 
Technology used in the interventions ranged from simple alarm devices (106) through 
medication event monitoring systems (MEMs caps) (109) to mobile phones (50, 107, 108). 
Uzma et al used mobile phones to allow research assistants to contact participants in the 
intervention arm by voice call once a week. Participants were reminded to avoid missing 
doses. (108) Both Lester et al and Pop-Eleches used short messages (SMS) or texts. Lester’s 
bulk text message was sent once a week and included a simple enquiry: “How are you?” or 
“Mambo” in KiSwahili. Participants were ask to text one of two standardised replies, “I am 
fine” or “Sawa” vs. “I have a problem” or “Shida”, within 48 hours. Those who did not 
respond or those that identified themselves as having a problem were called by a clinician 
to ascertain their status. (50) Pop-Eleches’s team randomised one third of participants to 
standard of care and the rest to one of four different text message schedules: daily long or 
short message or weekly long or short messages. Short messages were simply reminders to 
dose and longer messages included some supportive text such as “be strong and 
courageous, we care about you.” No reply was required. (107) Chung’s study randomised 
participants to one of four arms with two possible adherence interventions: alarm device 
alone, education alone (3 sessions of 30-45 minutes delivered by a counselor), both or 
neither. The alarm device could fit in the participant’s pocket, had to be carried at all times 
and beeped and flashed at the time doses were to be taken. (106) Sabin’s study from China 
used MEMS data to determine participant adherence. Those who were non-adherent 
(<95%) were flagged for additional adherence counseling, including review of the MEMS 
printout and an explorations of reasons for missed dosing.(62)  
In four studies, a biological measure was used as an outcome as well as an adherence 
methodology. A suppressed viral load is considered to constitute successful ART, but only 
three of the five studies included virological outcomes. (50, 106, 108) A fourth used 
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improvement in CD4 count. (109) The other study relied on adherence measures alone to 
determine success. (107) No study used self-reported adherence as the sole outcome. If no 
biological measures were used, either MEMS or tablet returns were used to quantitate 
adherence. (106, 107) 
Table 2.3: Adherence and biological outcomes of electronic reminder intervention studies. 
 No clinic feedback With clinic feedback 
Author Chung Pop-Eleches Pop-Eleches Lester Sabin Uzma 
Type of 
intervention 
Alarm 
device 
Daily text Weekly text Text 
message 
MEMS and 
counseling 
Voice call 
Biological 
outcome 
NS 
(VL) 
- - Significant 
(VL) 
Significant 
(CD4) 
Significant 
(VL) 
Adherence 
outcome 
NS  
(TR) 
NS  
(MEMS) 
Improved 
(MEMS) 
Improved 
(SR) 
Improved 
(MEMS) 
Improved 
(SR) 
 
Two of the studies, by Lester and Sabin, using weekly cell phone text enquiry with replies or 
MEMS monitoring with adherence feedback respectively, showed that the use of these 
electronic devices linked to clinic contact improved adherence by 12% at 12 months into 
ART [Table 2.2]. (50, 62) Each of these studies also confirmed improvement in outcomes 
using a biological marker (decrease in HIV-1 RNA and increase in CD4 cell count 
respectively). 
However, a third well-powered RCT in Kenya (Pop-Eleches et al) showed that weekly text 
message reminders without any further clinic contact also improved adherence: 13% more 
people maintained more than 90% MEMS adherence over 48 weeks and treatment 
interruptions of 48 hours or more were reduced. The long or short message content did not 
impact on outcome, and neither did the daily messages. Daily message were assumed to 
cause message fatigue in the participant and thus to be ignored. No biological outcomes 
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were presented. (107) A short RCT (Uzma) with only 8 weeks of follow-up showed benefit 
on self-reported adherence of a weekly phone call from clinic staff to participants on ART, 
with an increase in virological suppression.(108) One RCT (Chung) showed that an alarm 
alone (with no feedback) had no benefit on adherence as measured by pill count or on 
biological outcomes at 18 months into treatment. (106) 
The success of the weekly text messages in the two Kenyan studies, lead to the 
recommendation by the IAPAC group that technology, with a link to care, be included as 
adherence support: “Reminder devices and the use of communication technologies with an 
interactive component are recommended”. (5) This was echoed by the World Health 
Organisation in their 2013 ART guidelines: “Mobile phone text messages could be 
considered as a reminder tool for promoting adherence to ART as part of a package of 
adherence interventions”. (110, 111)  
Not all these studies will easily to expand to scale in a resource-poor setting. The three 
studies with improvements in CD4 cell count and viral load suppression all required direct 
interaction with another skilled human being: participants were called either as a routine or 
on their request, or received additional education at the clinic.(50, 108, 109) Only one of the 
two studies that did not require increased human resource input showed an improvement 
in adherence. Weekly text messages improved adherence measured by MEMS, but an alarm 
device had no impact on adherence as measured by tablet returns. The use of technology 
itself is a very attractive option in resource-poor setting due the possibilities of easily 
reaching many people in an acceptable manner, with little systematic cost or effort. 
However, further exploration of the use of text messaging, in more diverse settings should 
be undertaken before these recommendations become entrenched.  
  
page 63 
 
Review update and discussion 
The search for new studies with adherence as an outcome and a comparator arm conducted 
in July 2015, found that most of the new articles and reviews relating to adherence were 
focused on electronic adherence interventions. These articles are covered in the second part 
of this review (page 67). 
Three other recent reviews have focused on all adherence interventions in ART: 
Barnighausen et al. conducted a review of adherence literature in a sub-Saharan Africa, also 
in late 2011; Chaiyachati et al. conducted a review of all interventions to improve adherence 
to antiretroviral therapy in 2014; and Mbuagbaw et al. reviewed interventions for 
enhancing adherence to ART in high quality studies in May 2015. (111-113). 
Barnighausen et al conducted a review of studies to evaluate adherence specifically in sub-
Saharan Africa, at the same time as the IAPAC review was being conducted. Any ART study 
with adherence outcome and a control or comparator group was included. They identified 
26 studies, and described similar intervention categories to those used above: structured 
teaching programmes, treatment supporters, directly observed therapy, mobile phone text 
messages, changes in programme structure, including task shifting, and food rations. All of 
these improved adherence in this setting. They also noted that 14 of the studies used more 
than one intervention simultaneously; and that discrepant findings for a single intervention 
were commonplace. Of note, they concluded DOT to be of benefit, despite this review 
including four of the five papers I reviewed above. This was based on a 2010 meta-analysis 
by Hart et al. which noted benefit of DOT when observational studies were included in the 
analysis, though not if only randomised studies were used.(112, 114) 
Chaiyachati et al conducted a rapid systematic review (a review of previous reviews) of 
adherence interventions in both resource-rich and –poor settings, to inform the 2013 WHO 
antiretroviral guidelines. They only included recent reviews and RCTs conducted in the two 
years prior to the search. Their review again categorised studies into similar groups: 
“education, cognitive-behavioural interventions, treatment supporters, directly observed 
therapy, and active adherence reminder devices (such as mobile phone text messages)”. 
Each group had been tested in 20 or more rigorously conducted studies. The review 
included the majority of the studies identified by this author as well. They noted that while 
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each intervention group tested above has been shown to improve adherence through a 
number of rigorous studies, each intervention has also been found not to have an impact in 
similarly rigorous settings e.g. DOTs is a good strategy for prison populations, but not in 
other settings. They note that adherence is a form of behaviour and as such will be altered 
by “culture and circumstance”.(111) 
The final review, by Mbuagbaw, examined high quality studies with both a clinical (viral load 
or CD4 count) and an adherence outcome with follow-up of at least 80% of the cohort for a 
minimum of six months. Studies were not limited to resource-poor settings. Forty-nine 
studies were included in the results, of which only 10 had both adherence and clinical 
benefit. Factors which resulted in the success of these 10 were unclear. Successful study 
interventions included: dose simplification, text messages, use of a web-based life-skills 
programme, counselling and motivational interviewing. (113) 
To conclude, there are relatively few studies from resource-poor settings that examine 
interventions that might improve ART adherence. All of the interventions above could be 
supported by further evidence. Many studies examine more than one intervention at the 
same time (e.g. peer-support and DOT), making it difficult to evaluate which intervention 
has an impact on adherence. In addition, all the interventional studies discussed were of 
relatively short duration (12 to 18 months) making it impossible to project sustainability. 
Cost is an important consideration for interventions aiming to improve ART adherence in 
resource-poor settings: therefore there is a need for cost-effectiveness analysis for any 
effective ART adherence interventions, which is also currently lacking.  
Finally, in resource- poor settings, with few resources and large patient numbers, non-
adherent patients requiring additional counseling and support often compete for staff and 
clinic resources that are also needed to initiate people on ART. A number of studies 
reviewed here, as well as more recent studies, are focused on decentralising and simplifying 
ART care and support through task-shifting, peer education groups and peer-or community-
based care. (13, 101-103, 115) Further exploration of support using electronic reminders 
could aid in this decentralization. Such programmatic approaches to optimise the use of 
clinic staff might markedly reduce the burden on ART clinics without worsening adherence 
or biological outcomes, but these approaches will require more evaluation.  
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Contribution of this review to the development of the thesis  
Of the adherence interventions described above, those with the most success appeared to 
be pre-treatment literacy or education, task-shifting, food supplements and electronic 
reminders. The evidence for the use of peer support was minimal, and randomised studies 
using DOT only showed minimal benefit.  
By 2012, the South African ART programme had already task-shifted toward minimising the 
use of medical officers and increasing the use of nursing staff; using evidence from two large 
South African studies, CIPRA-1 and STRETCH.(81, 116) In addition, research at the HCTC site 
in shifting models of care from nurse-based at the clinic to counselor-based in off-site 
adherence clubs was already underway.(13) The South African ART guidelines also 
stipulated that three counselor-based group treatment literacy sessions should be offered 
to each ART-naïve participant.(10) The HCTC site has offered these structured group 
sessions since 2002, both in clinic hours and at weekends. (38) Food supplementation, 
although not ideal, is offered to those with concomitant tuberculosis and a low body mass 
index.  
Two areas of interest stood out for this author. The first was that, in all the studies reviewed 
above, there was no standard methodology for monitoring adherence. The second was that 
the intervention which seemed most promising for scaling up ART in a resource- poor 
setting and the one with the most scope for new knowledge was the use of electronic 
reminders, via a mobile phone. An intervention which could improve adherence and 
possibly retention in care, and that could be disseminated widely without requiring extra 
human resources would be very attractive. One large study from Kenya showed an 
improvement in adherence with the simple addition of weekly text messages. (107) 
In addition, Lloyd Marshall of Wisepill® had approached the Desmond Tutu HIV Foundation 
with his device. Early data showed use of this device to be acceptable and feasible.(60) The 
use of this device to monitor adherence, coupled with the capability of sending text 
reminders linked to ART missed dosing, and so avoiding message fatigue from routine 
messaging, seemed a unique opportunity to explore adherence measuring methodology and 
whether linking reminders directly to missed doses would impact on adherence and 
retention. This novel real-time approach to reminders had not been published before, and 
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solved two problems in one – finding a quality method of monitoring adherence and 
intervening rapidly with little human resource input required. 
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2.3. Part two- Impact of use of mobile phone technology on adherence to ART in 
resource-poor settings. 
Background 
As discussed in the introduction to this thesis (page 17), with the number of people living with HIV in 
resource-poor settings who need to be commenced on ART increasing, as newer country guidelines 
allow access to ART with higher CD4 cell counts, maintaining each individual in care, with high levels 
of adherence to first-line therapy becomes increasingly challenging.(10, 110) However, the mobile 
phone network has similarly expanded in many resource-poor areas over the past 10 years and most 
sub-Saharan African countries have extensive networks, at least in urban areas. In 2010 South Africa 
had more mobile phones than there were people [Figure 2.4]. (85) 
Figure 2.4: Gapminder bubble chart showing South Africa to have 101 mobile phone subscribers per 
100 people in 2010 (ringed blue bubble). Each country is represented by a bubble. The size of each 
bubble reflects the total population of each country, and the colour of the bubble indicates the 
continent as per the small map in the top right of the figure. The x-axis marks the income per capita 
and the y-axis the number of mobile phones per 100 people. (85) 
 
Initial studies using mobile phone voice calls in support of ART adherence have been published from 
2005, but with mixed results. (108, 117, 118) While Uzma at al, showed adherence and biological 
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benefit from a randomised voice call study in Pakistan, another randomised study from the United 
States showed that 16 scripted calls by nurses to participants over 96 weeks did not improve 
adherence or virological outcomes. (108, 118) A more recent study, from Huang  et al in China, also 
showed no benefit from a call to a mobile phone every second week.(117) Voice calls also require 
the time of an at least semi-skilled staff member. Human resources are finite in the face of the 
growing number of people taking ART, and there is much focus on task-shifting away from medical 
and nursing staff, as well as down-referral to more peripheral clinics and even community sites. (13, 
81, 116) Relying on support to individuals through voice calls is unlikely to be feasible. 
The use of mobile phone technology to support adherence is more easily scalable and affordable. 
Adherence support which is not focused on a health facility is also attractive, as the numbers of 
those on treatment who have never been ill increases. Such technology may also be more attractive 
to the young, who are more at risk of loss to care over time. Of the five randomised studies 
examining the use of electronic reminders described in the above review [Table 2.2], two studies 
from Kenya showed benefit of using text messages in improving adherence and possibly virological 
outcome. (50, 107) The World Health Organisation 2013 ART guidelines subsequently embraced the 
use of technology. (110) Initial reviews of the use of mobile phone messaging were enthusiastic in 
suggesting the use of automated technology might improve adherence (119-121). However, more 
recent studies, reviewed below, suggest the benefit may not be as universal as initially thought. 
This review will examine the evidence for the use of automated systems to send mobile phone 
reminders to improve adherence in ART in resource- poor settings; and examine cohort 
characteristics to determine whether particular subgroups may benefit more from such automated 
interventions than others. 
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Search methodology 
The objectives of this review were to summarise the findings of any randomised controlled 
trial examining the impact of mobile phone messaging, compared to standard of care, on 
adherence to antiretroviral therapy with focus on those conducted in a resource poor 
setting. Secondary objectives were to see whether particular populations benefit more than 
others from text messaging, and whether messaging characteristics might be more or less 
beneficial than others e.g. message frequency, message content and the need for a 
response to the message.  
Search strategy: the review was approached systematically; the author searched on-line 
electronic databases, using the terms “HIV/human immunodeficiency virus – MeSH term” 
AND “Antiretroviral therapy/ART/HAART – MeSH term” AND 
“Adherence/adherent/compliant/non-compliance/non-adherence/treatment 
failure/treatment success/ viral suppression (non-compliance/compliance) – MeSH term” 
AND “Mobile phone” OR “text messages”. We limited the search to articles published in 
English after 1995.  
The same searches were conducted in each of the following databases: MEDLINE (via 
PubMed), Africa-Wide (NIPAD), SCOPUS (Web of Science), Cochrane Central Register of 
Controlled Trials and Literatura Latino-Americana e do Caribe em Ciências da Saúde 
(LILACS). 
Types of studies: Only randomised controlled studies were included in the review. Primary 
outcome was either any measure of antiretroviral adherence or a biological measure, 
namely HIV-1 viral suppression or increase in CD4 cell count at the end of the study. Study 
populations included HIV-positive adults, adolescents or children taking treatment for HIV. 
Interventions using mobile phone messaging, or automated calls, were included.  
Data collection: The results of each search were imported into a reference manager 
programme (EndNoteX7®). Duplicate references were removed. The author reviewed all 
titles and abstracts, using titles, abstracts and other describing information to identify those 
articles which met the inclusion criteria based on study design, population included, type of 
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intervention and outcome measure. The full text was obtained for each of these article 
identifed and the references of these studies also searched for further relevant articles.  
Data extraction: the author extracted data into a data table which include the following 
fields: study design, including details of randomisation (to assess for bias), location, clinic 
setting, duration and year of publication; participant number and age; intervention details 
including type and frequency of intervention, message content, whether messaging was 
manual or automated and requirement for response to the message; outcome measures, 
including method of measuring adherence, CD4 count, HIV-1 viral load and the outcome 
results. Outcomes were summarised as no difference, improvement in adherence alone and 
improvement in adherence and biological marker. 
Data analysis: as there was little consistency between the outcome measures and 
intervention used amongst the studies, a narrative descriptive review is summarised below. 
Where necessary, intervention variables were compared with the outcome summary using 
proportions and percentages.  
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Results 
The search was repeated three times between January 2014 and August 2015. Figure 2.5. is 
a flow diagram showing the number of studies identified, and those reaching the final 
review. 
 
The field of mobile phone reminders is growing rapidly.(122) For example, in PUBMED there 
were 36 hits using the above search terms in March 2014 and 56 by August 2015. There 
were 12 duplicates in the combined 145 hits from searched databases. After review of these 
abstracts, 22 full text articles were selected for retrieval. That there have been six reviews of 
the topic since 2011, is a measure of the global interest in mobile phone reminder systems: 
three reviews focus solely on these interventions in ART (119-121) and another three 
reviews on broader ART adherence interventions, including sections on electronic 
reminders. (5, 111, 112) 
Of the 22 original publications which met inclusion criteria on initial review of the abstract, 
20 were reviewed in their entirety [Figure 2.5]. Two manuscripts could not be sourced (one 
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unpublished abstract and one unpublished thesis). Ten manuscripts were subsequently 
excluded for the following reasons: four had not yet published results (123-126), four used 
voice calls and not an automated system (108, 117, 118, 127) and the remaining two were 
not randomised studies (128, 129).  
Reviewed studies: structure and population. 
There were 12 studies which met all the inclusion criteria for the review i.e. randomised 
studies examining the use of electronic reminders to improve adherence in a population 
taking ART. Eight were conducted in a resource-poor setting. Full manuscripts were not 
sourced for two of them. (130, 131) Each study is described below, with the structure of the 
study, the included population and a summary of each intervention presented in Table 2.4; 
and the intervention details, outcome measures and results in Table 2.5. 
Bigna et al published a study examining the impact of mobile phone-based reminders on 
adherence to care for 242 parent-child pairs attending hospital-based paediatric clinics in 
three different districts in Cameroon [Table 2.4]. This is the only study including children. 
Pairs were randomised 1:1:1:1 to one of four arms: 1. standard of care, 2. SoC and a text 
message 48 hours before their appointment, 3. SoC and a call 48 hours before their 
appointment or 4. a text reminder 72 hours before AND a call 48 hours before the 
appointment. Calls and texts were completed by a staff member and included identical 
information: the date and time of their appointment as well as the address of the hospital 
and the treating doctor’s name. No messages were left on mobile phones. The median age 
of the children ranged from 1.8 to 5.0 years between the groups and that of the adults from 
36.5 to 50.5 years. Outcome was measured as the efficacy of each intervention, calculated 
as the proportion in each arm who attended their appointment. Attendance on the day of 
appointment was low (51%) in the SoC arm, compared to 75-89% in the intervention arms. 
Using intention to treat analysis, the odds of attendance were improved in all three arms 
[Table2.5], with no significant difference noted between the interventions. While the data 
Voice calls and / or text messaging improved visit attendance in parent-child pairs in this short 
study from Cameroon. 
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presented of good quality, the study was very short: completed within three months, as 
only one appointment per parent-child pair was included. No biological outcomes were 
collected. (132) 
A Brazilian study, by da Costa et al, assessed the effect of a text message intervention in 
women on ART at a hospital-based ART clinic. The participants were adults, and both ART-
naïve and non-naïve, had been on ART for at least three months and had a suppressed viral 
load. Women who owned mobile phones were randomised 1:1 to either SoC (which 
included treatment literacy) or SoC and only daily text message reminder timed 30 minutes 
pre-dose, five times a week (Monday, Wednesday, Friday, Saturday and Sunday) [Table 2.4]. 
Messages were sent using an automated web-based system, and the content of the 
messages was the same “Take good care of your health” over 4 months. Adherence was 
measure using self-report, tablet returns and MEMS. The methods stated that CD4 and viral 
load data was collected, yet no results were presented. Recruitment was poor: only 29 
women entered to the study. Data is only reported on 21 of these women [Table 2.5]. The 
study was underpowered, and despite excluding women who did not complete the study, 
showed was no improvement in adherence by any measure.  (52) 
Hardy et al examined the use of a personalised reminder system in the United States. Adult 
participants with self-reported poor adherence (<85%) at three or more months into ART 
were drawn from a tertiary hospital setting and were randomised 1:1 to either receive a 
beeper or a mobile phone, as well as $30 cash incentive for each visit ($90 in total). The 
beeper gave a single reminder beep at the time of dosing. Those who received mobile 
Text messages did not impact on adherence in women from Brazil in this short low quality 
study. 
This short study showed that text messages improved adherence in a small number of people 
from the United States. 
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phones were sent daily personalized text messages as reminders instead [Table 2.4]. 
Content was drawn from a participant interview and could include a joke, weather updates 
or current news items. The intervention ran for 6 weeks and adherence was measured using 
self-report, tablet return and MEMS. No biological outcomes were reported. Twenty-three 
participants, with a median age of 43 years, were randomised, and 19 completed the study. 
Data is only reported on these 19. MEMS adherence was significantly higher in the text 
message arm, but did not differ by other measures [Table 2.5]. 
 
Ikeda at al presented an abstract at the International AIDS conference in 2012, which has 
not yet been published. This group used text messaging to explore improvements in viral 
load outcome in Guatemala, where, like South Africa, there are more registered mobile 
phones than people. HIV-positive adults initiating ART at a clinic were randomised to receive 
a reminder text message at the time of their evening dose, for three months and could also 
call an educator if needed [Table 2.4]. Outcome was time to first viral load suppression, and 
suppression at 12 months. No adherence was quantified. The 118 people in the intervention 
arm achieved viral suppression in a median time of seven months, compared to 10 months 
in the 108 people in the control arm. At 12 months, those in the intervention arm were at 
lower risk of viral failure than the control arm: RR 0.36, 95%CI 0.25-0.51). Some details of 
this study, such as power, randomisation process and messaging system used are not 
specified in the abstract, so it was not possible to fully assess study quality [Table 2.5].(130) 
 
Text messaging improves viral suppression at 12 months in this study from Guatemala. 
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Table 2.4 Reviewed studies, structure, population and structure of interventions 
Author name Year Country n Setting Study 
design 
Type of 
patient 
Randomisation Control Intervention 
Bigna (132) 
(MORE CARE) 
2014 Cameroon 242 3 district 
hospitals: 
urban, semi-
urban &rural. 
RCT Adult-child 
pairs (naïve or 
non-naïve) 
Block 
randomization 
1:1:1:1, well-
described. 
SoC: no pre-visit text 
message or call 
 SMS (48hours before visit) or 
 Call (48hours before visit) or  
 SMS (72hours) and call 
(48hours) before visit 
da Costa (52) 2012 Brazil 29 Tertiary 
hospital 
RCT Adult women 
(naïve or non-
naïve), VL 
suppressed. 
1:1, in blocks 
of 20, well-
described 
SoC: treatment literacy by 
multi-disciplinary team 
(blinded to arm). 
SMS timed before dosing 
M/W/F/S/S.  
Hardy(51) 2011 United 
States 
23 Tertiary 
hospital 
RCT Adults noted 
non-adherent 
(SR<85%); ≥3 
months on 
ART. 
1:1, well-
described. 
Beeper at time of dosing SMS: personalised texts daily 
at time of dosing. Given a 
mobile phone (to 
standardise, but allowed 
unlimited calling).  
SMS reply required 
Ikeda (130) 2012 Guatemala 226 Outpatient HIV 
clinic 
RCT Adults, naïve  Not stated 
(abstract only) 
SoC: instruction on 
medication dosing at 
monthly visits. 
SMS reminder at time of 
evening dose for 3 months; 
24-hour number for an 
educator. 
Lester (50) 
(WelTel Kenya1) 
2010 Kenya 538 3 outpatient 
HIV clinics: 
diverse 
settings 
RCT Adults, naïve  1:1 random 
number 
generating 
programme. 
SoC: 3 counselling sessions as 
started ART (2 pre-ART, 1 at 
month 1). Support group 
encouraged. 
SMS on Mondays with health 
enquiry.  
SMS reply required. Called if 
no response within 48 hours. 
Maduka (53) 2013 Nigeria 104 Tertiary 
hospital 
RCT Adults noted 
non-adherent 
(<95%); ≥3 
months on 
ART. 
1:1, process 
clear. 
SoC: pre-treatment 
education in a group; 
admonitions by doctors or 
pharmacists at visits. 
SMS twice weekly. 
SMS reply preferred. Called if 
requested. 
AND monthly 1 on 1 
adherence counselling 
Mbuagbaw (133) 
(CAMPS) 
2012 Cameroon 200 District 
hospital. 
RCT Adults , 
≥1month on 
ART 
1:1, process 
clear. 
SoC SMS weekly, phone number 
to call if needed.  
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Author name Year Country n Setting Study 
design 
Type of 
patient 
Randomisation Control Intervention 
Musser (131) 2001 US 22 Not specified. RCT Adults, non-
naive. VL 
suppressed. 
Not specified SoC SMS: daily messages x 2 
weeks. 
SMS reply required. 
Orrell (134) 2015 South 
Africa 
230 Outpatient HIV 
clinic 
RCT Adults, ART 
naïve 
1:1, process 
clear. 
SoC (3 pre-ART education 
sessions and a home visit) 
SMS if dosing more than 
30minutes late;  
Adherence reports in clinic 
folder for clinicians to review. 
Pop-Eleches (107) 2011 Kenya 431 Outpatient HIV 
clinic  
RCT Adults , 
<3months on 
ART 
1/3 to control, 
2/3 allocated 
1:1:1:1 to 
intervention. 
SoC (n=139)  SMS daily – long, or 
 SMS daily – short, or 
 SMS weekly – long, or 
 SMS weekly – short. 
Given a Nokia phone.  
Sabin (62) 2015 China 120 Outpatient HIV 
clinic  
RCT Adults, naïve. 
stratified by 
adherence at 
3 months. 
Two strata - 
optimal (≥95%) 
or suboptimal 
adherence. 
Both 
randomised. 
SoC SMS if dosing more than 
30minutes late;  
Adherence reports discussed 
with participant at visits. 
Shet (135) 2014 India 631 2 public sector 
private sector 
outpatient HIV 
clinics 
RCT Adults, ART 
naïve 
1:1, process 
clear. 
SoC (three pre-ART 
counselling sessions) 
Automated voice call: 
weekly, which required a 
response (4 call attempts). 
SMS sent out 4 days after 
weekly message. 
Given mobile phone. 
 
ART = antiretroviral therapy n = number; RCT = randomised controlled trial; SoC = standard of care; SMS = text message; VL = viral load. 
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Table 2.5. Reviewed studies – intervention details, outcome measures and results. 
Author Interven-
tion  
Message 
content 
Message 
timing 
Auto-
mated 
Required 
response? 
Adherence 
measure 
Biological 
measure 
Duration Outcome Criticism Outcome 
summary 
Bigna 
(132) 
(MORE 
CARE) 
SMS or 
call 
Date and time 
of visit, clinic 
name and 
name of 
doctor. 
Before a 
clinic 
visit 
No No –used 
delivery 
notifica-
tion. 
Efficacy: 
adherence to 
clinic visit / 
presence at  
appt (%) 
None 3   
months 
Efficacy cf. control:  
 SMS only OR 2.9 (CI 1.3-6.3);  
 Call only OR 5.5 (CI 2.3-13.1);  
 Both OR 7.5 (CI 2.9-19.0) 
NS difference between arms and 
no synergy. 
Short: 
intervention 
used for only 
1 
appointment 
per pair. 
Adherence 
better 
da Costa 
(52) 
SMS "Take good 
care of your 
health" 
Pre-dose, 
M/W/F 
/S/S 
Yes No SR (30 days),  
TR and  
MEMS 
None 4  
months 
Adherence (%>95%) by (C vs I):  
 SR 84% vs 100% (p=0.24) 
 TR 38% vs 50% (p=0.60) 
 MEMS 46% vs 75% (p=0.19) 
NS by any adherence measure 
Short: 
Not ITT - 
randomised 
29, presented 
21. 
 
NS 
Hardy (51) SMS or 
beeper 
Varying, 
drawn from 
patient 
interviews 
(jokes, news, 
weather) 
Daily, 
pre-dose 
Yes Yes SR (7 day),  
TR and 
MEMs 
None 1.5  
months 
Adherence (%) by (C vs. I): 
 SR 72% vs 92% (p=0.07) 
 TR 69% vs 83% (p=0.15) 
 MEMS 56% vs 90% (p<0.01).  
Short. 
Not ITT – 
randomised 
23, presented 
19. 
Adherence 
better 
Ikeda (130) SMS Not specified Daily, 
pre-dose 
Not 
speci-
fied 
No None VL 12  
months 
Increased VL suppression in 
intervention arm at 12 months: 
RR 0.36 (CI 0.25-0.51)) 
Not yet 
published 
Biological 
better 
Lester (50) 
(WelTel 
Kenya1) 
SMS  "How are 
you?" 
Response: 
"well" or 
"problem". 
Weekly 
(M 
morning) 
No Yes SR (30 days)  
 
VL 12   
months 
Adherence (%>95%) by (C vs I):  
 SR 49% vs 62%, RR 0.81(CI 
0.69-0.94) and  
VL suppression: (C vs I) 48% vs 
57%, RR 0.84 (CI 0.71-0.99) 
  Adherence 
and 
biological 
better 
Maduka 
(53) 
SMS and 
counsel-
ling 
Pre-scripted, 
adherence 
information 
and dosing 
reminder. 
Twice 
weekly 
(M/Th 
morning) 
Yes Yes 
(preferred) 
SR (7 day) CD4 4   
months 
Adherence (%>95%) by (C vs I): 
 SR 55% vs 77% (p=0.02).  
CD4 count increase (C vs I): 231 
vs 382 (p<0.01).  
Combination 
strategy 
used; effect 
may be from 
counselling. 
Adherence 
and 
biological 
better 
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Author Interven-
tion  
Message 
content 
Message 
timing 
Auto-
mated 
Required 
response? 
Adherence 
measure 
Biological 
measure 
Duration Outcome Criticism Outcome 
summary 
Mbuagbaw 
(133) 
(CAMPS) 
SMS 11 varied 
motivational 
messages, 
with phone 
number.  
Weekly 
(W 
morning) 
No No – used 
delivery 
notifica-
tion. 
SR (7 day),  
VAS (7 day) 
PR 
None 6   
months 
Adherence (%>95%) by (C vs I): 
 SR RR1.01 (CI 0.87-1.16),  
 VAS RR1.06 (CI 0.89-1.29),  
 PR mean difference 0.1 (CI -
0.23-0.43). 
No biological 
outcome. 
NS 
Musser 
(131) 
SMS Uniform 
reminder 
message 
 Daily Not 
given 
Yes. SR (14day) None 0.5  
months 
Adherence (%): 
 SR OR2.03 (0.48-8.48) 
No biological 
outcome.  
NS 
Orrell 
(134) 
SMS 5 short 
reminder 
messages, 
chosen by 
participants 
30 
minutes 
after 
missed 
dosing 
Yes No Wisepill 
(electronic pill 
box) 
VL  12   
months 
Adherence(%) by (C vs I): 
 Electronic cumulative 80% vs 
82%, OR1.08 (CI 0.77-1.52) 
VL <40 copies/ml (C vs I): 69% vs 
65%, OR  0.77 (CI 0.42-1.4) 
 NS 
Pop-
Eleches 
(107) 
SMS Short: 
reminder. 
Long:  
reminder  &  
motivational 
message. 
Daily or 
weekly, 
midday. 
Yes No MEMs (3TC) None 12.. 
months 
Adherence (%>90%) by (C vs I): 
 MEMS 40% vs 53% (p=0.03) 
weekly. 
 MEMS 40% vs 47% (p=0.27) 
daily 
Content of message: NS. 
No biological 
outcome 
Adherence 
better 
Sabin (62) SMS 10 short, 
reminder 
messages 
chosen by 
participants. 
30 
minutes 
after 
missed 
dosing 
Yes No Wisepill 
(electronic) 
CD4 
VL 
6   
months  
Adherence (%) by (C vs I): 
 Electronic 89% vs 96% 
(p<0.01); similar for both 
strata.  
CD4 increase (C vs I): 28 vs 52 
(p=0.3); VL <40 copies/ml (C vs I) 
94% vs 98% (p=0.22) 
 Adherence 
better 
Shet (136) Automat
ed voice 
call 
Customised 
motivational 
message, 
dosing 
enquiry. 
Pictoral SMS 4 
days later. 
Weekly 
call, 
weekly 
SMS. 
Yes Yes TR VL  24 
months 
Adherence (%<95%) by (C Vs I): 
TR 22% vs 27%, IRR 1.24 (CI 0.93-
1.65) 
VL >400 copies/ml ( C vs I): 
15.5% vs 15.6%, HR 0.98 (CI 
0.67-1.45). 
Unclear if 
LTFU (7-9%) 
and deaths 
(6-7%) were 
classified as 
complete or 
as failures. 
NS 
Adh = adherence; apt = appointment; C vs I = control vs intervention; CI = 95% confidence intervals; HR = hazard ratio; IRR = Incidence rate ratio; ITT =  intention to treat; 
LTFU = loss to follow-up; NS =  not significant; OR = odds ratio; RR = relative risk; SoC = standard of care; VL = viral load. 
The study from Lester et al published in 2010 was the initial study that showed benefit of 
weekly text messages with improvement in both adherence and virological outcomes in an 
ART-naïve cohort from Kenya. This study was reviewed above (page 60). Standard of care 
included treatment literacy sessions before starting ART and support groups were 
encouraged. Weekly enquiries after a participant’s health were sent as a text message those 
in the intervention arm and a response was required. Those who requested input and non-
responders were called by a nurse [Table 2.4]. Both adherence (SR) and biological outcomes 
(VL) were assessed. The median age of participants was 37 years. The text message 
intervention significantly improved both adherence and virological outcomes [Table 2.5]. 
The study data was of good quality, it was well-powered and the randomization process was 
clear. Both intention to treat and per-protocol analyses were presented. This study, 
together with the study from Pop-Eleches, forms the basis of many recommendation to use 
electronic reminders to improve ART outcomes. (50, 107)  
In 2013, Maduka at al from Nigeria published a RCT describing the impact of a combination 
intervention: text messages and monthly one-on-one adherence counseling, also described 
as motivational interviewing, for four months. Only adults with known poor adherence after 
at least three months of ART were included. Adherence was measured by self-report, and 
CD4 cell counts were monitored pre- and post-intervention. The study was short, but well-
powered and the randomisation process was clear. The mean ages of the 104 participants 
were 35-36 years. Pre-intervention CD4 cell counts and adherence were not significantly 
different between the groups. Both adherence by self-report and CD4 cell count increases 
were better in the intervention group. Knowledge of drug names and dosing instructions 
also improved in the intervention group after the 4 counselling sessions. Although this is a 
high quality study, the impact of the text messages cannot be separated from the 
counselling intervention.(53) 
Text messaging improved viral suppression at 12 months in this good quality study from 
Kenya. 
This mixed intervention study from Nigeria showed that text messages and counselling 
improved adherence and CD4 cell count response. 
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Mbuagbaw et al presented the Cameroon Mobile Phone SMS trial (CAMPS) in late 2012. 
This was a RCT, including adults on ART for more than one month. Standard of care is not 
described, but the intervention included a weekly text containing a variety of interventional 
messages, and a number to call in need. No reply was required but delivery notifications 
were monitored. Adherence was measured using self-report (dose recall and visual 
analogue scale) as well as pharmacy refill data over 6 months, but neither CD4 cell count or 
viral load were reported [Table 2.4]. The study was well-powered and intention to treat 
analyses were presented. The randomisation process was sound. Two hundred participants 
were randomised, with a mean age of 39-41 years. There was no significant improvement in 
adherence by any of the three measures in the intervention arm [Table 2.5]. Although this 
study data is of good quality and uses weekly text messages similar to Lester et al, this 
intervention has no impact in this cohort. (50, 53) 
Musser wrote a dissertation for the University of Missouri-St. Louis in 2001 which has not 
yet been published. Data from this study was presented in one of the reviews.(119) This 
author could not access the dissertation. Adults needing ART, but with suppressed viral 
loads, in the United States were randomised to receive SoC or text messages for 14 days. 
Text responses to the messages were required. Details of site and randomisation were not 
available [Table 2.4]. Adherence was measured using self-report at two weeks; with no 
biological outcomes reported. These small numbers resulted in wide confidence intervals 
which crossed unity and so the outcome was not significant.[Table 2.5]. (131) 
The main intervention outcome study for this thesis was published by this author (Orrell et 
al) in 2015. The manuscript is presented as Chapter three (page 89), but the details have 
This well-structured study from the Cameroon showed no benefit of weekly text messages on 
adherence. 
This unpublished study from the United States showed no benefit of bi-directional text 
message on adherence over two weeks  
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been added to Tables 2.4 and 2.5 for completeness. Text messaging was used in this study 
only when a dose was missed, as noted by non-opening of the Wisepill® device. Both 
adherence and biological outcomes were presented. Randomisation was 1:1 and properly 
performed. On intention to treat analysis, reminder text messages did not improve overall 
adherence as measured by this electronic pill-box, nor were virological outcomes improved. 
(134) 
Pop-Eleches et al published the second paper from Kenya showing benefit of text messaging 
in 2011. Details of this study have also been presented above (page 60). In short, adults who 
had initiated ART within the previous three months were randomised to receive SoC, daily 
or weekly text messages. The content of the messages could be short (reminders) or long 
(reminder and motivational message) [Table 2.4]. Messages did not require a reply. 
Adherence was monitored using MEMS caps lids on lamivudine bottles . No biological 
measure was reported. The study was well-structured and the randomisation complex, but 
clear. Only weekly messaging showed an improvement in MEMS adherence over the SoC. 
Daily messaging did not improve adherence, and the content of the messaging also did not 
impact [Table 2.5].(107) 
A recent study published by Sabin et al, from China, used a similar intervention to this 
author. ART-naïve adults were recruited and stratified at three months into two optimal and 
sub-optimal adherence strata [Table 2.4]. Each strata was randomised to receive SoC or SoC 
with reminders 30 minutes after a missed dose. Feedback based on device-generated dosing 
data was given to each participant at clinic visits. Randomisation was clear and analysis was 
intention to treat. Adherence was measured electronically using the Wisepill® device and 
both CD4 cell count and viral load were measured. After a 3 month lead-in period, 119 
Our RCT from South Africa showed no benefit on adherence or biological outcomes of reminders 
after a missed dose. 
This Kenyan study showed adherence benefit of weekly messaging, with no reply was 
required.  
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adults were randomised in two strata. Overall, adherence improved in the intervention arm, 
with more of an effect seen in those in the sub-optimal adherence arm. However, no 
improvement in CD4 or VL outcome was noted at 6 months [Table 2.5].(62)  
The last of the manuscripts for review was by Shet et al in 2014. This RCT was conducted in 
ART-naïve adults from three HIV outpatient clinics in India. The intervention included a 
customized automated voice call and a text message. The voice call included a greeting, a 
health enquiry, and a dosing related question, which required a response through pushing 
“1” for yes or “2”for no [Table 2.4]. Language and gender of the voice call could be chosen. 
A neutral pictorial text message was sent four days later. Outcome was measured by tablet 
return and viral load. Analysis was by intention to treat and the randomisation process was 
clear. The 631 randomised participants were followed for 24 months. AT this point there 
was no significant difference in adherence by tablet return or risk of virological failure (>400 
copies/ml) [Table 2.5]. This is the largest and longest study using mobile phone reminders in 
the HIV field to date and again does not show benefit from these reminders.(135)  
Discussion 
The few studies described here have been the subject of multiple reviews. Three examine 
mobile phone interventions specific to improving ART outcomes: the first was a Cochrane 
review in 2012 by Horvath et al and included only the Kenyan studies by Lester and Pop-
Eleches. (50, 107, 121). The next, by Mbuagbaw et al, in 2013, included the same two 
studies as well as a third by the review author.(120, 133) A year later Finitsis et al’s review 
included eight studies (50-52, 107, 131, 133), two of which have not been reviewed here 
(137, 138) as they used pagers or alarm devices and not mobile phone technology.(119) All 
three reviews support the use of text messaging, and suggest weekly messages with an 
This short RCT from China showed an improvement in adherence, but not biological 
outcomes, with reminders after missed doses. 
This large study from India showed no adherence or biological benefit of automated calls and 
text messages over 2 years. 
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interactive component are optimal. This ties in with the recommendation from Thompson 
et al, in 2012, that “reminder devices and the use of communication technologies with an 
interactive component are recommended”.(5)  
Another review of adherence methodology by Barnighausen in 2011, also suggested that 
mobile phone text messages can increase adherence in a sub-Saharan Africa setting. A more 
recent review, however, is the first to note that while there is strong evidence that such 
interventions can improve adherence, there are also good studies showing no evidence of 
benefit.(111) 
Of the 12 studies reviewed here, five (42%) showed no benefit of text messages or 
automated voice calls on either adherence or viral loads. In addition the daily text arm from 
Pop-Eleches study also showed no benefit. All were randomised studies. Two however, by 
da Costa and Musser, should perhaps be classified as pilot studies as they were short (4 and 
0.5 months respectively) and included fewer than 30 participants each. (52, 131) The other 
four were substantive studies from Africa or India involving 200 or more adult participants 
either ART-naïve or within a few months of starting ART. (133-135) In each the messaging 
and study duration differed. Shet used a combination intervention of a weekly automated 
call followed by a message over 24 months.(135) Orrell used messages when only dosing 
was missed over a 12month period and Mbuagbaw used weekly texts over 6 months and 
Pop-Eleches used daily text messages over a year [Figure 2.6]. (107, 120, 134) Only Shet’s 
messaging system required participant feedback (bidirectional) [Figure 2.7]. Shet and Orrell 
reported a lack of benefit on virological outcome, whereas Mbuagbaw did not report a 
biological response.  
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Another 4 studies (33%) showed adherence benefit without biological benefit: three did not 
report any CD4 or VL outcome (Hardy, Bigna, Pop-Eleches) and one reported no 
improvement in either (Sabin). Two studies included adults noted to be non-adherent, one 
included naïve adults and the last used a mixed naïve / non-naïve population [Figure 2.8]. 
Bigna used calls vs text messages vs both and saw no difference between the arms, although 
all three were better than SoC. The successful intervention in Pop-Eleches used weekly text 
messages. Hardy sent daily reminders at the time of dosing and Sabin sent reminders only 
when a dose was missed [Figure 2.6]. Three of the four studies (Bigna, Pop-Eleches, Sabin) 
did not require participant feedback [Figure 2.7].  
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The remaining 3 studies (25%) showed improvement in both adherence and biological 
outcomes. Both Lester and Maduka’s studies had addition human resource intervention: 
Maduka combined automated twice-weekly text with monthly counseling sessions and 
Lester had a nurse call people who requested input after the weekly message [Figures 2.6 
and 2.7]. Ideka showed benefit from daily dose-linked text messages with no response 
required. Only Lester and Maduka presented adherence data: both self-report. Maduka 
selected adults known to be non-adherent and the others included a naïve adult cohort 
[Figure 2.8] 
Outcome measures: While the seven of twelve (58%) studies show some benefit, the 
remaining five do not. If viral load suppression is taken as the best measure of ART success, 
then only two studies achieve that goal (17%) [Figure 2.5]. While improving adherence in 
the early stages of treatment when the viral  load is still high is considered especially 
important, and such interventions might help to create good future tablet taking habits; 
essentially, improved adherence without biological benefit is likely to have no long-standing 
value. Here, three studies showing adherence benefit alone did not measure viral load 
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outcomes, an unfortunate omission which compromises the value of their studies.(51, 107, 
139) 
Of note, there is no consistent method used to measure adherence, reflecting the lack of 
clarity about best methods to use [Table 2.5]. Reassuringly, only the oldest study used self-
reported adherence as a sole outcome measure.(131) Others that used SR either included 
an objective measure in addition or included the viral load results.(50-53, 133) In more 
recent studies there is a positive trend toward the use of electronic devices to monitor 
adherence.(51, 62, 107, 134) While electronic monitoring is not available in or 
recommended for programmatic settings at present, the use of best-available methods 
while conducting research cannot be faulted. (5) 
 
Population:  The majority of studies included naïve adults. Bigna et al. examined adult-child 
pairs, but the intervention remained focused on the adults.(132) No key populations at 
increased risk of failure were explored. The impact of any intervention will be diluted in a 
naive population as the majority those in sub-Saharan cohorts achieve viral suppression at a 
year in their current programmes anyway.(31, 32, 40) There is only room for the 
intervention to work in a sub-set of a naïve population. Neither study that selected patients 
who had already achieved viral suppression noted any benefit, perhaps as this group had 
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already established reasonable tablet taking patterns.(52, 131) In contrast, all three studies 
that identified non-adherent adults showed adherence benefit.(51, 53, 62) Here, where the 
intervention is targeted to those most in need of this type of support, more impact is 
realized [Figure 2.8].  
Intervention: there were seven different types of call/message intervention, reducing in 
frequency from daily text messages, to five times a week messages, to twice weekly, to 
weekly [Figure 2.6]. The fewest messages would have been sent in those being reminded of 
missed doses.(62, 134) Due to concern about message fatigue and the success of weekly 
messages in Pop-Eleches and Lester’s studies more recent studies use weekly messaging, or 
post-dose reminders [Table 2.5]. However, there were both unsuccessful studies using 
weekly messages and successful ones using daily messages. Message content does not 
appear to have alter outcomes. This was measured directly in Pop-Eleches study, (107) but 
can be seen across the other studies presented here. Five studies used motivational 
messaging (50, 52, 107, 133, 135), with a range of results [Table 2.5]. The rest used short 
reminder messages or factual appointment information, also with a range of outcomes from 
no significance to improving all outcome measures. 
2.4. Conclusion. 
In 2015, the enthusiastic response to the Kenyan studies may have to be tempered. It 
cannot be said that all mobile phone interventions have benefit. While the trend toward a 
positive outcome cannot be doubted, future studies must prove virological as well as 
adherence benefits, and preferably explore adherence behaviour over a longer duration as 
expanded ART access in Africa heads into its second decade.  
Large numbers of people need care. A method of monitoring adherence to identify those 
more in need of support within the first few months of ART could reduce burden on ART 
programmes by allowing early streamlining of care. In our setting, most people who become 
lost to care in the first year are lost within the first 16 weeks.(134, 140) Those people could 
be offered a choice from a menu of increased support, based on interventions known to 
improve adherence e.g. food rations (page 59), educational or counseling interventions 
(page 50) or text messaging to connect more frequently with their health care team (pages 
60 and 71). Similarly, those who do well could also be identified early and the intensity of 
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their care reduced or offered from a non-clinic venue (page 56).(141) While more research 
is needed, electronic monitoring and mobile technology should allow us to tailor 
programmes, if not completely to an individual’s needs, at least to an option that most suits 
that person’s requirements.  
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Chapter three: A randomised controlled trial of real-time electronic 
adherence monitoring with text message dosing reminders in people starting 
first-line antiretroviral therapy.  
Authors: 
Catherine Orrell, Karen Cohen, Katya Mauff, David R. Bangsberg, Gary Maartens, Robin 
Wood. 
Publication status: 
Published: Journal of Acquired Immune Deficiency Syndromes, 2015 Dec 15;70(5):495-502. 
Synopsis:  
This manuscript shows the impact that a locally developed real time adherence monitoring 
device (Wisepill®) with an immediate text message dosing reminders has on adherence and 
treatment interruptions. 
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Abstract. 
Background: There are conflicting findings about whether mobile phone text message 
reminders impact on antiretroviral adherence. We hypothesized that text reminders sent 
when dosing was late would improve adherence and HIV viral suppression. 
Methods: ART-naïve participants, from a South African outpatient ART clinic, were 
randomised to standard of care (SoC, three pre-treatment education sessions), or 
intervention (SoC and automated text reminders if dosing >30 minutes late). Dosing time 
was recorded by real-time electronic adherence monitoring devices (EAMD), given to 
participants at ART start. CD4 cell count and HIV RNA were determined at baseline, 16 and 
48 weeks. Primary outcome was cumulative adherence execution by EAMD. HIV-1 viral 
suppression (<40 copies/ml) at week 48 and count of treatment interruptions (TIs) >72 
hours were secondary outcomes. Analysis was by intention to treat (missing=failure). 
Registration was with the Pan-African Clinical Trials Registry: PACTR201311000641402. 
Results: 230 participants were randomly assigned to control (n=115) or intervention (n=115) 
arms. Median adherence was 82.1% (IQR 56.6-94.6%) in the intervention arm, compared to 
80.4% (IQR 52.8-93.8%) for SoC (adjusted odds ratio (aOR) for adherence 1.08, 95%CI:0.77-
1.52). Suppressed HIV RNA (<40 copies/ml) occured in 80 (69.6%) of control and 75 (65.2%) 
of intervention; aOR for virological failure in intervention arm 0.77, 95%CI:0.42-1.40). In the 
intervention arm the count of TIs of >72hours was reduced (adjusted incident rate ratio 
0.84, 95%CI:0.75-0.94). 
Conclusion: Text message reminders linked to late doses detected by real-time adherence 
monitoring reduced the number of prolonged treatment interruptions, but did not 
significantly improve adherence or viral suppression.  
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Introduction.  
Increasing numbers of HIV-positive individuals are receiving antiretroviral therapy (ART) in 
resource limited countries such as South Africa.(6) While early concerns about poor 
adherence to antiretroviral therapy (ART) among HIV-positive individuals have proved 
untrue in sub-Saharan Africa (27, 142), treatment expansion to earlier stage disease, 
however, is creating new adherence challenges, including treatment interruptions and 
treatment failure.(15, 25, 31, 32) Reliably measuring and improving adherence to first-line 
therapy is a key component of the 2013 World Health Organisation (WHO) consolidated 
guidelines. (110)  
Electronic adherence monitoring, linked to text message adherence interventions, 
potentially offers a scalable and accurate adherence monitoring strategy and personalised 
adherence intervention.(5, 110) As in many low to middle income country settings, South 
Africa has a well-developed mobile phone network and a high proportion (87%) of the South 
African population has a mobile phone. (85, 143)  
Mobile phone text message reminders have had variable success at improving adherence. 
Of nine recent randomised controlled (RCT) studies, using text messaging or automated 
voice messages as an intervention, six have shown some improvement in adherence. (50, 
51, 53, 62, 144, 145) Two of these also noted improvement in a biological outcome, either 
HIV RNA or CD4 cell count. (50, 53) The other three RCTs showed no improvement, either in 
adherence as measured by self-report or tablet return, or in biological outcome. (52, 133, 
135) Many of these studies were of short duration: of 6 months or less.(51-53, 62, 133, 145) 
Most used messaging in a cyclical manner, usually once or twice weekly, so as not to induce 
message fatigue. Only one study to date has linked mobile phone text message reminders to 
real-time detection of missed doses. (62) 
We conducted a randomised controlled trial to determine whether text messages triggered 
by missed doses would improve overall daily adherence execution in ART-naïve South 
African adults commencing ART. We also examined the impact of the reminder messages on 
the frequency of treatment interruptions and HIV-1 RNA suppression. 
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Methods. 
Participants and setting:  
The Hannan Crusaid Treatment Centre (HCTC) in Gugulethu, Cape Town is a large public 
sector urban ART outpatient clinic which provides free ART to 7500 HIV-positive individuals. 
From 2012-2014, multidisciplinary clinic staff included three medical officers, three nurse 
practitioners, seven clinic-based counsellors and 18 community care workers as described 
elsewhere.(38) During the period of this study ART-naïve individuals could access ART with 
clinically advanced disease or a CD4 count of <350 cells/uL according to the South African 
National ART Guidelines.(10, 146) 
Standard of care:  
Treatment preparedness: All ART-naive individuals attending the site received three group 
treatment preparedness sessions prior to or within the first month of commencing ART. 
These sessions were delivered by HIV-positive peer counsellors. The information included 
details about HIV (e.g. what are HIV and a CD4 cell; the importance of the HIV RNA), the ART 
to be prescribed (including possible side effects, the important of daily adherence and the 
consequences of poor adherence) as well as advice on healthy living with HIV. All individuals 
were given a plastic 7-day pill-box on the day they commenced ART. 
Antiretroviral therapy: First-line ART in South Africa at the time of the study included 
tenofovir, lamivudine and efavirenz, given as three separate tablets once a day. Towards the 
end of the study period in October 2013, a fixed dose combination (FDC) became available, 
but priority was given to naïve patients entering care and few of the study participants were 
switched to the FDC during the study. Zidovudine, stavudine, nevirapine and lopinavir in 
combination with ritonavir were available as alternative agents. 
Clinical visits and laboratory sampling: Individuals attended the clinic twice prior to 
commencing ART and then on day 1 of treatment; after which they attended every four 
weeks to collect ART and be reviewed by a clinician until week 16. Subsequently they 
attended every eight weeks to collect ART with clinical review every 16 weeks. A CD4 count 
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was completed prior to starting treatment and at week 48, and an HIV-1 RNA was drawn at 
weeks 16 and 48 (and both annually thereafter).(146)  
Adherence monitoring: Tablet returns were counted at every visit where ART was dispensed 
in all participants. Peer counsellors counted the returns and calculated the percentage of 
tablets taken from the last dispensing to the current dispending date. This was recorded in 
the clinical notes prior to the individual seeing the clinician. All participants with tablet 
count adherence less than 90%, or viral RNA >40 copies/ml, received additional adherence 
counselling which included an individualised education session with a peer counsellor and 
monthly dispensing with clinician review until adherence improved.  
Missed clinic visits: A tracking list was generated for all missed visits at the end of each 
month. Individuals were added to this list if they were more than four weeks late for an 
appointment i.e. no clinic visit, blood draw or ART dispensing had occurred in the last eight 
weeks for those in the first 16 weeks of therapy, or within the last 12 weeks for those after 
16 weeks on ART. All those on the community tracking list were called by a community care 
worker and, if they could not be contacted by phone, visited at home. This process was 
repeated every week for up to three attempts. . If tracking was unsuccessful the individual 
was classified as lost to follow-up. 
Study design:  
The study was a randomised controlled trial in ART-naïve individuals attending the HCTC, 
investigating the impact of a real-time electronic adherence monitoring device (EAMD), 
called Wisepill®, on adherence to ART over 48 weeks. All participants received the EAMD on 
study entry, in exchange for the plastic pillbox given by the clinic on ART commencement, 
and were randomised to either: 1) standard of care (described above, with Wisepill device in 
lieu of the pillbox) or 2) reminder text messages linked to non-opening of the device.  
Inclusion and exclusion criteria: Participants were recruited from ART-naïve adults and 
adolescents (≥15years) commencing treatment at the HCTC. Possession of their own mobile 
phone was required for inclusion into the study. Written informed consent or, in the case of 
participants younger than 18 years, assent, was given by each participant. Entry into the 
study was offered consecutively to all eligible participants presenting to the clinic.  
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Study visits and sampling: All participants received care at the HCTC as per the standard of 
care detailed above. (25, 33) Participants were seen by study staff, in addition to their clinic 
visit, at their first visit to the clinic (screening visit), their first day of ART (day 1, baseline 
visit), and at weeks 16, 32 and 48 on treatment. Study staff included a study coordinator 
and three research assistants, who collected the study data and completed the 
questionnaires with each participant, but who offered no clinical care or adherence support. 
Study visits were timed to coincide with booked clinic visits to minimise inconvenience to 
the participant. Participants were reimbursed for local travel (R20 or ~US$2) at each study 
visit and in addition, for the three on-treatment study visits (weeks 16, 32 and 48), were 
given a gift of a T-shirt, bag or mug valued at R80 (~US$8) to compensate them for their 
time.  
Demographic and psychosocial details, including age, gender, weight, height, anxiety and 
depression scores using the 14 question Hospital Anxiety and Depression Score (HADS), 
alcohol abuse as assessed by the four-question CAGE score (Have you ever felt you should 
Cut down on your drinking; have people Annoyed you by criticizing your drinking; have you 
ever felt bad or Guilty about your drinking; and, have you ever had a drink first thing in the 
morning to steady your nerves or to get rid of a hangover (Eye opener)?)(147), and details of 
any friends or family to whom they had disclosed their HIV status were collected at the 
screening visit. (148, 149) Non-disclosure was defined as not having revealed his/her HIV 
status to anyone outside of the clinic. 
Blood was drawn by the study coordinator or the clinic nurse for CD4 cell count (FACS 
Count™, Beckton Dickinson, NJ, USA) and HIV-1 RNA (HIV-1 RNA 3.0 assay®, Bayer 
Healthcare, Leverkusen, Germany), at screening, weeks 16 and 48. Baseline HIV RNA and 
CD4 cell count at week 16 were the only samples drawn in addition to those routinely 
completed by the clinic. Prescribed ART and WHO clinical stage were recorded at the 
baseline visit. Participant’s eligibility for the study was confirmed and randomisation 
occurred thereafter. 
Self-reported three-day recall of adherence, questions on EAMD acceptability, disclosure 
status and the CAGE questionnaire were asked by the study counsellors at weeks 16 and 48. 
The 14-question HADS was completed again at week 48. Weight was measured and current 
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ART confirmed at all visits. At all visits mobile phone numbers were confirmed and note was 
made of participants on TB treatment or who were pregnant. 
Throughout the study, clinic adherence monitoring and tracing after a missed visit 
continued as per standard of care. The EAMD was returned and exchanged for a standard 
pill box at the end of study visit, 4 weeks after the week 48 visit. Participants were 
reimbursed R150 (~US$15) at this visit. 
Randomisation: Participants were randomized 1:1 to control and intervention arms. 
Allocation to study arm was concealed in sealed individual opaque envelopes, which were 
numbered from 1 to 230 and opened consecutively after a participant met study entry 
criteria. The random number sequence and envelopes were generated off-site. The 
envelopes were opened by the study nurse, blinded to the allocation, on-site. Staff (both 
study and clinic) and participants were not masked to arm allocation after randomisation.  
Adherence monitoring:  The Wisepill® device is a locally-produced electronic device the size 
of a mobile phone which can store up to a week of medication in a seven compartment pill 
box. (150) This EAMD has been used in other resource-limited settings to measure 
adherence. In these studies the device was shown to be reliable, and adherence by EAMD to 
be significantly associated with viral suppression.(60, 63) All participants received a 
Wisepill® device and were given additional internal pill boxes with instruction on refilling 
and replacing these weekly. On opening, a signal was sent in real time via the wireless 
telecommunications network to a secure central computer in Somerset West, Cape Town.  
Each EAMD gave a daily “heartbeat” signalling that it was still on-line and checking the 
battery voltage. Charged batteries lasted for about three months. Each participant was 
given a wall charger to use at home as well as the option of bringing their device to the clinic 
for recharging. If the “heartbeat” showed a low voltage, a message was sent to the 
participant reminding them to charge the device: “Sicela utshaje ibhokisi yakho yeepilisi 
okanje uyizise ekliniki sikutshajele. Please charge your Wisepill box or bring to the clinic so 
we can charge it for you”. In addition, a weekly low battery report was sent to the study co-
ordinator, who called these participants and reminded to charge their EAMD.  
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Intervention: All participant’s preferred daily dosing time was recorded in the Wisepill® 
system. Intervention participants received a text message if the device was not opened 
within 30 minutes of the scheduled dosing time. This window was chosen by the 
participants as they did not want to be woken by a later message (due to evening dosing of 
efavirenz regimens). The first five participants randomised were asked to construct a simple 
message that would remind them to take their tablets, but not disclose their HIV-status to 
others at home or in the community. These message options were then made available for 
the rest of the cohort, in either English or Xhosa. Once each participant in the intervention 
arm had chosen a message, they received the same message throughout the study when 
their dosing was late. Messages included “Have you forgotten something?” (Awulibelanga 
nto?), “Just take it!” (Yithathe!), “Wake up” (Vuka!), It’s 8 o’clock! (Ngu 8 o’clock!) or their 
study number (e.g.XX9999). In addition, for the intervention participants, a report of on-
time, late and missed doses over the previous 4 months was placed in their clinical folder for 
the ART clinician to review every 16 weeks during the study. 
Outcomes and statistical analysis: Participants were classified by the following retention in 
care outcomes prior to calculating the primary adherence and virologic outcomes: 
 Completed study: these participants were in care at the clinic at the time of the end of 
study visit. 
 Transfer out: some participants requested a transfer to another ART clinic. Transfer out 
date was recorded as the last date the participant attended the HCTC. These participants 
were censored at transfer out date.  
 Death: Deaths were ascertained from clinical notes or from discussion with the family. 
Date of death is usually clear, but if not, date of last contact with the clinic was used. These 
participants were censored at date of death.   
 Loss to follow-up (LTFU): Participants were considered LTFU if they had not attended the 
clinic, had blood drawn or collected medication for more than 12 weeks. In addition they 
could not be traced, as per standard of care for missed visits, and were not known to have 
transferred out or to have died. The date of LTFU was taken as the last date they attended 
the clinic. For per protocol analyses, these participants were censored at their LTFU date. 
For intention to treat analyses these participants were censored at their calculated week 
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48 date, i.e. the date of randomisation plus 336 days. EAMD opening data recorded after 
last date in clinic and before calculated week 48 date were included in the analysis. 
The primary outcome was adherence execution as measured by the EAMD. Adherence 
execution was calculated by the number of days the container was opened over the number 
of days in the period in care (for those who completed the study, transferred out or who 
died); and for the period from randomisation to calculated week 48 for those LTFU. Multiple 
openings on one day were truncated at 100%. Days without battery charge were censored.  
The adherence data were modelled both as categorical and continuous variables. A 
fractional logit model (continuous data assessed using a generalised linear model with a 
logit link) was used for the continuous data and a logistic regression model using a logit 
transformation was used for the categorical data. The cut-off for the categorical adherence 
data was informed by the median of the continuous data. We used an intention to treat 
approach for this primary outcome.  
Retention in care, virological suppression and number of >72 hour treatment interruptions 
were secondary outcomes. Those who completed the study or who were transferred to care 
elsewhere were considered retained in care. Those who died or were lost to follow-up were 
considered lost to care. The impact of the intervention on retention in care was modelled 
using a multinomial logistic regression model.  
The impact of the intervention on virological outcomes (both to <40 copies/ml and <400 
copies/ml) was modelled using linear mixed effect models. The impact of the intervention 
on the number of treatment interruptions was modelled using Poisson regression. 
Treatment interruptions were defined as interruptions of 72 hours or longer, i.e. 3 or more 
missed doses, as it has previously been shown that sustained missing of doses has more 
impact on virological outcome than single missed doses, with each day beyond two missed 
days increasing the risk of virological breakthrough.(17)  
Data were analysed using Stata 13.0 (Stata Corporation, College Station, USA). Descriptive 
statistics were used to summarise the baseline characteristics of the participant group. The 
Chi-squared test was used to compare proportions and the two-sample t-test to compare 
continuous variables. Variables were pre-selected for inclusion in the multivariate analyses. .  
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Role of funding source:  
The sponsors of the study had no role in the design and implementation of this study, nor in 
manuscript preparation. All authors had full access to the study data. CO developed the 
initial manuscript and all authors approved the submission. 
Ethical approval:  
The University of Cape Town Faculty of Health Science Research Ethics Committee gave 
approval to conduct this study. Each participant provided written informed consent or 
assent. The trial was registered in the Pan African Clinical Trials Registry, number 
PACTR201311000641402. 
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Results. 
Between July 2012 and April 2013, 319 participants were screened and 230 were 
randomised. Eighty-nine people were not randomised, due to the reasons given in Figure 
3.1. Baseline characteristics were similar between those who randomised and those who 
were not, as well as similar by randomisation arm (Table 3.1). The mean age of the enrolled 
cohort was 34.5 (±9.1) years, with 150 (65.2%) women. Median CD4 count at start was 
225.5 (IQR 133-287) cells/mm3. All participants had detectable HIV RNA at baseline. There 
was no significant difference in either HADS scores or the CAGE score at baseline by 
randomisation arm. 
Figure 3.1: Flow diagram describing the outcome of the 319 individuals screened and the 
230 individuals randomised to the study.
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Most participants were started on efavirenz-based regimens (n=228, 99.1%) and two on 
nevirapine-based regimens. All ART included lamivudine. The majority (n=225, 97.8%) were 
started on tenofovir as the second nucleoside reverse transcriptase inhibitor (NRTI). 
Depression (n=74, 32.1%), anxiety (n=89, 38.7%) and alcoholism (n=35, 15.2%) were highly 
prevalent. Most participants had disclosed their status to at least one other person (n=219, 
95.2%).  
Table 3.1 – Baseline demographic, clinical, treatment and psycho-social characteristics of 
participants by arm. 
  Control  Intervention p-
value 
N 115 115  
Female sex: n(%) 77 (67.0) 73 (63.5) 0.678 
Age in years:    mean (sd) 34.3 (9.0) 34.6 (9.2) 0.779 
Height (cm): mean (sd) 164.0 (8.6) 164.1 (8.6) 0.932 
Weight (kg): median (IQR) 68.4 (60.1-79.6) 67.0 (56.1-80.0) 0.320 
WHO stage: n(%) 
                        1 
                        2 
                        3 
                        4 
  
42 (36.5) 
24 (20.9) 
36 (31.3) 
13 (11.3) 
  
42 (36.5) 
23 (20.0) 
39 (33.9) 
11 (9.6) 
0.946 
CD4 count: median (IQR) 229 (136-292) 225 (121-283) 0.543 
Log HIV RNA (copies/ml): median 
(IQR) 
4.8 (4.4-5.4) 5.0 (4.5-5.4) 0.324 
Range of HIV RNA at baseline 
(minimum – maximum copies/ml) 
109 – 1 481 459 1 021 – 2 381 184  
NNRTI at start: n(%) 
Efavirenz 
Nevirapine 
  
115 (100.0) 
0 (0.0) 
  
113 (98.3) 
2 (1.7) 
0.498 
NRTI at start*: n(%) 
Tenofovir 
Zidovudine 
Stavudine 
  
114 (99.1) 
1 (0.9) 
0 (0.0) 
  
111 (96.5) 
3 (2.6) 
1 (0.9) 
0.361 
HADS depression score of 8 or 
above (borderline or case)** 
43 (37.4) 31 (27.0) 0.09 
HADS anxiety score of 8 or above 
(borderline or case)** 
51 (44.3) 38 (33.0) 0.08 
Non-disclosure 5 (4.4) 6 (5.2) 0.757 
CAGE ≥2 20 (17.4) 15 (13.0) 0.359 
* All were taking lamivudine or emtricitabine in addition. 
** Hospital Anxiety and Depression Score.  
 
The 230 participants were in care for a median of 380 days (IQR 359-414 days). Only one 
person withdrew consent during the study. The majority (n=186, 80.9%) remained in care at 
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the site and most also completed the study visits, as noted in Figure 3.1; or were transferred 
to care at another site (n=16, 6.9%). Nineteen participants (8.3%) were lost to follow up and 
eight (3.5%) died.  
Primary outcome - adherence:  
At week 48, there was no difference in median adherence by self-report or tablet return by 
arm. By tablet return, the median adherence was 100% in both arms (IQR 95-110% in the 
intervention arm and 94-100% in the control arm). By self-report, median adherence was 
100% in both arms (IQR 100-100% in both arms). 
Median adherence by EAMD was 82.1% (IQR 56.6-94.6%) in the intervention arm and, 
80.4% (IQR 52.8-93.8%) in the control arm. This difference was not significant either when 
modelled as a continuous variable (Table 3.2) or as a categorical variable in a logistic 
regression model, using adherence >80% as the cut-off value (model not shown). Age was 
the only variable significantly associated with adherence execution (Table 3.2). The number 
of pills taken, relative to the number of pills not taken, increased by 27% for each 10 year 
increase in age: OR 1.27 (95%CI 1.05-1.52). Gender, non-disclosure, anxiety and depression 
scores, as well as baseline CD4 cell count did not impact on adherence execution in this 
model.  
Table 3.2. Generalised linear model (GLM) of cumulative adherence by EAMD over time on 
study. (Data from 230 participants included in the model) 
Adherence  Odds Ratio Std. Error p-value  95% Confidence Interval 
Intervention arm 1.08  0.19  0.642  0.77 - 1.52 
Age*   1.02  0.01  0.014  1.00 - 1.04 
Anxiety score >8 1.05  0.19  0.797  0.74 - 1.49 
Depression score >8 0.74  0.14  0.100  0.51 - 1.06 
CD4    1.00  0.00  0.699  1.00 - 1.01 
Male sex  0.96  0.17  0.802  0.68 - 1.34 
Non-disclosure  0.72  0.30  0.368  0.32 - 1.63 
Screen CAGE ≥2 1.05  0.45  0.819  0.67 - 1.67 
*The number of pills taken, relative to the number of pills not taken, increases by 27% for 
each 10 year increase in age: OR 1.27 (95%CI 1.05-1.52).  
 
EAMD data revealed there were 82311 participant dosing days recorded; 40188 were in the 
intervention arm 42123 in the control arm. Of these, 8362 (10.1%) were dead battery days. 
Dead battery days were evenly distributed by arm.  
In the intervention arm 19142 text messages were sent to 114 individuals, equating to 
47.6% of doses not being taken within 30 minutes of the specified dosing time. The most 
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popular message was “Have you forgotten something?” in English, chosen by 31 (26.9%) 
participants; followed by “Vuka” chosen by 27 (23.5%). There was no difference in 
adherence execution by message. After the message, on 5340 occasions (13.2%) the EAMD 
was opened, in a median time of 22 minutes (IQR 6-47 minutes). There was no evidence of 
reminder fatigue by weeks on study. In the control arm 23255 (55.2%) of doses were taken 
on time, and on 4069 occasions (9.7%) dosing was taken later that day, without reminder.  
Figure 3.2 shows the median time (in minutes) from the dosing time specified by each 
participant to the actual time of dosing. The density on the y-axis reflects the probability or 
frequency of the dose being taken at each time point. More people in the control arm took 
their tablet on time while a subset of those in the intervention arm (solid line) waited for 
the text message at 30 minutes post-specified dosing time before dosing.  
 
Figure 3.2: Graph showing the median time (in minutes) from the dosing time specified by 
each participant to the actual time of dosing. The area under the curve equals to one, and 
the density (y-axis) shows the probability of patients taking their dose at that time point. 
More people in the control arm, (dotted line) dose on time. In the intervention arm (solid 
line) the effect of individuals waiting for the text message at 30 minutes after their specified 
dosing time can be seen. 
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Secondary outcomes – HIV RNA:  
At week 16, 198 of 230 (86%) participants had a HIV RNA available. 143 (72%) achieved a 
HIV RNA of <40 copies/ml: 73 of 97 (75.3%) in the intervention arm and 70 of 101 (69.3%) in 
the control arm. At week 48, of the 182 participants remaining in care, 155 (85.2%) had a 
HIV RNA of <40 copies/ml: 75 of 86 (87.2%) in the intervention arm and 80 of 96 (83.3%) in 
the control arm. There were 32 missing values at week 16 and 48 missing values at week 48. 
Using intention to treat analysis, where the missing values equalled failure, a mixed effects 
model showed no difference in the odds of virological failure (>40 copies/ml) in the 
intervention arm (OR 0.77, CI 0.41-1.4, p=0.393). Only a baseline HIV RNA of >5 log 
copies/ml significantly increased the chance of virological failure (OR 2.03, CI 1.1-3.9, 
p=0.034). The model is shown in Table 3.3. There was similarly no difference in virological 
outcome by arm using per protocol analysis where missing values were kept as missing 
values.  
Table 3.3: Linear Mixed effect model for virological failure (VL>40copies/ml at weeks 16 and 
48). Missing results equalled failure. 
HIV RNA > 40 copies/ml  OR  Std. Error p-value  95% 
Confidence Interval 
Intervention arm  0.77  0.23  0.393  0.42 - 1.40 
BMI* 0.96  0.03  0.195  0.91 - 1.02 
B-l VL >5 log copies/ml  2.03  0.68  0.034  1.05 - 3.91 
Age 0.97  0.02  0.143  0.94 - 1.01 
Male sex 0.91  0.33  0.800  0.45 - 1.86 
CD4 count 0.99  0.00  0.187  0.99 - 1.00 
Week 48 0.67  0.17  0.109  0.41 - 1.09 
* BMI = body mass index 
Secondary outcomes – treatment interruptions (TIs):  
The median duration of treatment interruptions was 8 (IQR 5-15) days, with no difference 
by study arm. However, using a Poisson regression model for estimation of incidence rate 
ratios (IRR), the count of treatment interruptions of >72 hours in the intervention arm was 
significantly less than in the control (Table 3.4). This was seen in both univariate analysis, 
where there was an 18% reduction in the count of these TIs in the intervention arm (IRR 
0.82, 95%CL 0.74-0.92), and in multivariate analysis (aIRR 0.84, 95%CI 0.75 – 0.94; p=0.003), 
as shown in Table 4, compared to control. Additional factors associated with TIs were age, 
which was protective. A 14% reduction in frequency of TIs was noted for each 10 year 
increase in age (aIRR 0.86, 95%CI 0.80-0.92). There was a 36% increase in the frequency of 
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TIs for those with a HADS depression score >8 (aIRR 1.36, 95%CI 1.21-1.53) and a 30% 
increased frequency of TIs in men compared to women (aIRR 1.3, 95%CI 1.15-1.47).  
Table 3.4: Poisson regression model for count of treatment interruptions (ITT, 230 
participants used in the model). 
Count of TI >72hours IRR Std. Error p value 95% Confidence Interval 
Intervention arm 0.84 0.049  0.003  0.75 - 0.94 
Age*   0.99 0.003  0.000  0.98 - 0.99 
Baseline CD4  0.99 0.000  0.616  0.99 - 1.00 
Male sex  1.30 0.079  0.000  1.15 - 1.47 
Anxiety score >8 0.96 0.058  0.466  0.85 - 1.08 
Depression score >8 1.36 0.083  0.000  1.21 - 1.53 
Screen CAGE ≥2  1.08 0.087  0.331  0.92 - 1.26 
Non-disclosure  1.19 0.163  0.194  0.91 - 1.56 
* The relative count of TI for each 10 year increase in age decreased by 14%: aIRR 1.86 
(95%CI 0.80-0.92) 
 
Secondary outcomes – retention in care:  
The characteristics of those who died, were lost to follow-up and transferred out, as in 
Figure 3.1, were compared to those who had completed the study using a multinomial 
logistic regression model (model not shown). There was no difference between those who 
died, were lost to follow-up or transferred out and the completed group by intervention 
arm.  
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Discussion. 
Our randomised controlled trial found that the use of a novel, wireless, electronic 
adherence monitoring device, which generated a text message reminder for device 
openings >30 minutes late, significantly reduced the frequency of treatment interruptions 
longer than 72 hours, but had no effect on overall adherence execution, retention in care, or 
HIV RNA suppression among ART-naïve individuals attending a South African community 
clinic. Time from message to dose ingestion did not fatigue over the study, suggesting 
durability of the intervention effect. However, participants in the intervention arm were 
more likely to take their dose outside of the 30 minute dosing window, suggesting that they 
relied on the intervention to remind them to dose.  
The intervention significantly reduced the frequency of treatment interruptions of over 72 
hours, which was a pre-specified endpoint. This is an important finding as treatment 
interruptions >72 hours have been shown to be a significant cause of virologic failure and 
acquisition of drug resistance independent of average overall adherence among participants 
receiving NNRTI treatment. (17, 43, 151) The intervention altered the pattern of adherence 
behaviour, changing the frequency of longer treatment interruptions, despite similar 
median adherence. Text message reminders made it more likely that participants on the 
intervention arm would dose at least every 72 hours, while those in the control arm had 
longer gaps in dosing. 
The median duration of treatment interruptions was 8 days, with an IQR of 5-15 days. 
People on NNRTI-based regimens, like the participants in our study, have a 50% chance of 
viral rebound after a 14 day interruption, although this risk of failure decreases with the 
duration of viral suppression before the interruption occurs. (17, 152, 153) It is likely that 
the treatment interruptions in our study were either too short or occurred after sufficient 
viral suppression to generate a difference in viral suppression at week 48. (17)  
Age, gender and depression were significantly linked with an increased frequency of 
treatment interruptions.  Specific populations, namely younger people, men and those with 
symptoms of depression, might benefit from focussed adherence interventions. Younger 
people were also more likely to have poor adherence execution, and to be lost to care. 
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Further exploration of simple adherence interventions, such as the one used in this study 
would be warranted in these young people.   
Transfers to care at other clinics (6.9%), and losses to care (8.2%) were similar to what has 
previously been reported at this site.(40, 154). Eight people (3.5%) died; a smaller 
proportion than noted in the same earlier studies, likely reflecting earlier entry to care with 
the expansion of the South African ART programme and raise in baseline CD4 cell count 
inclusion criteria (from 200 to 350 cells/mm3) in August 2011. (146) The intervention in this 
study did not impact on these losses. Those who were lost to care were younger than those 
who remained in care and were more likely not to have disclosed their HIV status to anyone 
else.  
Our study has several strengths including objective monitoring of adherence, 12 month 
follow-up, and use of HIV-1 RNA as an outcome.  One potential limitation of the study is that 
adherence in this cohort is already excellent.(38) All participants received a higher level of 
adherence support at our clinic than is routine in most settings, including thorough 
treatment preparedness, regular clinic pill counts and extra support through education and 
home visits should adherence flag. All of these interventions are known to improve 
adherence. (155, 156). A further potential limitation is that we sent our text messages to the 
participant’s own mobile phones and, despite regular confirmation of telephone numbers, 
other than the increased numbers of people dosing at the time the message was sent 
(Figure 2), we do not have data to confirm that all messages were actually received.  
In summary, our study found that electronic monitoring with text reminders for late doses 
reduced the frequency of treatment interruptions without a difference in overall adherence 
or HIV RNA suppression in the context of high levels of adherence support. While systematic 
reviews and meta-analyses have concluded that text messaging is a potential option to 
support adherence to antiretroviral therapy, (5, 111, 112, 119, 120, 157, 158) future studies 
are needed to determine best timing of the reminders and whether the level of adherence 
support supplied by electronic monitoring can replace intensive counselling linked with 
home visits in this population.   
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Synopsis: 
This short report illustrates how an existing locally developed pharmacy database (iDART) is 
better used to monitor cohort retention than standard cohort monitoring processes. 
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Abstract. 
Introduction: Monitoring of antiretroviral therapy (ART) delivery scale up is operationally 
complex, yet crucial to on-going programmatic success. Current cohort monitoring systems 
(paper or electronic) can be unwieldy. Pharmacy dispensing reports may provide quick and 
cost-effective methods of determining numbers starting treatment and retained in care. 
Methods: Reports of the number of individuals in ART care generated quarterly over one 
calendar year (July 2010 to June 2011) from the Access-based ART cohort database at a 
resource-poor clinic in South Africa (cohort report) were compared to numbers in care 
generated from the electronic dispensing system used in the clinic over the same time 
period (dispensing system report). Staff time taken to generate the reports with both 
systems was estimated. 
Results: The cohort reports at the end of September and December 2010, March and June 
2011 showed a linear increase in numbers on therapy with 814, 875, 903 and 928 
individuals in care at the end of each quarter respectively. By dispensing system reports, the 
number of people per quarter on ART was 779, 829, 852 and 886. These numbers were 
largely within an acceptable margin of 5% of each other. Staff time to generate the cohort 
report amounted to 30.9 hours per month, compared to 0.2 hours a month for the 
dispensing system report. 
Conclusion: Electronic dispensing system reports are easy to generate and comparable to 
clinic cohort reports when used to identify individuals remaining in care. Dispensing reports 
are much more time efficient.  
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Background. 
Monitoring of the rapid scale up of antiretroviral therapy (ART) delivery in resource-poor 
countries is complex, yet crucial.(159) The primary purpose of determining how many 
individuals commenced and remain on ART over a particular period is for forecasting ART 
supplies and service. These data provide a measure for judging progress and determining 
where funds are being used effectively. The number of people remaining on therapy is an 
indicator of the United Nations General Assembly Special Session report (UNGASS). Another 
purpose of these data is for clinical monitoring of individuals. Identifying those remaining on 
therapy by necessity identifies those who are not, thus allowing for those who are lost-to-
follow-up to be recalled. 
Monitoring systems vary from site to site, by resources available and local expertise. Paper-
based systems cannot work efficiently with large patient numbers. Electronic clinical data 
capture systems are being used in some Sub-Saharan African ART sites, including South 
Africa and Malawi, but consume clinical time and require infrastructure.(160, 161) 
Alternatively, pharmacy dispensing records could provide an accurate, quick and cost 
effective record of drug collection and hence retention in care over a defined time 
period.(57, 84) Coupling the clinical monitoring system to that for drug stock levels reduces 
duplication and streamlines the required reporting processes.  
The aim of this study was to determine whether the pharmacy record can provide an 
adequate estimate of the number of patients commencing and retained on ART compared 
to the currently used clinic cohort reports.  
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Methods. 
Setting:  
Masiphumelele is a small community of 17 000 individuals, with an HIV prevalence of 
25%.(162) Masiphumelele has one clinic that offers primary care services. Patients requiring 
ART were supported by a multi-disciplinary team. ART was dispensed according to the South 
African National ART guidelines, a non-nucleoside reverse transcriptase inhibitor (NNRTI)-
based first-line and a protease inhibitor-based second-line regimen.(146, 163) This service 
has been described previously both in terms of staff providing care and losses to care over 
time.(37, 81) 
Data collection:  
Clinic cohort reports: clinicians completed a data capture form for each patient visit, which 
was transferred weekly to the University of Cape Town for clerks to enter into an Access® 
database. A data manager generated monthly and quarterly reports through pre-prepared 
queries detailing individuals commencing ART and those retained in care. Another list of 
those not retained in care or “lost-to-follow-up” was generated to commence the recall 
process. 
Four consecutive clinic cohort quarterly reports were analysed from the ART Access® 
database. The number of patients commencing ART and those remaining on therapy at the 
end of each quarter were calculated from the difference between the number of patients 
ever started and those known to have died, transferred-out and defaulted by the end of 
each quarter. For this study, the clinic cohort reports were considered the gold standard. 
Pharmacy reports: Pharmacy records were kept using the Intelligent Dispensing of ART 
(iDART) system, a pharmacy application developed from open source software. iDART 
recorded each ART bottle’s bar code as it was scanned out and linked it to the individual 
receiving the drug.  
A pharmacist or pharmacy assistant generated two automated reports from the iDART 
system. The clinic indicator report included the total number of individuals initiated on ART 
as well as the total number of individuals seen per quarter. Each of these numbers was 
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compared as a simple ratio with the clinic cohort report of numbers commenced and 
remaining on therapy at the end of the same four consecutive quarters. 
The ART drug usage report, reported stock consumption i.e. the number of bottles of each 
antiretroviral dispensed in the reporting period. As each ART bottle contains 30 days’ 
supply, this report was used to calculate the number of months of medication dispensed per 
individual by totalling the number of bottles of efavirenz, nevirapine and lopinavir/ritonavir 
dispensed per quarter (each individual will only be taking one of these at a time) and 
dividing by the number of individuals seen during that reporting period.  
Comparative analysis: 
Data are presented as numbers and proportions. Clinic based and pharmacy based records 
were compared using simple ratios to compare whether patient retention on therapy as 
determined by pharmacy records was within our defined acceptable limit (+/-5%) of patient 
retention as determined by clinic cohort analysis. 
Ethical clearance: 
Ethics approval for collection of clinical data from individuals on ART at Masiphumelele has 
been received from the University of Cape Town Research Ethics Committee.  
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Results. 
Clinic cohort report results: Patient data collected from the Masiphumelele quarterly reports 
at the end of September 2010, December 2010, March 2011 and June 2011 showed an 
increase in numbers on therapy with 814, 875, 903 and 928 adults and children cumulatively 
in care at the end of each quarter respectively (Table 4.1). Sixty-seven, 63, 63 and 52 
individuals commenced therapy over the same four quarters.  
Dispensing system report results: The numbers of individuals who were collecting ART per 
quarter by iDART clinic indicator report was 779, 829, 852 and 886. Seventy-six, 75, 69 and 
52 commenced treatment per quarter (Table 4.1). 
Table 4.1: Comparing clinic cohort reports and iDART clinic indicator reports:  
a. Total adults and children commencing antiretroviral therapy per quarter.  
 01Jul10 to 
30Sep10 
01Oct10 to 
31Dec10 
01Jan11 to 
31Mar11 
01Apr11 to 
30Jun11 
 Adult Child Adult Child Adult Child Adult Child 
Clinic cohort report 65 2 60 3 60 3 50 2 
iDART clinic indicator 
report 
74 2 69 6 66 3 50 2 
Ratio (iDART/clinic) 1.13 - 1.19 - 1.09 - 1.0 - 
b. Total adults and children retained on antiretroviral therapy per quarter.  
 01Jul10 to 
30Sep10 
01Oct10 to 
31Dec10 
01Jan11 to 
31Mar11 
01Apr11 to 
30Jun11 
 Adult Child Adult Child Adult Child Adult Child 
Clinic cohort report 768 46 826 49 854 49 893 49 
iDART clinic indicator 
report 
737 42 784 45 807 45 846 43 
Ratio (iDART/clinic) 0.96 - 0.95 - 0.94 - 0.95 - 
 
Comparison of clinic cohort and dispensing system reports is presented in Table 4.1. For each 
quarter iDART overestimated numbers starting therapy by up to 13% and underestimated 
numbers retained in care by up to 6%. For the first, second and fourth quarters, the 
numbers retained on ART by clinic cohort report correlated well with the dispensing report 
of individuals collecting drugs (within 5%). For the third quarter the totals correlated less 
well.  
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As each bottle contains 1 month of medication, the expected number of bottles an adult 
should receive per quarter would be three, as seen in the first (3.14 per adult) and fourth 
(3.17 per adult) quarters described. In the second quarter, each adult received an increased 
average of 3.8 bottles of either NNRTI or PI and in the third, a reduced average of 2.86 
bottles. 
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Discussion. 
This report is part of the first study in Southern Africa to explore the practicality of using 
pharmacy dispensing records to estimate the number retained in ART care per quarter in a 
resource-poor setting. The pharmacy dispensing report of individuals collecting ART closely 
reflected the clinic cohort reports, but in two of the four quarters monitored, the stock 
dispensed was either more or less than expected. 
The number of people on ART at the end of the quarter as per the clinic cohort report might 
be expected to differ from that of the dispensing reports. As prescriptions were generated 
at the weekly multidisciplinary meeting where all pre-treatment individuals were discussed, 
treatment start is captured easily, though there may be a lag time from dispensing ART to 
the capturing of that information in the clinical database, reflected as more individuals 
starting therapy per quarter in Table 4.1. Losses to care (deaths, loss-to-follow-up and 
transfers-out) are more difficult to capture in the clinic cohort report, while being 
immediately reflected in the dispensing reports as those individuals do not collect ART. 
While there was an active clinical tracing process, at the date of any report there may be 
individuals lost-to-follow-up or who have died who have not yet been identified as such, so 
giving increased numbers in care by clinic cohort report, again reflected in Table 1, where 
the numbers were slightly more than, but within 6% of, the dispensing report in all four 
quarters.  
While the existing iDART system at Masiphumelele clinic cannot initiate a tracing process for 
those who miss their ART collection date, this is something feasible for the iDART system 
and is being explored in other South African clinical settings. This would allow coupling of 
the current clinical and dispensing reporting systems and reduce duplication of effort. 
In the October to December quarter, more drugs were dispensed than expected (3.80 
bottles per person) and in the January to March quarter less drugs were dispensed than 
expected (2.85 bottles per person). This reflected the migratory process in greater Cape 
Town area, where many go home to their province of origin over the holiday season. Many 
of these people will not seek care while away and interrupt ART. To pre-empt this, ART 
clinics, including Masiphumelele, over-dispense in the months prior to December. This, and 
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more loss-to-follow-up as people fail to return, results in the under-dispensing noted in the 
first quarter of the year. 
There are weaknesses in this report. Assessment of time taken to complete each report was 
not accurately assessed, but many more staff are required to generate the clinic cohort 
report than the pharmacy report. There may also be errors in the dispensing process such as 
failure to scan the bar code at the time of dispensing, which would impact on numbers in 
the dispensing reports.  
Conclusion. 
Electronic dispensing system reports are comparable to clinic cohort reports when used to 
identify individuals starting or continuing on antiretroviral therapy, but are easier to 
generate. In our setting, transmission of such reports to the central pharmacy would 
improve forecasting for the annual surge in ART dispensing, and reduce time when ART is 
not available. These reports could readily be used to identify those lost to care. 
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Chapter five: Population efavirenz pharmacokinetic data, cytochrome 2B6 
genotyping and electronic adherence monitoring:  successful prediction of 
virological response in a South African community-based ART-naïve cohort. 
Authors:  
Catherine Orrell, Andrzej Bienczak,  Karen Cohen, David R. Bangsberg, Gary Maartens, Robin 
Wood, Paolo Denti. 
Publication status: 
Submitted to the International Journal of Antimicrobial Therapy on 12th December 2015. 
Synopsis:  
This paper illustrated that while mid-dose efavirenz concentrations can predict treatment 
outcomes, metaboliser status does not; and that the current therapeutic lower limit of 
1mg/ml may be too high. 
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Abstract. 
Background: Efavirenz concentrations are highly variable, in part due to polymorphisms in 
cytochrome P450 (CYP) 2B6, which makes therapeutic drug monitoring (TDM) attractive. We 
hypothesised that efavirenz concentrations, with CYP 2B6 metaboliser genotype status, 
could predict virological outcomes. 
Methods: South African ART-naïve participants were studied after initiation of efavirenz-
based ART. CD4 cell count and HIV-RNA were determined at weeks 0, 16 and 48. Efavirenz 
mid-dose concentrations were drawn at weeks 16 and 48. CYP 2B6 genotyping (516G→T 
and 983T→C) determined metaboliser genotype status. Cox proportional hazards modelling 
was used to predict virological outcome. Comparison of Akaike Information Criterion values 
explored the most predictive lower limit of mid-dosing efavirenz concentration. 
Results: 180 subjects with both efavirenz concentrations and HIV-RNA were studied. Median 
efavirenz concentrations were 2.3 mg/L (IQR1.6-4.6) and 2.21 mg/L (IQR1.5-3.9) at weeks 16 
and 48 respectively. Extensive, intermediate or slow CYP2B6 metaboliser genotype occurred 
in 49 (27.2%), 84 (46.7%), and 39 (21.7%) participants respectively. Log2 efavirenz 
concentrations [adjusted hazard ratio (aHR) 0.81, 95% confidence interval (95%CI) 0.72-
0.92] and baseline CD4 cell count [aHR0.994, 95%CI0.989-0.998] were predictive of 
virological outcome. For each doubling in efavirenz concentration there was a 21% 
decreased hazard of virolological failure; for each 50 cell increase in baseline CD4 count 
there was a 31% reduced hazard of non-suppression. The most predictive lower limit for 
mid-dosing efavirenz concentration was 0.7 mg/L. 
Conclusion: Mid-dosing efavirenz concentrations predicted virological outcome. The 
currently recommended lower therapeutic limit (1 mg/L) for TDM is higher than our finding. 
CYP2B6 metaboliser genotype did not add predictive value.  
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Introduction. 
Efavirenz is a good candidate for therapeutic drug monitoring (TDM)because there are 
reliable assays, its plasma concentrations are characterised by high inter-individual 
variability, low concentrations have been linked with viral non-suppression, and high 
concentrations with toxicity.(64, 65, 68) However, the relationship between efavirenz 
concentrations and viral suppression has not always been consistent in studies, perhaps due 
to the development of high level resistance to non-nucleoside reverse transcriptase 
inhibitors, which emerges rapidly with efavirenz-based ART. (64, 65, 68, 71, 164, 165)  
The high inter-individual variability of efavirenz concentrations is explained in part by 
polymorphisms in CYP2B6, the gene which encodes for the cytochrome P450 (CYP) enzyme 
CYP2B6.(41, 166, 167) The prevalence of genetic slow metabolisers is high in sub-Saharan 
African populations.(41) Metaboliser genotype status (ultra-slow, slow, intermediate, or 
extensive) did not impact virological outcomes in a recent analysis of pooled studies 
conducted by the AIDS Clinical Trials Group, but the impact of genotype status on virological 
failure has not been fully explored in a South African population.(168) 
The lower limit of the currently recommended therapeutic range (1-4 mg/L) for efavirenz is 
controversial. (165, 169, 170) Marzolini et al. reported that mid-dose efavirenz drug 
concentrations of less than 1 mg/L were associated with increased rates of virological 
failure.(169) While pharmacokinetic data from the 2NN study suggested an increase in 
virological failure with trough concentrations of <1.1mg/L, the authors did not recommend 
using this cut-off value to predict virological outcomes as the sensitivity was low.(170) 
Recently published data from the Encore 1 study noted that only a small proportion of those 
failing treatment had mid-dosing efavirenz concentrations of <1.0 mg/L. (165) 
We hypothesised that mid-dosing interval efavirenz drug concentrations, together with 
knowledge of CYP2B6 metaboliser genotype, would be predictive of virological outcome in a 
sub-Saharan African population starting first-line ART. We also examined the lower 
threshold concentration of efavirenz for therapeutic benefit.  
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Methods. 
Participants, setting and standard of care:  
Participants were recruited at the Hannan Crusaid Treatment Centre (HCTC), a large 
outpatient antiretroviral treatment centre in Cape Town. The cohort included ART-naïve 
adults and adolescents who were eligible if they had their own mobile phone and were 
willing to sign written informed consent.  
All those entering the treatment programme at the HCTC received three group counsellor-
driven treatment literacy sessions prior to commencing non-nucleoside reverse 
transcriptase inhibitor- (NNRTI-) based ART. (25, 33) They were also visited at home by a 
community care worker to confirm address and home circumstances. Those with a raised 
viral load or low adherence based on a count of tablet returns (<90%) received a stepped-up 
adherence package, including tailored counselling, monthly drug dispensing and further 
home-visits. Participants were traced by phone call and home visit if they were more than 4 
weeks late for a clinic visit.  
Sub-study design: 
The parent study was a randomised controlled trial over 48 weeks investigating adherence 
to ART and has been described in detail elsewhere.(134) Participants also had the option of 
joining a non-randomised voluntary pharmacokinetic and pharmacogenetic sub-study, 
which required additional blood sampling.  
Visits and sampling: 
Sub-study visits included screening, baseline, weeks 16 and 48. Visits were timed to coincide 
with booked clinic visits to minimise inconvenience. Participants were reimbursed for local 
travel (R20 or ~US$2) at each visit and offered a gift of a T-shirt, bag or mug valued at R80 
(~US$8) or less for each on-study visit.  
Demographic and psychosocial details were collected at screening. Prescribed ART was 
recorded at baseline (week 0). Weight and current ART confirmed at all visits. Blood was 
drawn for CD4 cell count (FACS Count™, Beckton Dickinson, NJ, USA) and HIV-1 viral load 
(HIV-1 RNA 3.0 assay®, Bayer Healthcare, Leverkusen, Germany) at screen, and at weeks 16 
and 48. At weeks 16 and 48, for those who gave additional consent, blood was drawn for in 
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a lithium Heparin tube for mid-dosing interval efavirenz concentrations, in the window 
between 9h and 16h after self-reported efavirenz intake time, and in an EDTA tube for 
CYP2B6 pharmacogenetic analysis.  
At weeks 16 and 48, most blood samples for efavirenz concentration and viral load were 
drawn on the same date. However, in a number of participants, viral load measurements 
were obtained up to 4 weeks before the scheduled pharmacokinetic visit (as part of 
standard of care) or afterwards (when the measurement had to be repeated due to issues 
with the measuring procedure). Samples were kept cold (4oC) until transfer to the 
laboratory within 2-3 hours of blood draw.  
Pharmacokinetic analyses:  
Samples were centrifuged at 3500 revolutions/minute for 10 minutes and plasma pipetted 
into cryovials which were labelled and frozen at -80oC. Samples were analysed for efavirenz 
concentrations using a validated liquid chromatography MS/MS method.  
Pharmacogenetic analyses:  
Samples were centrifuged at 3000 rpm for 30 minutes. The white blood cell layer (buffy 
coat) was transferred to a labelled cryovial and frozen at -80oC. Three CYP2B6 single 
nucleotide polymorphisms (SNPs) previously associated with efavirenz concentrations were 
chosen and analysed: rs3745274 (516G→T), rs28399499 (983T→C) and rs4803419 
(15582CT). Genomic DNA was extracted from 100 μL of stored buffy coat, re-suspended 
in a total volume of 300 μL of lysis buffer and 30 μL of proteinase K from the Maxwell 16 LEV 
Blood DNA kit (Promega, UK) and incubated at 57oC for 30 minutes at 1000 rpm. The DNA 
was extracted as per manufacturer’s instructions on the MaxWell automated extraction 
platform (Promega, UK) and eluted in 100 μL elution buffer.  
The quantity and quality of extracted DNA was determined using the Qubit DNA BR Assay kit 
(Molecular Probes – Life Technologies, USA) and the Qubit 2.0 Flurometer (Invitrogen – Life 
Technologies, USA) as per manufacturer’s instructions. Once the quantity of DNA was 
determined it was diluted to 20 ng/μL using sterile nuclease-free water and 1 μL aliquoted 
into one well per sample in a 96 well plate. The DNA samples were left at room temperature 
for 12 hours, to lyophilize. 
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Amplification and genotyping of each participant for the presence of SNPs in their CYP 2B6 
gene was performed using fluorescently labeled minor groove binding (MGB) allele-specific 
probes (Applied Biosystems). Participants were genotyped for CYP2B6 (516G→T, rs3745274; 
983 T→C, rs28399499; and 15582 C→T, rs4803419), using 1 μL of lyophilized DNA and 
1xTaqMan®Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems, Foster City, 
USA) to a total volume of 12.5 μL. The cycling conditions consisted of an initial enzyme 
activation step of 95oC for 10 minutes, followed by a denaturation step of 95oC for 15 
seconds and a combined annealing and extension step for 1 minute at 60oC. All 
amplification reactions were performed on the ViiA7 (Applied Biosystems, Foster City, USA). 
We used a simplified version of Holzinger et al’s metaboliser status classifications, as used 
by Dooley et al.(166, 171) Each individual was classified as an ultra-slow, slow, intermediate 
or extensive metaboliser. The effect of 516GT|983TC SNP vector was tested as 4 metabolic 
subcategories: extensive metabolisers (EM) – 516GG|983TT, intermediate metabolisers (IM) 
- 516GT|983TT or 516GG|983TC, slow metabolisers (SM) – 516TT|983TT or 516GT|983TC, 
ultra-slow metabolisers (USM) – all participants 983CC irrelevant of 516 G→T genotype.(70, 
166, 171)  
Study outcome:  
The outcome was viral load at week 16 or week 48. 
Statistical analysis: 
Descriptive statistics were used to summarise the baseline characteristics of the participant 
group and mid-dosing interval efavirenz concentrations using Stata 13.0 (Stata Corporation, 
College Station, USA) 
Prediction of virological outcome: The change in the relative risk of viraemia was estimated 
using Cox proportional hazards regression model (Andersen-Gill repeated outcomes 
framework) with Efron approximation and interval censoring using the software R with 
package survival.(172-176) Each time interval runs from the preceding to the current viral 
load measurement. Viral loads were converted into dichotomised outcome: an event 
(classified as non-suppression) was defined as viraemia >400 copies/mL at week 16 and 
viraemia >40 copies/mL at week 48. The following variables were tested for their effect on 
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change in hazard of viral non-suppression: efavirenz concentrations, age, gender, baseline 
CD4, baseline viral load (log10-transformed) and metaboliser status.  
Due to some pharmacokinetic and viral load (VL) samples falling before or after planned 
sampling window at week 16 and 48, time censoring was used. For samples scheduled for 
week 16 measurements taken between weeks 12 and 20 from treatment start were 
included in the analysis; for week 48 we analysed samples falling between weeks 32 and 64. 
Mid-dose efavirenz plasma concentrations were matched with viral load measurements 
taken on the same day or the next closest measurement within the time censoring interval.  
Missing categorical covariates were imputed as the population mode and missing 
continuous covariates were imputed as population median. A sensitivity analysis was 
conducted to test the effect of these imputations by dropping all participants with imputed 
covariate values. 
All variables were tested for their effect on the risk of viral non-suppression in a univariate 
analysis and included a priori in the full multivariate model. Backwards elimination process 
was performed starting with the covariate with the least significant p-value until all 
remaining predictors had p<0.05 (final model). 
Subsequently, the threshold of efavirenz mid-dosing concentration that was the most 
predictive of an increased risk of viral non-suppression (at levels described above) was 
derived as previously proposed by Bienczak et al.(177) Briefly, the threshold was selected by 
comparing the Akaike Information Criterion (AIC) values generated by Cox proportional 
hazard regression models testing efavirenz concentration dichotomised at different cut-off 
values. The AIC value was profiled by testing all models using concentration cut-offs 
between 0.1 and 5 mg/L in increments of 0.005 mg/L. The cut-off resulting in the lowest AIC 
value was chosen as the desired threshold, since this corresponds to the dichotomisation of 
efavirenz concentrations that is most predictive of virological non-suppression. The 
robustness of the estimated threshold was confirmed using a re-simulation approach: the 
original dataset was re-simulated 500 times introducing a normally distributed random error 
on the detected concentrations and the estimation procedure for the best cut-off value was 
repeated on each of the re-simulated datasets. The magnitude of the error was set to the 
unexplained residual variability estimated in population pharmacokinetic model by Dooley 
et al. (additive error = 0.0846 mg/L, proportional error = 9.31%.(171) The results of the re-
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simulation procedure were used to derive 90% confidence interval on the concentration 
threshold (5th to 95th percentile of the values estimated from the 500 re-simulated data 
sets).  
Ethical approval:  
The University of Cape Town’s Faculty of Health Science Research Ethics Committee gave 
approval to conduct this study. Each participant provided written informed consent. The 
trial was registered in the Pan African Clinical Trials Registry, number 
PACTR201311000641402. 
Role of funding source:  
The sponsors of the study had no role in the design and implementation of this study, nor in 
manuscript preparation. All authors had full access to the study data. CO developed the 
initial manuscript and all authors approved the submitted manuscript. 
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Results. 
Baseline characteristics and genotypes: 
One hundred and eighty of the 230 individuals enrolled into the parent study had matched 
efavirenz mid-dose concentrations and viral load data: 25 at week 16 only, 54 at week 48 
only and 101 at both time points. Baseline characteristics are detailed in Table 5.1. The 
majority of this population were female. A total of 336 mid-dose efavirenz level samples 
were available from the 180 individuals: 170 at week 16 and 166 at week 48.  
CYP2B6 genotype frequencies and metaboliser types are presented in Table 5.1. In this sub-
Saharan African population, 20% of the cohort had slow or ultra-slow metaboliser status. 
The genotypes frequencies from all three SNPs were in Hardy-Weinberg equilibrium. 
Table 5.1: Baseline characteristics of cohort used in the analyses. 
Variable Cohort with both efavirenz TDM and viral load 
Baseline Week 16 Week 48 
Number: n 180 126 156 
Female sex: n(%) 118 (65.6) 79 (62.6) 103 (66.0) 
Age (years): median (IQR) 32.8 (27.4-40.7) 33.4 (28.1-41.4) 34.7 (28.8-42.6) 
Weight (kg): median (IQR) 67.0 (58.4-79.8) 67.4 (59.1-79.1) 69.5 (59.0-80.0) 
WHO stage: n(%) 
                        1 
                        2 
                        3 
                        4 
 
68 (37.8) 
36 (20.0) 
57 (31.7) 
19 (10.6) 
  
CD4 count (cells/mm3): median 
(IQR) 
229 (129-287)   
Log10 viral load (copies/mL): median 
(IQR) 
4.9 (4.4-5.4)   
Viral load > 400 copies/mL (week 
16) or 40 copies/mL (week 48): 
n(%) 
180 (100) 8 (6.3) 18 (11.5) 
Genotype CYP 2B6 516 G>T: n(%) 
                       GG  
                        GT 
                        TT 
                        Missing: 
 
75 (41.7) 
73 (40.6) 
24 (13.3) 
8 (4.4) 
 
46 (36.5) 
56 (44.4) 
18 (14.3) 
6 (4.8) 
 
69 (44.2) 
64 (41.0) 
21 (13.5) 
2 (1.3) 
Genotype CYP 2B6 983T>C: n(%) 
                        TT 
                        TC 
 
131 (72.8) 
40 (22.2) 
 
94 (74.6) 
26 (20.6) 
 
117 (75.0) 
36 (23.1) 
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Variable Cohort with both efavirenz TDM and viral load 
Baseline Week 16 Week 48 
                        CC 
                        Missing 
1 (0.6) 
8 (4.4) 
0 (0.0) 
6 (4.8) 
1 (0.6) 
2 (1.3) 
Genotype CYP 2B6 15582C>T: n(%) 
                        CC 
                        TC 
                        TT 
                        Missing 
 
144 (80.0) 
27 (15.0) 
1 (0.6) 
8 (4.4) 
 
103 (81.7) 
17 (13.5) 
0 (0.0) 
6 (4.8) 
 
127 (81.4) 
26 (16.7) 
1 (0.6) 
2 (1.3) 
Metaboliser genotype: n(%) 
                       Extensive  
                        Intermediate 
                        Slow 
                        Ultra-slow 
                        Missing 
 
49 (27.2) 
84 (46.7) 
38 (21.1) 
1 (0.6) 
8 (4.4) 
 
31 (24.6) 
60 (47.6) 
29 (23.0) 
0 (0.0) 
6 (4.8)  
 
44 (28.2) 
77 (49.4) 
32 (20.5) 
1 (0.6) 
2 (1.3) 
 
Efavirenz concentrations: 
Table 5.2 describes efavirenz concentrations by metaboliser genotype and visit week, using 
all efavirenz concentrations available. While the median (IQR) concentrations overall for 
each visit were within the recommended therapeutic range (1-4 mg/L), those with ultra-
slow and slow efavirenz metaboliser genotype had higher median efavirenz concentrations 
throughout the study than those with extensive or intermediate metaboliser genotype 
(Table 5.2, Figure 5.1).  
At weeks 16 and 48 a total of 10 (5.9%) and 13 (7.8%) participants respectively had efavirenz 
concentrations <1 mg/L, the majority of whom had extensive and intermediate metaboliser 
genotypes. At weeks 16 and 48 a total of 43 (25.3%) and 33 (19.9%) participants respectively 
had concentrations >4 mg/L, the majority of whom had slow or ultra-slow metaboliser 
genotype.  
Table 5.2: Median (IQR) EFV concentrations in mg/L by visit week and metaboliser genotype. 
Metaboliser 
genotype 
EM IM SM USM p-value Median n 
Week 16 
1.51 
(1.34-1.73) 
2.24 
(1.69-2.76) 
7.75 
(5.22-10.60) 
- <0.001 
2.27 
(1.64-4.60) 
170 
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Week 48 
1.50 
(1.23-1.94) 
2.19 
(1.67-2.84) 
6.79 
(4.84-9.20) 
7.98 
(7.98-7.98) 
<0.001 
2.21 
(1.53-3.91) 
166 
EM –extensive, IM – intermediate, SM – slow, USM – ultraslow. p-value obtained through Kruskal-
Wallis test.  
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Figure 5.1: Median (IQR) efavirenz concentrations in mg/L by visit week and metaboliser 
genotype. 
 
Virological outcomes:  
At 16 weeks 118 (93.6%) of 126 participants had a viral load of <400 copies/mL, 8 (6.4%) had 
viral loads >400 copies/mL. At 48 weeks 137 individuals (88.4%) of 155 participants had a 
viral load of ≤40 copies/mL; 27 (11.6%) had viral loads >40 copies/mL.  
Virological outcome model: 
Of the 180 participants, 101 contributed measurements at both time points, 25 only at week 
16 and 54 only at week 48. We analysed a total of 281 matched viral load and plasma 
efavirenz mid-dose concentrations (126 at week 16 and 155 at week 48). The only 
categorical covariate with missing values was the metaboliser status, which was imputed in 
10 patients as intermediate, the population mode. A sensitivity analysis was conducted by 
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dropping all participants with the missing values and revealed that the imputation had no 
significant effect on the results. 
The results of univariate and multivariate analysis using the Cox proportional hazards model 
are presented in Table 5.3. Systemic exposure to efavirenz expressed as log2 mid-dose 
concentration and baseline CD4 count proved to be the most significant predictors of the 
risk of viral non-suppression. The use of log-transformed efavirenz concentrations provided 
a better model fit than the use of the original values (results not shown) and it estimated a 
23% decrease in the hazard of viral non-suppression (p=0.0005) for every doubling in drug 
concentration (corresponding to one unit increase in log2 scale). Similarly, for every 50 cell 
increase in baseline CD4 count there was a 31.5% reduction in the hazard of non-
suppression (p=0.0018).  
Table 5.3: The results of Cox proportional hazards univariate and multivariate analysis.  
Parameter 
Univariate Models 
 
Full Multivariate Model 
 
Final Multivariate Model 
 
HR (95% CI) p-val HR (95% CI) p-val HR (95% CI) p-val 
Log2 
efavirenz 
Conc 
[mg/L] 
0.76 
(0.64-0.91) 
0.0035 
0.78 
(0.68-0.90) 
0.0005 
0.77 
(0.67-0.89) 
0.0005 
Baseline 
log10 VL 
1.83 
(0.94 - 3.53) 
0.0734 
1.40 
(0.82-2.37) 
0.2182   
Baseline 
CD4 
0.9935 
(0.9895-
0.9976) 
0.0019 
0.9945 
(0.9908-
0.9983) 
0.0040 
0.9937 
(0.9898-
0.9977) 
0.0018 
Age 
[years] 
0.9639 
(0.9111-
1.0200) 
0.2010 
0.9534 
(0.8908-
1.0204) 
0.1682   
Sex 
(ref. M) 
0.5884 
(0.2588-
1.3380) 
0.2060 
0.5289 
(0.2090-
1.3388) 
0.1789   
Metabolic 
Status 
(ref. FM + 
IM) 
1.07 
(0.43-2.65) 
0.8810 
1.78 
(0.61-5.21) 
0.2891   
HR – hazard ratio; CI – confidence interval; VL – viral load; FM – fast metaboliser; IM – 
intermediate metaboliser 
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There was a trend towards an increased risk of viremia for participants with a higher 
baseline viral load (for every 10 fold increase in the baseline viral load there was an 83% 
higher hazard of non-suppression p=0.07). No significant effect was detected for age, sex, 
and metaboliser genotype status. 
All tested variables were included a priori in a “full” multivariate model, which found similar 
associations to the univariate analysis. After adjusting for the effect of other covariates, the 
trend towards increased risk of non-suppression for slow versus extensive combined with 
intermediate metabolisers increased, but still did not achieve statistical significance.  
In the final multivariate model, higher efavirenz concentration and higher CD4 count were 
both associated with decreased risk of viral non-suppression. The analysis was repeated 
excluding participants with imputed covariate values, with no change to the associations 
observed.  
Threshold of mid-dose efavirenz concentration for prediction of non-suppression. 
Dichotomised efavirenz concentration was then tested to identify the most predictive cut-
off value. Figure 5.2a presents the profiling of the model AIC values when using efavirenz 
concentration cut-off values between 0.4 and 4 mg/L, while Figure 5.2b shows the 
distribution of the estimates obtained with the re-simulation procedure. The model with the 
lowest AIC value used a cut-off between 0.63 and 0.74 mg/L (90%CI 0.24-1.56), so the value 
of 0.7 mg/L was selected. Observations with efavirenz mid-dose concentrations below this 
threshold had 4.43 times greater hazard of virological failure (95%CI 1.58 -12.3, p=0.004).  
The procedure was repeated using dichotomised concentrations in the multivariate model 
including the effect of baseline CD4 count, and it produced a similar value (results not 
shown).  
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Figure 5.2a: the comparison of the AIC values in models with dichotomised efavirenz mid-
dose concentrations using cut-off values ranging between 0.4 and 4 mg/L in increments of 
0.005 mg/L. The dots represent the AIC values for each tested concentration cut-offs 
generated from the original dataset, while the blue line is the median AIC value for tested 
concentration cut-offs from 500 re-simulated data sets.  
Figure 5.2b: the distribution of optimal cut-off values obtained from the 500 re-simulated 
datasets.  
 
Discussion. 
We found that mid-dosing interval efavirenz concentrations significantly predicted 
virological outcomes. Our model showed that the most predictive cut-off value for viral 
suppression was approximately 0.7 mg/L, which is lower than the currently recommended 
lower limit of 1 mg/L. Lower baseline CD4 cell counts were also predictive of poor virological 
outcome. The proportion of individuals in this South African cohort with heterozygous or 
homozygous variants in CYP2B6 was similar to others reported from this community. (69, 
70, 171) The higher efavirenz concentrations we found with slower metaboliser genotypes 
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were similar to those from other groups. (165) However, CYP2B6 metaboliser genotype 
alone did not predict virological outcomes.  
When testing the effect of efavirenz mid-dose concentration without dichotomising, the 
model found a 24% decrease in risk of virological failure for every doubling of efavirenz 
concentration.  The use of log-transformed concentrations suggests that relative changes in 
efavirenz plasma levels(a fold increase), as opposed to absolute changes (an increase of 1 
mg/L), are more robust predictors of reduction in risk of non-suppression, as previously 
reported in Bienczak et al. (177). 
Our analysis raises the question of whether the lower limit of the currently recommended 
therapeutic range (1 mg/L) is too high.(169, 170) The Encore 1 study has shown equivalent 
virological outcomes with a 400 mg dose of efavirenz compared to the standard 600 mg 
dose, despite significantly lower efavirenz exposure.(165) Only a small proportion of those 
with efavirenz concentrations <1 mg/L failed in this study. Our model shows that the most 
predictive cut-off value for virological outcome was 0.7 mg/L. Previous studies have shown 
that CYP2B6 metaboliser genotypes, which have a marked impact on efavirenz 
concentration, are not associated with failure.(168) The likely explanation for the lack of 
correlation between CYP2B6 metaboliser genotype and virologic outcomes in our study and 
in the pooled ACTG studies is that other factors, notably adherence, are more important 
determinants of efavirenz concentrations.  
Participants with lower CD4 cell count at baseline had a significantly increased hazard of 
virological non-suppression. Participants with high baseline viraemia had poorer virological 
outcomes, but this did not reach statistical significance in out model. Our data support 
earlier commencement of ART.  
Our study has several limitations. Time of efavirenz dose was not observed, although most 
patients reported taking their medications in the evening. The timing of viral loads was not 
under the control of the study staff and resulted in a large number of efavirenz samples 
being excluded from the analysis because they fell outside our time windows. As the focus 
of this study was on virological outcomes, we did not collect adverse event data and could 
not assess the impact of metaboliser genotype or high efavirenz concentration on toxicity. 
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The wide confidence interval for the mid-dose efavirenz concentration cut-off we found is 
due to the fact that only a limited number of patients had a viral load >400 c/mL at week 16 
and/or 40 c/mL at week 48. A larger study is needed to confirm our findings and increase 
the robustness of the estimated values.  
In summary, we have shown that, in an ART-naive cohort, efavirenz mid-dosing interval 
concentrations at week 16 and 48 predict virological outcome.  In addition, we confirm that 
knowledge of an individual’s metaboliser genotype is not per se predictive of viral non-
suppression. Our analysis suggests that the currently recommended lower limit of 
therapeutic range for efavirenz is too high. Efavirenz TDM using a revised cut-off of 0.7 mg/L 
may be of use in a routine clinical setting, to identify patients at risk of virological failure.  
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Synopsis:  
This paper shows how differing measures of adherence: electronic monitoring using 
Wisepill®, self-report, tablet returns, drug concentrations and iDART pharmacy refill data, 
compare within one cohort at predicting virological failure and antiretroviral drug 
resistance.  It also illustrates how an existing locally developed pharmacy database (iDART) 
can be used to monitor adherence. 
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Abstract. 
Background: Incomplete adherence to antiretroviral therapy results in virologic failure and 
resistance, but it is unclear which of the many available adherence measure best predicts 
these outcomes. We compared real-time electronic methods with patient-reported and 
objective adherence measures in an ART-naïve cohort in South Africa. 
Methods: We recruited ART-naïve participants from a community ART clinic. We 
prospectively collected demographic and disease data, CD4 count and HIV-RNA at weeks 0, 
16 and 48. HIV-RNA >500 copies/ml triggered a genotype. We quantified adherence using 
self-report (SR), clinic-based pill count (CPC), average adherence by pharmacy refill (PR-
average), calculation of medication-free days (PR-gaps), efavrienz therapeutic drug 
monitoring (TDM) and an electronic adherence monitoring device (EAMD). We modelled 
associations between adherence measures and virologic and genotypic outcomes using 
logistic regression, and derived the area under the curve (AUC) from the receiver operator 
characteristic (ROC) analyses to assess performance of adherence measures in predicting 
outcomes. 
Results: we enrolled 230 participants. Median (IQR) adherence by the various measures 
was: SR 100% (100-100), CPC 100% (95-107), PR-average 103% (95-105), PR-gaps 100% (95-
100) and EAMD 86% (59-94) at week 48. Efavirenz concentrations were therapeutic 
(>1mg/ml) in 92%. At week 48, retention in care was 81% (186/230), and 83% (155/186) 
achieved HIV-RNA <40 copies/ml. EAMD, PR-average and PR-gaps best predicted virological 
outcome at week 48 with AUC ROC of 0.73 (95%CI 0.61-0.83), 0.73 (95%CI 0.61-0.85) and 
0.72 (95%CI 0.59-0.84) respectively. EAMD, PR-gaps and PR-average were all highly 
predictive of the presence of resistance mutations at week 48, with AUC ROC of 0.92 (95%CI 
0.87-0.97), 0.86 (0.67-1.0) and 0.83 (95%CI 0.65-1.0) respectively. SR, CPC and EFV 
concentrations were poorly predictive of virological or resistance outcomes.  
Conclusion: Adherence data from EAMD and pharmacy refill measures predicted resistance 
and virological failure similarly. Pharmacy refill data is a pragmatic option for monitoring 
adherence in resource-limited settings where electronic monitoring is unavailable. 
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Introduction. 
Consistent ART adherence is critical to realising the clinical and prevention benefits of 
ART.(5, 16, 178). Despite this, there is no gold standard identifying adherence levels and/or 
patterns that place individuals at risk for virologic failure and drug resistance in a clinical 
setting.(44, 49, 54)  
A variety of ART adherence measures have been used in both observational and 
intervention studies. Self-report is the most frequently used method, but is imprecise and 
overestimates adherence, similar to clinic-based pill counts.(44, 47, 49, 54) Pharmacy refill 
data also overestimate adherence, but are more consistently associated with virological 
failure and mortality. (57-59) Electronic drug monitoring methods have been most closely 
associated with virologic failure, despite underestimating adherence due to storage and 
ingestion of medications outside of the device (pocket-doses). (44, 54, 63) Therapeutic drug 
concentration monitoring has been associated with virologic outcomes, though its precision 
relative to other adherence monitoring approaches is poorly understood. (5, 64, 65)  
Few studies have directly compared or ranked the ability of multiple adherence monitoring 
methods including subjective, objective, electronic and drug concentrations in one cohort to 
predict virological failure (42, 61, 79) and data comparing of multiple adherence measures 
with drug resistance is lacking.(179)  
Our study compared six adherence measures: self-report (SR), clinic-based pill count (CPC), 
pharmacy refills (PR-average), calculation of medication free days or gaps (PR-gaps), 
therapeutic drug monitoring (TDM), and real-time electronic drug monitoring. All adherence 
measures were collected in a prospective ART-naïve cohort starting first-line ART, in order 
to explore which measure best predicted virological or resistance outcome at 16 and 48 
weeks into treatment. 
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Methods. 
Participants and setting:  
This study is a sub-study of a randomised controlled study recruited at the Hannan Crusaid 
Treatment Centre, a large outpatient antiretroviral treatment centre in Cape Town. This site 
and the randomised study have been described in detail elsewhere (38, 134) The cohort 
included ART-naïve adults and adolescents starting first-line ART, who were eligible if they 
had their own mobile phone and were willing to sign written informed consent. In addition, 
all patients had a baseline CD4 count below 350 cells/ul or a stage 3 or 4 AIDs-defining 
illness in keeping with the national HIV guidelines for starting ART.(146) 
Study design: 
The parent study was a randomised controlled trial over 48 weeks investigating the impact 
of mobile phone message reminders when missed doses were detected by a real-time 
EAMD on adherence to ART. All participants received the EAMD on study entry to record 
daily ART dosing times. Real-time EAMD was measured using Wisepill®, which is the size of a 
mobile phone and holds a week of medication in an internal and removable seven 
compartment pill box container. Participants were instructed on refilling and replacing the 
internal pill box container weekly. On opening, a signal was sent via the mobile-phone 
network to a secure central computer, thus recording tablet taking or treatment 
interruptions in real time. This device has been used in other resource-limited settings. (60, 
62) The main study did not show a difference in cumulative adherence by study arm, as 
measured by the EAMD, and this sub-study includes data from participants without 
reference to study arm. 
All participants starting ART received three group counsellor-driven treatment preparedness 
sessions prior to commencing ART. (25, 33) They were visited at home by a community care 
worker to confirm address and ascertain home circumstances. All participants commenced a 
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART regimen. Counts 
of pill returns were done at each scheduled clinic visit. Those with a raised HIV-RNA (>1000 
copies/ml) or non-optimal clinic-based pill count adherence (<90%) received additional 
adherence support, which included tailored counselling, monthly drug dispensing and 
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follow-up home-visits. Participants were traced by phone and home visit if they were more 
than 4 weeks late in attending a scheduled clinic visit.  
Study visits: 
There were six study visits: screening, baseline, weeks 16, 32 and 48, and end of study. Visits 
were timed to coincide with scheduled clinic visits to minimise inconvenience to the 
participant. Participants were reimbursed for local travel (~US$2) at each visit and for the 
three on-study visits (weeks 16, 32 and 48) were given a gift of a T-shirt, bag or mug valued 
at R80 (~US$8) or less. If participants came to a standard of care clinic visit but did not 
attend the corresponding study visit, tablet return and virological data were extracted from 
their clinic folder. 
Demographic and psychosocial details, including age, gender, weight, height as well as 
assessments for depression, anxiety and alcohol use, were collected at screen. The 14-
question Hospital Anxiety and Depression Score (HADS) was used to assess anxiety and 
depression and the CAGE score used to assess alcoholism.(147, 148) Blood was drawn for 
CD4 cell count (FACS Count™, Beckton Dickinson, NJ, USA) and HIV-RNA (HIV-1 RNA 3.0 
assay®, Bayer Healthcare, Leverkusen, Germany) at baseline, 16 week and 48 week visits. 
Mid-dose efavirenz concentrations were drawn at weeks 16 and 48. The time of blood draw, 
and the self-reported time of most recent ART dosing were recorded. Finally, weight was 
measured and current ART confirmed at all visits.  
Adherence data: 
For pill counts, average pharmacy refill data and self-recall, the data used was that typically 
available to clinic staff during a consultation with a patient.  
Three-day self-recall (SR): At weeks 16 and 48, study staff asked each participant: “Did you 
swallow your pills yesterday / two days ago / three days ago?” Percent doses taken over 
three days was calculated from the participants’ responses.  Study staff were not part of the 
clinical team. Data were only available if a participant attended the study visit. 
Clinic-based pill count (CPC): Participants were instructed to bring any remaining tablets to 
each study visit. Returned tablets were counted by the clinic counsellors. CPC adherence 
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was calculated using the difference between the number of tablets dispensed and the 
number returned and dividing by the number of days between the date of dispensing and 
the current visit date (adjusted for the number of doses per day). At week 16 this would give 
an adherence over the previous one month period and at week 48 an adherence over the 
previous two month period. For the analyses, only the tablet count related to dosing 
efavirenz, nevirapine or, for those who switched to second-line, lopinavir/r dosing was used. 
Pharmacy refill – average method (PR-average): An electronic dispensing system (iDART) 
was used at the site to record the date of ART dispensed and the quantity given to each 
participant. (140, 180) Obvious errors, such as date and dispensing duplications were 
removed. A cumulative PR-average measure was obtained by dividing the number of days of 
efavirenz, nevirapine or lopinavir tablets each patient received between study 
randomisation date and either week 16 or week 48, by the number of days they were in 
care over the same period.  
Pharmacy refill – gaps method (PR-gaps): This measure uses pharmacy dispensing volumes 
and refill visit dates to determine the number of medication-free days in a dispensing 
period. The method allowed for patients to accumulate medication within the study period 
given that most received two additional days of supply each 30 days dispensed. The number 
of medication-free days are subtracted from the number of days in the period, and divided 
by the number of days in the period to give an adherence percentage. The method has been 
shown to predict virological suppression. (58) 
Therapeutic Drug Measuring (TDM): At weeks 16 and 48 visits a sample was taken to 
quantify mid-dosing interval efavirenz concentrations. Mid-dosing interval samples were 
drawn in the morning, after dosing the previous evening. Self-reported time of the evening 
dose was recorded. Samples were kept cold (4oC) until transfer to the laboratory within 2-3 
hours of blood draw. Samples were centrifuged at 3500 revolutions/minute for 10 minutes 
and plasma pipetted into cryovials which were labelled and frozen at -80oC. Efavirenz 
concentrations were analysed using a validated liquid chromatography MS/MS method. 
EAMD data: The daily EAMD data for each participant, from date of randomisation to weeks 
16 or 48, were downloaded from the Wisepill® server. Each device is contacted by the 
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server daily, called a “heartbeat”, to determine functionality and record battery voltage. An 
adherent day was defined as any recorded EAMD opening from 06h00am on that day to 
05h59am the following day. Days with battery voltage <3660V or no heartbeat were 
censored. Cumulative adherence data for EAMD was calculated as the number of adherent 
days divided by the number of days in care.  
Study outcome:  
The primary outcome was virological failure defined as a single HIV RNA of >400 copies/ml 
at week 16 or >40 copies/ml at week 48. (181, 182)  
The secondary outcome was development of HIV-1 drug resistance. Genotype resistance 
tests were done on all those with HIV RNA >500 copies/ml (the minimum HIV-RNA for 
amplification) at weeks 16 or 48. Nucleic acid was extracted with the NucliSens EasyMag 
automated extraction system (bioMérieux, Boxtel, The Netherlands). Genotyping was 
performed by a reverse transcriptase PCR followed by a nested PCR and dideoxynucleotide 
terminator sequencing of PR and RT using a homebrew assay that amplifies HIV-1 nucleotide 
positions 2250 to 4229 (HXB2 numbering), spanning the complete PR gene and RT codons 1 
to 262 and using gene-specific sequencing primers. (183) Participants with one or more 
major resistance mutation as defined by the 2014 IAS update of drug resistance in HIV-1, 
causing resistance to ≥1 of the three drugs in their regimen were classified as 
resistant.(184).  
Each participant had one of four possible study end points:  
Completed study: participants in care at the clinic on the date of the end of study visit. 
Transferred out: participants transferred to another clinic for care during the study period 
and the transfer out date recorded. 
Death: Date of death as recorded in the medical record. 
Loss to follow-up (LTFU): Participants were considered LTFU if they had not attended the 
clinic for more than 12 weeks and were not known to have transferred out or to have died. 
The date of LTFU was taken as the last date they attended the clinic.  
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Statistical analysis: 
Data were analysed using Stata 13.0 (Stata Corporation, College Station, USA). Descriptive 
statistics (number, percentage, median and interquartile ranges) were used to summarise 
the baseline characteristics of the participant group and to tabulate the adherence data.  
All available adherence data were used from each individual who had a HIV-RNA drawn 
within a 4 week window around week 16 (weeks 12 to 20) or a 16 week window around 
week 48 (weeks 32 to 64) in a per-protocol analysis from the time they entered care until 
the date of the respective viral load. 
Univariate and multivariate logistic regression models were used to explore each adherence 
measure’s relationship to virological failure and genotypic resistance at weeks 16 and 48. 
Both outcomes were binary, categorised as described above. The data for each adherence 
measure was continuous. Other variables included in the models (age, baseline CD4 cell 
count and baseline HIV-RNA) were specified prior to the analysis. Receiver Operator 
Characteristics (ROC) were generated to view the overall predictive power of the univariate 
and multivariate models. The area under the curve derived from the ROC, with 95% 
confidence intervals, was used to compare the prediction of virological failure or resistance 
by each adherence measure.  
We also explored associations between EFV concentration and virological failure by 
categorizing EFV concentrations as: below limit of quantification (0.0195mg/ml), >0.0195 
to<1.0 mg/L or ≥1.0 mg/L. We used the Fisher’s exact test to compare proportions. The log10 
values of EFV mid-dose drug concentrations were included as a continuous variable in the 
univariate and multivariate models described above. Log10 values shift the distribution curve 
of the EFV concentration values toward normal for regression modelling. 
Ethical approval:  
The University of Cape Town Faculty of Health Science Research Ethics Committee gave 
approval to conduct this study. Each participant provided written informed consent. The 
trial was registered in the Pan African Clinical Trials Registry, number 
PACTR201311000641402. 
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Results. 
Two-hundred-thirty antiretroviral naïve HIV-positive participants were recruited onto the 
study between July 2012 and March 2013. Baseline characteristics are described in Table 
6.1. The cohort is typical of other African ART cohorts, with a predominance of women. The 
majority were clinically well. More than a third of the cohort had anxiety or depression 
scores (>8) that required further assessment and 15% were alcoholic on CAGE score (≥2). A 
minority had not disclosed their HIV-status to any other person.  
Table 6.1: Baseline demographic, clinical treatment and psychosocial characteristics of all 
230 study participants. 
Variable Full cohort With VL at 
week 16 
With VL at 
week 48 
Number: n 230 160 180 
Female sex: n(%) 150 (65.2) 108 (67.5) 121 (67.2) 
Age in years: mean (sd) 34.5 (9.1)  34.8 (8.9) 35.0 (9.4) 
Height (cm): mean (sd) 164.0 (8.6) 164.1 (8.2) 164.0 (8.1) 
Weight (kg): median (IQR) 67.3 (57.8-79.6) 67.2 (58.0-80.0) 68.1 (58.7-80.4) 
BMI: median (IQR) 24.3 (21.3-29.8) 24.2 (21.5-29.9) 24.6 (21.5-30.7) 
WHO stage: n(%) 
                        1 
                        2 
                        3 
                        4 
  
84 (36.5) 
47 (20.4) 
75 (32.6) 
24 (10.4) 
 
58 (36.3) 
34 (21.3) 
54 (33.8) 
14 (8.8) 
 
73 (40.6) 
39 (21.7) 
51 (28.3) 
17 (9.4) 
CD4 count (cells/mm3): median 
(IQR) 
225 (133-287) 229 (132-288) 233 (144-287) 
Log HIV-RNA (copies/ml): median 
(IQR) 
4.9 (4.4-5.4) 4.9 (4.4-5.4) 4.8 (4.4-5.4) 
NNRTI at start: n(%) 
                         Efavirenz 
                         Nevirapine 
  
228 (99.1) 
2 (0.9) 
 
158 (98.8) 
2  (1.2) 
 
178 (98.9) 
2 (1.1) 
NRTI at start*: n(%) 
                        Tenofovir 
                        Zidovudine 
                        Stavudine 
  
225 (97.8) 
4 (1.7) 
1 (0.4) 
 
159 (99.4) 
1 (0.6) 
- 
 
177 (98.3) 
3 (1.7) 
- 
HADS depression score of 8 or 
above (borderline or case)**: n(%) 
74 (32.1) 55 (34.3) 58 (32.2) 
HADS anxiety score of 8 or above 
(borderline or case)**: n(%) 
89 (38.7) 64 (40.0) 70 (38.9) 
Non-disclosure: n(%) 11 (4.7) 8 (5.0) 7 (3.9) 
CAGE score ≥2: n(%) 35 (15.2) 22 (13.8) 25 (13.9) 
* all were taking 3TC or FTC as a second NRTI. 
** 14-question Hospital Anxiety and Depression Score.  
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Antiretroviral therapy: 
All participants except two initiated efavirenz-based ART; and the remaining two on 
nevirapine-based ART. Both non-nucleoside reverse transcriptase inhibitors (NNRTI) were 
given with two background nucleoside reverse transcriptase inhibitors. Tenofovir was used 
in 97.8% (Table 6.1).  
Retention in care: 
At the end of the study 186 participants remained in care (80.8%) at the study site and a 
further 16 (7.0%) had transferred to care elsewhere. Eight participants (3.5%) had died and 
19 (8.3%) were lost to follow up. One participant withdrew consent. The median number of 
days in care was 385 (364-415 days). 
Virological outcome: 
At week 16, 160 participants had HIV-RNA drawn within the 12 to 20 week window and 149 
(93.1%) were suppressed to ≤400copies/ml (Table 1). At week 48, 180 had a HIV-RNA 
available, of whom 154 (85.6%) were suppressed to ≤40 copies/ml (Table 6.1).  
Adherence measures: 
Table 6.2 describes the median adherence by each measure at weeks 16 and 48, for all 
participants with a HIV-RNA drawn at that visit. Self-report and efavirenz concentrations 
were only available if study protocols were completed. Tablet returns and pharmacy refill 
data were available for all those who attended the clinic, whether or not they attended for 
study procedures. EAMD data were available for all study participants.  
The subjective measure, SR, gave the highest adherence with the most individuals reporting 
100% adherence (median 100%, IQR 100-100%). Clinic-based pill count and both pharmacy 
refill measures also gave a median adherence of 100% at week 16 and 48, but widened 
inter-quartile ranges highlighted some variations within the participants. Cumulative 
adherence by the EAMD showed the lowest median adherence at both visits: 93% (IQR 74-
98%) at week 16 and 86% (IQR 59-94%) at week 48. Median efavirenz concentrations were 
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2.3 (IQR 1.6-4.4)mg/L at week 16, and 2.1 (IQR 1.5-3.4) mg/L at week 48, both largely within 
the currently recognised therapeutic range of 1.0-4.0 mg/L at both time points.  
Table 6.2: Median adherence percentage with inter-quartile range at each study visit, by 
adherence measure. Self-report and EFV concentrations are measured on the date of the 
visit. Tablet counts cover the 30 days (week 16) or 60 days (week 48) before the visit. 
Pharmacy refill and EAMD adherence are cumulative data from baseline to latest time in 
care. 
 n Week 16 n Week 48 
Self-report (%): median (IQR) 140 100 (100-
100) 
169 100 (100-100) 
Pill count (%): median (IQR) 160 100 (92-100) 178 100 (95-107) 
Average pharmacy refill (%): median 
(IQR)* 
158 104 (101-
105) 
178 103 (95-105) 
Gaps pharmacy refill (%): median(IQR)* 158 100 (100-
100) 
178 100 (95-100) 
EAMD adherence (%): median (IQR)* 160 93 (74-98) 180 86 (59-94) 
EFV concentration (mg/L): median(IQR) 136 2.3 (1.6-4.4) 156 2.1 (1.5-3.4) 
Viral suppression: n(%) 160 149 (93.1) 180 154 (85.6) 
*cumulative per protocol measures.  
Failure prediction models: 
At week 48, adherence measured by EAMD, PR-average, PR-gaps and TR significantly 
predicted virological failure (>40 copies/ml) both in univariate and multivariate analyses. 
Odds ratios and adjusted odd ratios for these models are presented in Table 6.3: The odd 
ratio gives the reduction in the risk of failure or resistance for each 10% increase in 
adherence as quantified by the specified method. Neither log mid-dosing interval efavirenz 
concentrations included as a continuous variable nor self-reported adherence predicted 
failure. For all multivariate models, an increased CD4 cell count at baseline was associated 
with reduced odds of failure. Four full models (EAMD and PR-average at weeks 16 and 48) 
are presented in supplementary Table 6.4.  
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Table 6.3: Odds ratios (OR) or adjusted odds ratios (aOR) with 95% confidence intervals (CI) 
for failure or resistance given a 10% increase in the adherence variable (or a 1 log increase 
in EFV concentration) in each logistic regression model. Univariate models use only the 
adherence variable in the model with the outcome variable, multivariate models include the 
adherence variable and three baseline variables (CD4 cell count, log HIV-RNA and age) with 
the outcome variable. There are four outcome variables: the risk of virological failure to >40 
copies/ml at week 48, the risk of virological failure to >400 copies/ml at week 16, the risk of 
resistance (presence of ≥1 IAS major mutation at genotyping) at weeks 16 and 48. 
Adherence 
measure 
Univariate model Multivariate model 
 OR (95%CI) p-value aOR (95%CI) p-value 
Virological failure (>40 copies/ml) at week 48: 
EAMD* 0.87 (0.82-0.94) <0.001 0.89 (0.82-0.95)  0.001 
PR-average 0.78 (0.70-0.88) <0.001 0.78 (0.69-0.87) <0.001 
PR-gaps 0.69 (0.56-0.82) <0.001 0.68 (0.56-0.82) <0.001 
CPC 0.89 (0.82-0.96)  0.004 0.88 (0.80-0.96)  0.004 
Log10EFV 0.40 (0.16-1.03)  0.059 0.52 (0.19-1.37)  0.184 
SR 0.98 (0.89-1.08)  0.698 0.98 (0.88-1.09)  0.720 
Resistance (presence of ≥1 major mutation) at week 48: 
EAMD 0.74 (0.64-0.87) <0.001 0.68 (0.53-0.88)  0.003 
PR-average 0.77 (0.69-0.87) <0.001 0.77 (0.66-0.89) <0.001 
PR-gaps 0.74 (0.65-0.85) <0.001 0.77 (0.66-0.89)  0.001 
CPC 0.85 (0.77-0.94)  0.002 0.82 (0.69-0.98)  0.031 
Log10EFV 0.14 (0.04-0.45)  0.001 0.14 (0.02-0.78)  0.025 
SR 0.92 (0.83-1.02)  0.102 0.92 (0.78-1.08)  0.316 
Virological failure (>400 copies/ml) at week 16: 
EAMD 0.93 (0.86-1.01)  0.085 0.96 (0.87-1.06)  0.459 
PR-average 0.68 (0.55-0.83) <0.001 0.66 (0.50-0.73)  0.004 
PR-gaps 0.64 (0.51-0.82) <0.001 0.64 (0.47-0.88)  0.006 
CPC 0.89 (0.78-1.03)  0.133 0.94 (0.78-1.13)  0.491 
Log10EFV 0.17 (0.04-0.75)  0.020 0.20 (0.03-1.47)  0.115 
SR 0.92 (0.83-1.03)  0.163 0.98 (0.83-1.01) 0.765 
Resistance (presence of ≥1 major mutation) at week 16: 
EAMD 0.93 (0.85-1.01)  0.085 0.96 (0.86-1.07)  0.435 
PR-average 0.85 (0.72-0.99)  0.036 0.87 (0.72-1.06)  0.171 
PR-gaps 0.85 (0.71-1.01)  0.066 0.88 (0.69-1.11)  0.287 
CPC 0.90 (0.80-1.01)  0.069 0.93 (0.82-1.06)  0.316 
Log10EFV 0.34 (0.08-1.81)  0.228 0.43 (0.07-2.66)  0.362 
SR 0.93 (0.83-1.03)  0.147 0.97 (0.85-1.11)  0.647 
*EAMD = electronic adherence monitoring device data; PR-average= average pharmacy refill 
data; PR-gaps= pharmacy refill gaps data; CPC=clinic-based pill count data; EFV = efavirenz 
mid-dosing interval data; SR= 3-day self-recall data. 
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Table 6.4: Full multivariate logistic regression models predicting virological outcomes at 
week 16 and 48 using EAMD and PR-average adherence measure. 
 
6.4a. Full model predicting virologic outcomes at week 48, with EAMD as the adherence 
measure (n=179) 
Week 48 failure Odds Ratio Std. Error p-value 95% confidence intervals 
Week 48 EAMD 0.97 0.01 0.001 0.95-0.99 
Age (years) 0.97 0.03 0.221 0.92-1.02 
Baseline CD4 0.99 0.00 0.070 0.99-1.00 
Log baseline VL 1.06 0,53 0.901 0.40-2.82 
 
6.4b. Full model predicting virologic outcomes at week 48, with PR-average as the 
adherence measure (n=177) 
Week 48 failure Odds Ratio Std. Error p-value 95% confidence intervals 
Week 48 PR-
average 
0.94 0.12 <0.01 0.92-0.97 
Age 0.97 0.03 0.366 0.92-1.03 
Baseline CD4 0.99 0.00 0.013 0.99-1.00 
Log baseline VL 0.77 0.42 0.635 0.27-2.23 
 
6.4c. Full model predicting virologic outcomes at week 16, with EAMD as the adherence 
measure (n=159) 
Week 16 failure Odds Ratio Std. Error p-value 95% confidence intervals 
Week 16 EAMD 0.99 0.01 0.459 0.97-1.01 
Age 0.87 0.05 0.024 0.77-0.98 
Baseline CD4 0.99 0.00 0.007 0.98-1.00 
Log baseline VL 3.99 3.44 0.109 0.73-21.6 
 
6.4d. Full model predicting virologic outcomes at week 16, with PR-average as the 
adherence measure (n=157)  
Week 16 failure Odds Ratio Std. Error p-value 95% confidence intervals 
Week 16 PR-
average 
0.91 0.03 <0.01 0.85-0.97 
Age 0.88 0.05 0.029 0.78-0.98 
Baseline CD4 0.99 0.00 0.014 0.98-1.00 
Log baseline VL 9.07 10.8 0.063 0.89-92.5 
 
The ROC curves in Figure 6.1a show the predictive value of each adherence variable on 
virological failure (univariate models) at weeks 48. Figure 6.2 is a comparison of AUC ROC 
for each measure, with 95% confidence intervals. EAMD (ROC AUC 0.73, 95%CI 0.61-0.83), 
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PR-average (ROC AUC 0.73, 95%CI 0.61-0.85), and PR-gaps (ROC AUC 0.72, 95%CI 0.59-0.84) 
best predicted failure. 
At week 16, using <400 copies/ml as the definition of failure, analyses showed that both 
pharmacy measures were predictive of failure, in both univariate and multivariate models. 
Log10 EFV concentration also reached significance in the univariate model (for every 10 
times or 1 log increase in EFV concentration, the odds of failure reduced by 83%), but the 
other adherence measures did not (Table 6.3 and Figure 6.3b).  
Figure 6.1: Receiver Operating Characteristic (ROC) curves showing prediction of virological 
failure (>40 copies/ml) and resistance at week 48 by six adherence measures. Univariate 
model data are shown.  
Figure 6.1a shows prediction of virological failure to <40 copies/ml at week 48 using 
adherence measures at week 48. 
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Figure 6.1b shows prediction of resistance at week 48 using adherence measures at week 
48.  
 
Figure 6.2: Comparison of AUC ROC, with 95% confidence intervals, for week 48 virological 
failure (Figure 2a) and week 48 resistance (Figure 2b), by each of six adherence measures.  
Figure 6.2a     Figure 6.2b.  
 
*EAMD: electronic adherence monitoring device data; PR-ave: pharmacy refill average data; 
PR-gaps: pharmacy refill gaps data; CPC: clinic-based pill count data; EFV: spot efavirenz 
concentrations; SR: 3-day self-recall data. 
Categorical analysis of EFV concentrations:  
At week 48, using the Fisher Exact test, those with an EFV concentration below the limit of 
quantification (n=3) were more likely to fail (p=0.046) than those with sub-therapeutic 
concentrations (>0.0195 to <1 mmol/L, n=9) or those whose concentrations were 
therapeutic (≥1.0mmol/L, n=144). At week 16 there was no relationship between the same 
three categories of EFV concentration and virological failure. 
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Resistance outcome: 
All 14 of the participants whose HIV RNA was >400 copies/ml at week 16 qualified for HIV-1 
resistance genotyping. One specimen was lost and one could not be amplified (HIV-RNA 534 
copies/ml). Two of the remaining 12 participants had no major resistance mutations. Eight 
(66.7%) participants expressed the K65R mutation, conferring resistance to tenofovir, and 
three the M184V mutation, conferring resistance to lamivudine/emtricitabine. Of those with 
K65R at week 16, four continued to have raised viral loads at week 48, one transferred to 
care elsewhere, so week 48 data was not available, and three had suppressed virus.  Two of 
the four with raised viral loads continued to have the K65R mutation present at week 48, 
and two did not. Of the three patients with the M184V mutation at week 16, all had raised 
viral loads at week 48. The M184V mutation was seen in two of these. 
All 10 who expressed resistance had NNRTI mutations, including L100I, K101E, K103N, 
V106M, Y181C, Y188C/Y/L, G190A/G/S and H221HY. Despite only efavirenz and nevirapine 
being used, mutations conferring resistance to etravirine and rilpivirine were noted in 3 
participants: one each of V90I, E138A and V179D. Supplemental Table 6.5a shows the 
resistance patterns expected from these mutations. The majority of those failing with 
available genotype had high level resistance to the NNRTI and tenofovir by week 16. 
Twenty-seven participants had a HIV RNA of >40 copies/ml at week 48. Fourteen (51.9%) 
had HIV RNA >500 copies/ml and qualified for HIV-1 resistance genotyping. One specimen 
was lost and two could not be amplified (HIV-RNA 2331 and 45745 copies/ml). One of the 
remaining 11 participants had no major resistance mutations. Two (18%) participants 
expressed the K65R mutation and four (36%) the M184V mutation. As at week 16, the 
majority of the remaining mutations, in all 11 who expressed resistance, were NNRTI 
mutations, including L100I, K101E, K103N, V106M, Y181C, G190A, H221HY and F227L. 
Again, mutations to etravirine and rilpivirine were noted in 3 participants: one with E138A 
and two with V179D. Supplemental Table 6.5b shows the expected resistance patterns. The 
majority of those failing with available genotype had high level resistance to the NNRTIs.  
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Tables 6.5a and 6.5b. Resistance patterns for those with raised HIV-RNA that could be 
amplified at weeks 16 and 48: n(%),according to the Stanford University HIV Resistance 
Database genotypic interpretation algorithm.  
Table 6.5a: resistance patterns at week 16. 
Week 16 Susceptible Low level 
resistance  
Intermediate 
resistance 
High level 
resistance 
n 
Lamivudine (3TC) or 
emtricitabine (FTC) 
2 (16.7)  7 (58.3) 3 (25.0) 12 
Abacavir (ABC) 2 (16.7) 1 (8.3) 7 (58.3) 2 (16.7) 12 
Zidovudine (AZT) 11 (91.7) 1 (8.3)   12 
Stavudine (d4T) 3 (25.0) 1 (8.3) 8 (66.7)  12 
Tenofovir (TDF) 4 (33.3)   8 (66.7) 12 
Efavirenz (EFV) 2 (16.7)     10 (83.3) 12 
Nevirapine (NVP) 2 (16.7)     10 (83.3) 12 
Etravirine (ETR) 4 (33.3) 2 (16.7) 5 (41.7) 1 (8.3) 12 
Rilpivirine (RPV) 4 (33.3) 1 (8.3) 2 (16.7) 5 (41.7) 12 
 
Table 6.5b: resistance patterns at week 48. 
Week 48 Susceptible Low level 
resistance  
Intermediate 
resistance 
High level 
resistance 
n 
Lamivudine (3TC) or 
emtricitabine (FTC) 
6 (54.5)  1 (9.1) 4 (36.4) 11 
Abacavir (ABC) 6 (54.5) 2 (18.2) 1 (9.1) 2 (18.2) 11 
Zidovudine (AZT) 11 (100)    11 
Stavudine (d4T) 7(63.6)  3 (27.3) 1 (9.1) 11 
Tenofovir (TDF) 8 (72.7) 1 (9.1)  2 (18.2) 11 
Efavirenz (EFV) 1 (9.1)     10 (90.9) 11 
Nevirapine (NVP) 1 (9.1)     10 (90.9) 11 
Etravirine (ETR) 5 (45.5) 1 (9.1) 3 (27.3)   11 
Rilpivirine (RPV) 5 (45.5) 2 (18.2) 1 (9.1) 2 (18.2) 11 
 
Resistance prediction models: 
Each adherence variable was modelled against the risk of resistance alone (univariate) and 
with age, CD4 cell count at baseline and log baseline HIV-RNA (multivariate) in logistic 
regression models for prediction. Adherence as quantified by EAMD, PR-average, PR-gaps, 
TR and log10 EFV concentration were all significantly predictive of resistance in both 
univariate and multivariate analyses at week 48 (Table 3). Self-report was non-significant in 
either model. Reduced age and decreased CD4 cell count at baseline significantly increased 
the odds of resistance in all multivariate models at week 48.  
page 153 
 
The area under each of the receiver operator characteristic curves in Figure 6.1b shows the 
predictive value of each adherence measure in the univariate models on resistance at weeks 
48, with 95% confidence intervals for inter-measure comparison shown in Figure 6.2b. While 
cumulative EAMD best predicted resistance with the narrowest 95% confidence intervals 
(AUC ROC 0.92, 95%CI 0.87-0.97), it was not significantly better than either pharmacy refill 
measure (PR-average AUC ROC 0.86, 95%CI 0.67-1.0; PR-gaps AUC ROC 0.83, 95%CI 0.65-
1.00). 
Only PR-average predicted resistance at week 16 (AUC ROC 0.72, 95%CI 0.57-0.90). ROC 
data from the univariate models is presented in Figure 6.3b and odds ratios in Table 6.3. 
Reduced age and decreased CD4 cell count at baseline significantly increased the odds of 
resistance in all multivariate models at week 16. 
Figure 6.3 Receiver Operating Characteristic (ROC) curves showing prediction of failure 
(>400 copies/ml) and resistance at week 16 by each of the six adherence measures: figure 
6.3a shows the AUC ROC using >400 copies/ml as the definition of failure; and figure 6.3b 
shows the prediction of genotypic resistance at week 16 by each of the six adherence 
measures.  
Figure 6.3a shows prediction of virological failure to <400 copies/ml at week 16 using 
adherence measures at week 16.  
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Figure 6.3b: Prediction of week 16 genotypic resistance by week 16 adherence measures.  
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Discussion. 
We found high levels of adherence using both spot and cumulative measures. SR yielded the 
highest adherence estimate, but was not significantly associated with viral suppression or 
resistance outcomes. We found that cumulative EAMD adherence data and pharmacy refill 
measures best predicted virological failure and development of resistance at week 48. 
Pharmacy refill measures best predicted failure and resistance at week 16. 
Self-reported adherence measures to monitor adherence are widely used. (50-53) Most 
studies find that self-reported measures overestimate adherence, likely due to recall and 
social desirability bias, making this measure unreliable for research purposes or clinical 
monitoring. However, a self-report of incomplete adherence can be clinically useful in 
triggering adherence intervention. (55) 
In contrast, four of the five objective adherence measures predicted virological failure: CPC, 
PR-average, PR-gaps and EAMD data. Average pharmacy refill data has been shown to 
predict virological outcomes and mortality reliably in the past. (5, 57, 59) Our group has 
shown that short term pharmacy gap adherence predicted virological failure on second-line 
ART. (58) Software to calculate PR-average or PR-gaps could easily be added to electronic 
dispensing systems, which are widely used in resource-limited settings. Clinic-based pill 
count is not widely recommended as it are subject to “pill dumping” and can be complex to 
perform in a large clinic. (5) Nonetheless, CPC performed reasonably well in this study. 
While EAMD are often considered the gold standard adherence measure they not routinely 
used in clinical care. However, recent data shows EAMD can reduce costs associated with 
HIV RNA monitoring and real-time devices can detect early virologic rebound before 
established failure. (5, 185, 186) With the availability of newer, more affordable real-time 
technologies, electronic strategies should be reconsidered.  
In categorical analysis, at week 48, the three participants with EFV concentrations below the 
limit of quantification were more likely to have virologic failure. By altering the distribution 
of the concentrations through the use of log values in the regression model, we found that 
the log values of mid-dose EFV concentration were predictive of resistance at week 48, with 
wide confidence intervals, but not of failure. Most drug concentrations were therapeutic, 
possibly reflecting white coat pre-visit dosing, leaving few with concentrations below 
therapeutic where virological failure would be more likely. The few participants with sub-
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therapeutic concentrations limit the interpretation of this data. Larger studies including 
more participants with sub-therapeutic EFV concentrations are needed to adequately 
explore the ability of TDM to predict virological failure and resistance.  
Most of those remaining in care at both week 16 and week 48 had virological suppression. 
However, the majority of those who had detectable HIV RNA also had resistance that would 
compromise at least one drug in their antiretroviral regimen, even at 16 weeks into therapy. 
While both pharmacy refill adherence measures at week 16 predicted virological failure to < 
400 copies, only the PR-average method predicted this early resistance. Using early 
pharmacy refill data to predict those with failure is practical and easy to achieve. EAMD data 
was highly predictive of resistance at week 48, as were both pharmacy refill measures and, 
to a lesser extent, pill count data. 
The collection of multiple adherence measures, prospectively in a single cohort is a strength 
of our study as it allowed direct comparison of multiple adherence measures, which has not 
been achieved in many other studies.(61, 64) Our study was based on maximum use of 
existing adherence data and used a per protocol approach to analysis, with those who did 
not have virological data at weeks 16 or 48 treated as missing for the predictive models. 
Losses to care in this cohort were similar to those previously reported at this site, and all 
participants had data included in the cumulative adherence measures. (40, 154) A study 
limitation, however, was that SR and CPC data were only available for the one or two 
months preceding the week 16 or 48 visit and not over the complete study period. These 
measures may have performed better over a cumulative period.  
In conclusion, adherence as measured by pharmacy refill measures and electronic 
monitoring were the best predictors of resistance and virological failure in this prospective 
study. Pharmacy refill data is widely available and would be the more immediately 
implementable option, particularly in resource-poor settings, but consideration should be 
given to the use of either measure as preferable adherence monitoring strategies. 
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Chapter seven: Discussion and conclusion.  
7.1. Synthesis of results. 
Objective one: The primary outcome of the randomised controlled trial (Chapter three) 
answered the first objective of this thesis. Text reminders after missing a dose did not 
improve cumulative adherence nor improve retention in care. However, text reminders did 
alter adherence behaviour, but these changes were more subtle than we anticipated. 
Messaging reduced the number of treatment interruptions of more than 72 hours and 
altering adherence patterns. Such detail of daily adherence patterning can only be explored 
using electronic adherence monitoring; all other measures give less granular data e.g. 
median adherence over the past month. (187) The impact of the text messages could also 
be seen in the tendency of those in the intervention arm to wait for the message before 
dosing (Figure 3.2). 
Objective two: The iDART system can be used to monitor adherence and retention in care 
more accurately. Two adherence measures generated from pharmacy dispensing data were 
shown in Chapter six to be equivalent in predicting virological failure and resistance at week 
48 to the Wisepill device. In addition, Chapter four showed that the pharmacy database 
more rapidly and accurately identified those who discontinued care than standard cohort 
reporting processes. Generating lost to care or discontinuation reports for tracing also took 
less staff time with iDART than cohort reporting. This is important as ART access expands 
and resources in sub-Saharan Africa become further stretched. Adherence in many local 
cohorts continues to be monitored using tablet return and self-report, while pharmacy data 
is available but neglected.  
Objective three: In an ART-naïve population efavirenz levels might be expected to be 
predictive of virological outcomes. This was not evident using multivariate linear regression 
modelling (Chapter six) at week 16 or 48, due to small numbers of individuals with sub-
therapeutic efavirenz concentration at either time point.(65, 68) Efavirenz is routinely 
overdosed, using the 600mg dose, with many more people having supra-therapeutic levels 
(>4mg/L) than sub-therapeutic levels (<1mg/L).(165) Log transformation of the efavirenz 
concentrations allowed for better exploration of the lower range of efavirenz 
concentrations (Chapter five). Both log efavirenz concentrations and baseline CD4 count 
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were predictive of virological outcome using Cox proportional hazard modeling that 
included all available efavirenz concentration data.  
Whereas slower metaboliser status was linked to increased EFV concentration, it was not 
linked to virological outcome. Slowing of cytochrome 2B6 metabolism from wild type tends 
to increase efavirenz levels to above the therapeutic range. (71, 164, 168) Analysis also 
showed a cut-off mid-dose efavirenz concentration of 0.7 mg/L as the most predictive lower 
limit related to a decreased risk of virological failure. This contributes to growing data 
suggesting the lower limit of the normal therapeutic range (1.0mg/L) is too high 
(1mg/L).(165)  
Objective four: Comparison of multiple adherence measures was presented in Chapter six. 
While adherence in the RCT cohort was generally good (Table 6.2), reflective of the whole 
Gugulethu cohort, two measures stood out.(38) Cumulative Wisepill electronic adherence 
data and pharmacy refill data were significant predictors of both virological failure and 
development of HIV-1 resistance. Use of these measures would reduce the discrepancy 
between adherence and virological outcome seen with the use of pill count data.(38) Data 
from Wisepill is more granular and can be responded to on a daily basis, but pharmacy refill 
measures are widely available. Tablet returns and efavirenz concentrations were less good 
at predicting virological failure, while self-report obtained from routine questioning had no 
value.  
7.2. Discussion. 
Impact of electronic reminders 
Adherence:  
On review of the literature pertaining to electronic reminders in ART, it appeared that 
reminder text messages after a missed dose should benefit adherence. While the ideal 
format of messaging intervention was not completely clear (page 82), in 2012, success had 
been shown with weekly messaging, which did not induce message fatigue.(50, 107) 
Assuming a median adherence of 90%, based on prior data from this cohort, we anticipated 
that missed dose reminder messages would need to be sent once a week or less.(38) Simple 
message content to act as a dose trigger also appeared adequate, as studies using 
motivational messages did not show added benefit related to the messaging type.(107) 
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Sabin et al designed a study in China that was very similar to ours, with reminders sent 30 
minutes after a missed dose, also based on the adherence literature as of 2012.(62) 
However, in contrast to our study, her intervention showed strong adherence benefit. Our 
intervention did not show benefit on cumulative adherence, nor on virological outcome. 
One important aspect where our study differed from that of Sabin et al, is that we studied 
only ART-naïve patients. Our cohort of ART-naïve adults showed relatively good median 
adherence (over 80% using Wisepill and 90% with other measures), with more than 67% 
(155/230) of those starting ART achieving viral suppression at a year at the site. All patients 
in this cohort received pre-treatment education and adherence support from a counselor if 
pill count adherence was less than 90%, or their week 16 viral load was raised. It is likely 
that the effect of the adherence intervention was minimised by the many who were 
adherent, and who would have been adherent even without any intervention. We were 
looking for an effect where the signal, poor adherence, was small. All of the studies 
reviewed which pre-selected known non-adherent patients showed adherence and/or 
biological benefit (Figure 2.8). (51, 53, 62) The results were more diverse when naïve 
participants were included. (50, 107, 130, 131, 135) 
The Wisepill reminder text message intervention was largely designed to impact on daily 
medication dosing. We assumed that most missed doses were forgotten or missed 
accidentally. If this was this case, then a dosing reminder should be enough to initiate a 
dosing process. A non-response to a reminder implies more purpose than forgetfulness to 
the missed dose. While a large proportion of missed doses have been attributed to 
forgetfulness, other reasons for missing doses must also be considered.(142, 188)  
The median age in our population was 34.5 years. For every 10 years younger there was a 
27% reduction in the odds of pills being taken. Younger people are already known to be at 
risk of poor adherence.(189) Despite the expectation that younger people would respond 
positively to the use of mobile phone technology, we did not see this in our study, and there 
are there no other studies in the literature examining whether mobile phone technology can 
be used specifically to reach the young.  
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Non-disclosure is a commonly cited reason for poor adherence , but in our study only a 
small proportion of individuals (<5%) had not disclosed their HIV status to any others. 
However, depression, anxiety and alcohol use, which might lead to more missing of doses, 
were highly prevalent (Table 3.1). Management options for these mental illnesses in the 
South African public sector are limited. Social isolation or issues of stigma were also not 
addressed in this study. Others have attempted to address social isolation with text 
messaging: for example, Pop-Eleches designed motivational text messages with the 
assistance of the local staff and community, but no benefit over simple reminders was 
shown.(107, 133, 135) Mental illness and social isolation might be better addressed by 
direct human contact. Bidirectional messaging, generating a phone call as a response to a 
request or on non-response to a text requiring a reply, does seem to improve adherence 
and potential biological outcomes: two of the three studies with biological benefit allowed 
for a phone call to those in need.(50, 53) 
While there remains some need for human interaction, as well as electronic reminders, this 
support does not need to be provided by expensive clinicians. Task-shifting to nursing staff 
is already common practice in South Africa.(81, 116) Less-intensive models of care 
supported by lay staff and encouraging patients to form their own networks of support have 
shown great success (page 56).(13, 115) Perhaps a further step to community-based care 
could be taken for stable patients.(101) 
Treatment interruptions: 
The reduction in treatment interruptions of >72 hours in the intervention arm of the RCT 
has important implications. Treatment interruptions increase the risk of resistance and it is 
important to minimise them.(17, 38, 43) Regular messaging prompted individuals to dose at 
least once every three days, compared to the control arm where there were longer gaps in 
treatment (Figure 7.1).   
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Figure 7.1: 
 
The pharmacokinetic profiles of tenofovir and efavirenz with longer half-lives, may maintain 
therapeutic drug concentrations with dosing every third day.(17) Real-time electronic 
adherence monitoring could allow exploration of a range of interventions to address 
treatment interruptions immediately as they happen, in order to prevent both viral 
rebound, with potential resistance development, and treatment discontinuation.  
Some populations were at increased risk of treatment interruptions, including younger 
people (Chapter 3), where the relative count of treatment interruptions increased by 14% 
for every 10 year decrease in age. Men, and those with high depression scores, were also at 
increased risk of treatment interruption and might benefit from electronic reminders or 
another real-time intervention.  
Retention in care: 
While the focus of the study was the impact of electronic reminders on adherence to daily 
dosing, or adherence ‘implementation’, we also examined retention in care at 48 weeks. 
The outcomes of participants included in the RCT were entirely reflective of the cohort in 
care at the site at a year. This included rates of transfer to other sites, deaths and rates of 
treatment discontinuation.(40)  
In the RCT cohort, 19 individuals (8.2%) were lost to follow up by a year, which matches 
cohort data from the same cohort in 2010 and 2013, and was less than the anticipated 10% 
when designing the RCT.(140, 154) Of note, most (more that 50%) of these losses to care 
occurred before week 16, and all before week 32 i.e. very early on in treatment.(190)  
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A further 16 individuals (6.9%) were transferred to care at other clinics during the year.(40, 
154) Those who were lost to follow-up or who transferred out were again more likely to be 
young. The text message intervention also did not have any impact on loss to follow-up, or 
on transfers to care elsewhere. 
In summary, while the text message reminders did not improve overall adherence or viral 
suppression, some interesting lessons were learnt. The impact of reminders on treatment 
interruption is significant and requires more exploration; younger adults were at higher risk 
of poor adherence, loss to care and treatment interruptions; and the impact of the text 
messaging reminders might have been maximized by identifying non-adherent individuals 
prior to intervening. 
Adherence measurement methodologies 
Comparing the six differing methods of quantifying adherence was novel (Chapter five). No 
other study has compared subjective, objective and electronic methods of measuring 
adherence together with therapeutic drug monitoring in a single cohort. Another strength of 
the study was the use of resistance as a secondary outcome. Again, this cohort had good 
overall adherence execution, reflective of the support at the site.(38) Most of the measures 
overestimated adherence, or lacked the sensitivity to identify non-adherence, with self-
report achieving a median and IQR of 100% (Table 6.2). Only Wisepill data showed lower 
median adherence values, as anticipated for electronic devices.  
These adherence measures were compared directly using univariate linear regression 
models to generate the area under receiver operating characteristic curves (AUC ROC). The 
AUC ROC quantifies the overall ability of the model to discriminate between individuals with 
the outcome of interest, i.e. failure or resistance, and those without. A larger AUC ROC 
denotes better prediction of the outcome. A ROC AUC of 1.0 would denote excellent 
prediction (Figure 7.2) and one of 0.5 would be worthless.  
Self-report has an AUC ROC of 0.5-0.56 for both failure and resistance, so rendering this 
measure more or less useless for measuring outcomes. Simply asking whether a person has 
taken their medication or not usually results in a positive answer. Other communication 
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styles, using problem solving or motivational interviewing skills might improve chance of a 
missed dose being reported, but these were not explored here. 
Figure 7.2 
 
Both Wisepill and pharmacy refill adherence were highly predictive of virological failure 
(ROC AUC 0.73-0.76) and even more so of HIV-1 resistance (ROC AUC 0.82-0.91) at week 48 
(Figures 6.1 and 6.2). While it was hypothesised that Wisepill data might improve outcome 
prediction compared to pill count data, the success of the pharmacy refill measures on 
predicting outcomes was unanticipated, even though the benefit of pharmacy systems in 
identifying those lost to care had already been shown (Chapter 4).(57) This finding 
emphasizes the importance of utilising pharmacy systems. Drug dispensing data can be used 
for both day to day adherence management as well as for retention tracking. Clinical staff 
already have experience with pharmacy systems, and data from the electronic dispensing 
record could be incorporated into existing clinic management tools. While use of pharmacy 
data requires consistent and accurate data capture, the method utilises staff and resources 
already in place. All clinics in the Western Cape use electronic dispensing systems. The 
disadvantage of pharmacy methods is that the data cannot pick up short term interruptions 
in treatment, and discontinuation from care would only be noted once the next pharmacy 
pick-up date was missed. 
Wisepill data also gives an excellent reflection of adherence when used well. Improvements 
in the device are making it easier to use. Battery life has been prolonged to six months, so 
reducing days when the battery is flat/dead; and data is stored on the device when not near 
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a cell phone tower, to be uploaded later. All data is kept in “the cloud” and the device will 
continue to collect data from an individual anywhere in the country, allowing between clinic 
transfer without a loss of data. Experience in using the Wisepill is increasing world-wide, and 
data analysis tools are also improving.(62, 63) Regular automated reports of those with 
lapses in dosing or problem devices can be generated. Monthly pie charts of patient dosing 
behaviour are available for patient feedback (page 28). Data is more granular and detailed 
than that of pharmacy data as the device has the advantage of noting missed dosing in real-
time, allowing immediate intervention. However, it still costly and regular use in a clinic 
setting might require extra staffing. Costs could potentially be offset by a reduction in the 
number of viral loads: 92% of those with adherence ≥85% were successfully suppressed, 
compared to 77% of those with lower adherence in our study.  
The clinic-based pill count methodology, which has been used to measure adherence in the 
Gugulethu cohort since 2002, was weakly predictive of failure (AUC ROC 0.64) and 
resistance (AUC ROC 0.67) at week 48. This measure requires the effort of the counseling 
team to count tablets and calculate percentage adherence since the previous visit. 
Pharmacy refill measures were better predictors of virological outcomes that pill counts and 
could be automatically generated by ART programmes with electronic dispensing, thus 
saving staff time. 
Early in treatment, at week 16, only pharmacy refill measures impacted on virological failure 
and no measure predicted HIV-1 resistance. Each adherence measure was used in a 
multivariate model, which included the CD4 cell count and HIV-1 RNA from baseline, as well 
as age. At week 16 the predictive value for the multivariate model alone (with no adherence 
variables included) was already very high (AUC ROC 0.88) and improved only slightly by the 
addition of the pharmacy refill adherence variables (AUC ROC 0.91) and not at all by the 
other measures. This early in treatment, knowledge of pre-treatment clinical status appears 
to be more important than knowledge of an individual’s adherence. However, by week 48 
the increasing value of the adherence measure can be seen with 5-10% improvements in 
the AUC ROC with Wisepill and pharmacy refill measures. A limitation of these per-protocol 
analyses is that the participant required a viral load to be included in the analysis. We have 
no information on those who did not return to the clinic at week 16.  
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In summary, Chapters 4 and 6 show the potential of the pharmacy dispensing system in 
monitoring both adherence and retention outcomes and should be used more widely for 
both purposes. Both of the pharmacy refill adherence measures used in Chapter 6 as well as 
electronic adherence monitoring using the Wisepill device have the potential to predict 
treatment and resistance outcomes at week 48. Data from the Wisepill substantially 
reduced the discrepancy between adherence and virological outcome. Pharmacy refill 
measures and Wisepill stand out as the best options for monitoring adherence throughout. 
Therapeutic drug monitoring as an adherence tool  
Drug concentrations have not been used to measure adherence in any of the mobile phone 
intervention studies. Initial exploration in our adherence comparison paper (Chapter 6) 
showed that modelling EFV concentration using linear regression did not result in prediction 
of virological outcomes at either week 16 or 48, as most EFV concentrations were within the 
therapeutic range. The few individuals with drug concentrations below the limit of 
quantification (n=3) at week 48 did have worse virological outcomes when compared 
categorically to those with detectable efavirenz, but the confidence intervals were wide, 
due to the small sample size. Categorical analysis at above and below 1mg/L, the current 
suggested lower therapeutic threshold, however, showed no association of lower 
concentrations with failure (Chapter 6). 
Two procedures assisted to clarify the impact of efavirenz concentration on virological 
outcome in Chapter 5. Log transforming the data changed the distribution to spread out the 
lower concentrations more likely to impact on virological outcome (Figure 7.3). The Cox 
proportional hazard model also allowed incorporation of both week 16 and week 48 data 
into one model. This model showed that efavirenz concentrations highly significantly 
impacted on virological outcomes (for every time efavirenz concentration doubled, the 
hazard of failure decreased by 21%). In addition, the efavirenz concentration below which 
rate of failure increased (0.7mg/L) fell in-between the lower limit of assay quantification 
(0.0195mg/L) and the lower end of the predicted therapeutic range (1mg/L), which fitted 
with the categorical analyses completed in Chapter six and described above.  
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Figure 7.3 
 
Genotypic metaboliser status did not impact on virological outcome. Even in those who 
were extensive metabolisers, the lower inter-quartile range of drug concentration remained 
higher than the cut-off value of 0.7 mg/L established here. However, low efavirenz 
concentrations do drive virological failure. It is likely to be poor adherence that pushes the 
concentrations below the critical threshold, rather than metaboliser status.  
The identification of drug within the body is the only means of being certain that the 
medication has actually been taken. All other adherence measures can be modified by the 
individual without drug being ingested. Our findings suggest that efavirenz therapeutic drug 
monitoring could be used programmatically to predict failure particularly in those with poor 
adherence. However, pharmacogenetic sampling, which is unaffordable, would not be 
required.  
Novel messages 
While the lack of positive impact on cumulative adherence and virological outcomes with 
the Wisepill text message reminder intervention was disappointing, there have been a 
number of novel outcomes from this work. This is the first time that text messaging has 
been noted to reduce treatment interruptions, a potentially important finding that can be 
explored further.  
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This was the also the first time that pharmacy refill data and electronic data were directly 
compared and learning that pharmacy refill is on a par with electronic methods in resource-
poor settings is a crucial piece of information that should be implemented 
programmatically.  
We have shown that in a naive cohort, contrary to prior recommendations, efavirenz 
therapeutic drug monitoring is a potentially useful adjunct to routine adherence measures. 
We have also confirmed that the lower threshold of the normal range for efavirenz is set too 
high and have contributed to data supporting the use of a lower dose of EFV.(165) 
Strengths and limitations 
There were a number of strengths to this work. It comprised a blend of observational cohort 
data together with more rigorously collected data from a randomised controlled trial to 
improve the depth of evidence on which adherence messages are based. As the 
characteristics of the RCT cohort in terms of demographic information, adherence and 
discontinuation data are comparable with those of the observational cohorts, data from the 
RCT can be easily generalised to the whole cohort and potentially more widely, as the 
Gugulethu cohort is representative of many other sub-Saharan cohorts.  
The study included adherence as measured by objective and electronic methods, not only 
subjective methods; and, critically, presented biological outcome measures in addition to 
these. The RCT was completed over a 12 month period – which can be seen as a strength, as 
many adherence studies are of much shorter duration (See Tables 2.1, 2.4, 2.5). However, 
there is still a need for such detailed adherence data to be collected over a much longer 
time frame, as people spend more years on ART.  
There were a number of study limitations. Due to the two-year window of funding for the 
RCT, we had to recruit rapidly (over 6 months). In order to recruit the 230 individuals 
needed to power the study within that time frame, a naïve cohort had to be selected. As 
discussed above, this seems likely to have reduced the impact of the intervention, by 
reducing the number of participants in the study with poor adherence and for whom the 
text message reminder might have had benefit. In addition, the Hannan Crusaid Treatment 
Centre site has been the focus of research attention relating to adherence in the past. 
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Multiple efforts to support adherence to ART were already in place, including pre-treatment 
literacy sessions, regular monitoring of objective adherence measures and a stepped-up 
adherence intervention should adherence drop <90% or viraemia be noted.(38) 
As the study was completed in a community ART clinic, we had to be pragmatic about data 
collected from the clinic visits. Study-specific data, such as EFV concentrations, were 
collected on time. However, viral load results, other than those drawn at baseline, were 
taken from clinic records. This resulted in a number of data points having to be excluded 
from modeling analyses as timing of clinic visit (for viral load draw) and study visit (for drug 
level draw) did not coincide. 
Lastly, we have not yet explored Wisepill data to its full advantage. The strength of this data 
lies in the richness of the daily dosing information available. Most outcomes in this study 
were compared to cumulative Wisepill adherence measures or treatment interruptions used 
as a categorical variable. The data will be analysed further with the assistance of a 
statistician with skill in non-linear mixed effects, so that we can explore the impact of actual 
daily dose timing on drug levels and virological outcomes. 
Future research in the field of adherence 
Adherence (initiation, implementation and discontinuation) remains a major obstacle to 
successful management of ART. Although adherence interventions in resource-poor settings 
have not been well researched, there are enough positive messages to suggest forward 
direction. There is also enough information to promote some methods of monitoring 
adherence i.e. electronic and pharmacy methods, and to minimise the use of others i.e. pill 
counts and self-report in a research setting.  
In July 2015, I was invited to attend the Bill and Melinda Gates Foundation Adherence 
Experts Consultation in Vancouver, together with others who have research interests in the 
field (Appendix 3). The conclusion of this meeting was that, with the ongoing push to 
expand access to ART to those with higher CD4 counts, and eventually to treat all individuals 
at the point of HIV diagnosis, it is important to move toward differentiated care.(10, 18) 
Separating those who manage to take ART successfully within the first few months of 
treatment from those who do not would assist ART programme scale up and maximize the 
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benefit of adherence interventions. Identifying the poorly-adherent patients early in care, 
before missed visits and raised viral loads, would allow intervention prior to treatment 
failure and thus maintain individuals on simpler, safer and more cost-effective first-line 
treatment regimens (Figure 7.4).(25, 51, 53, 62)  
The initial identification of people who are poorly adherent within the first few weeks of 
treatment, while crucial, could be complex. Currently, many of those would might benefit 
from an adherence intervention are never identified as they discontinue ART before they 
reach the current first assessment point. In our setting, this is the week 16 viral load. Many 
who enter care are lost within these first four months.(190) In this thesis, we have shown 
that pharmacy refill data predicts virological outcome at week 16 and could be used to 
identify individuals who are late for a collection even more rapidly. However, in 16 weeks, 
there are at most four pharmacy collections, and an individual could have been off 
treatment for a month before this is noted. This is where the Wisepill device could be used 
for its strengths as a monitoring tool: those who miss a fourth dose could be contacted 
immediately [Figure 8.4]. Identifying early non-adherence then allows for exploration of 
reasons for poor adherence and support for the individual to improve tablet taking 
behaviour and develop good adherence habits.  
The majority who require less care and who can establish good adherence habits early in 
treatment could have care delivered and adherence monitored away from a medical setting 
(Figure 7.4). Current planning includes task-shifting towards lay staff or community-based 
models of care.(13, 101, 115) However, those who self-select into this adherent group, 
should still have adherence monitored. As Vrijens at al. noted, life issues which impact on 
adherence will change over time and it cannot be assumed that once a person is adherent 
that their circumstance will not alter.(4) There needs to be the possibility for individuals to 
receive more care should their adherence falter, and similarly for individuals in the high-
intensity care system to move into the down-scaled model of care.  
Both of the best methods for measuring adherence, as identified in this thesis, would allow 
for remote monitoring of patients at any site. Wisepill uses a South Africa-wide cell phone 
network and data can be collected from anywhere in the country. New options for 
dispensing are being explored in other South African research sites e.g. an automatic drug 
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dispensing machine for ART is planned for areas of high population density such as shopping 
malls (Ian Sanne – personal communication). Pharmacy data would then also be stored in 
“the cloud” allowing access to medication and adherence monitoring through pharmacy 
refill data across the country as well. Both of the adherence measurement methodologies 
that we have identified as most predictive of ART outcomes can be scaled up to allow those 
who are well, to continue to be treated as well people, even once on ART (Figure 7.4).  
Figure 7.4. Schematic of future adherence approaches. 
 
Treatment intensification for those with poor adherence could be offered as a menu of 
possible interventions or a sequence of options of increasing intensity. We have shown that 
text reminders reduce significant treatment interruptions, and others have shown similar 
reminders improve cumulative adherence and virological outcomes.(50, 62, 107) Other 
interventions, including education and counselling methodologies, peer or family support 
and food parcels or other incentives could be tailored to what is available at a site, and also, 
within reason to the individual. For some who are forgetful, a reminder may be adequate; 
others with barriers such as social isolation and fears of stigma might respond to counseling 
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approaches; and for yet others, poverty or scarcity of food may be the major barrier. For 
these individuals adherence should still be monitored with some intensity, definitely using 
pharmacy refill measures, and possibly with electronic methods and therapeutic drug 
monitoring. 
As we identified, some populations are at increased risk for poor adherence e.g. younger 
people and those with depression. However, with the use of an identification system as 
described above, these criteria alone do not have to label an individual as a poorly adherent. 
Each individual would be given the opportunity to self-identify, independent of other risk 
categories. These key populations may need support tailored to their needs: e.g. their own 
clubs, different type of text messaging or youth-friendly spaces.  
More research is needed to explore classification of individuals as good or poorly adherent 
early in treatment. While we would suggest the best methodology would be the use of 
pharmacy refill data or electronic monitoring, the precise cut-off adherence point and 
timing of the streamlining process will need to be determined. Both simplified models of 
care, with adherence monitored remotely, will need to be expanded; and research into 
successful adherence intensification processes should be prioritised. 
Policy changes  
The South African ART programme and provincial clinical services need to adapt to the 
current challenges of ART: a growing cohort of individuals being eligible for treatment and a 
change in the health profile of those entering care. Based on findings of this thesis, 
recommendations would be to utilise pharmacy systems for program evaluations and 
monitoring individual adherence, including the triaging of patients early after ART initiation 
for streamlining of care. Locally feasible and robust options to both intensify and simplify 
care, including the use of electronic reminders, should be explored.  
The benefit of the use of pharmacy refill methods in monitoring adherence is clear and 
could be acted upon immediately. The Western Cape Provincial Department of Health has 
rolled out the use of an electronic patient management system (eKAPA) across all of its 
clinics. Most clinics also have electronic dispensing systems (iDART and others), but there is 
no provision for the patient management system to connect with or collect data from the 
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pharmacy systems. At a local level, integration of the systems should be manageable and 
this one intervention could improve patient tracking and adherence monitoring across the 
Province. 
7.3. Conclusion. 
This thesis has examined current interventions which improve ART adherence, explored the 
benefits of electronic reminders, compared methods to quantitate adherence in a 
community ART cohort In South Africa, and established utility of EFV TDM in a community 
setting.  
For electronic reminders, decreased frequency of messaging and the incorporating of an 
interactive component with a staff member seem most beneficial. Our study did not show 
that reminders after a missed dose improved adherence significantly, but did show that 
treatment interruptions were minimised, a benefit that might have had more impact had a 
non-naïve population been selected.  
Wisepill, as an adherence monitoring tool, has the advantage of identifying missed doses 
rapidly and is ideal for identifying those with poor adherence and initiating immediate 
interventions, including text-messaging in real time.(63) Using electronic adherence 
monitoring may be valuable in the first few months to a year of treatment to allow 
streamlining of care.  
Pharmacy dispensing data is an exciting and under-utilised resource. Electronic dispensing 
systems are in place at most clinics locally. Programmatic support should be given to 
incorporating the use of pharmacy data into both patient-level adherence monitoring and 
programme-level evaluation. Pharmacy resupply monitoring should also be used to monitor 
community-based treatment sites.  
We found that therapeutic drug monitoring has a place in individual adherence assessment. 
Low EFV concentrations can predict poor virological outcomes in naïve population. Despite 
pharmacogenetic variation in individual EFV metabolism, this information is not required for 
an individual in the context of virological failure. 
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As we move into the second decade of ART delivery in South Africa, we need to ensure that 
treatment options are acceptable, effective and can be used at scale. We need to think 
broadly about systems to support the influx of those needing treatment who are healthy 
and channeling the use of our clinic and human resources to those at most need. We need 
flexible and robust adherence monitoring systems, such as those identified here that more 
closely reflect virological outcomes, to allow for differing needs by each individual and 
differing needs within one individual over time.  
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1. Study synopsis:  
Antiretroviral treatment (ART) options are limited in resource-poor settings, due to large 
numbers requiring treatment and the cost of supplying it. First-line ART is three times 
cheaper than second-line ART, is easier to take and is better tolerated, thus maintaining 
individuals on first line is essential for programme success. Although adherence in adults 
from resource poor countries is generally reported as excellent, it may be overestimated, as 
much of this data is generated from tablet return and pharmacy dispensing data. More data 
is becoming available describing discordance between accepted measured adherence 
standards and virological failure. In addition, the limited data available on adolescents in 
resource poor countries on ART, suggests difficulties with adherence. This study will use a 
locally developed real time electronic adherence monitoring device (EAMD) to explore and 
improve adherence in individuals commencing new treatment in an established ART cohort 
in Gugulethu, Cape Town, and use adherence, virological and pharmacokinetic data to 
examine adherence-failure discordance. 
Objectives: To determine whether a real-time electronic adherence monitoring device 
(EAMD) with text message and dosing feedback improves adherence, retention in care and 
virological outcomes among individuals receiving new antiretroviral therapy. To determine 
whether population pharmacokinetic data explain the discordance between adherence and 
virological response.  
Primary endpoint: the proportion of patients with a cumulative adherence by EAMD >95% 
at week 48 by arm.  
Study population and randomisation: Two hundred and twenty ART-naive HIV-positive 
patients who are eligible for ART will be recruited from the Hannan Crusaid Treatment 
Centre, Gugulethu, Cape Town. All will receive an EAMD, then be randomised:  
ARM 1(n=110): Standard of care, using the EAMD to monitor adherence only i.e. without 
any feedback.  
ARM 2 (n=110): Arm one with the addition of the use of the EAMD text message service 
when dosing late, and EAMD dosing feedback at 4-monthly visits.  
Statistical analyses: Data analysis will occur once all patients complete 48 weeks on study. 
The primary analysis will be an intention-to-treat analysis of any treatment failure with use 
of Cox proportional hazards regression. Differences in specific reasons for treatment failure 
(e.g. lost to follow-up, toxicity, death, etc) will be compared by treatment group with hazard 
ratios and 95% confidence intervals. Differences in time to failure will use Kaplan-Meier 
analyses. Group comparisons with the log-rank statistic will be regarded as significant if p 
values are less than 0.05. 
Schedule of events: All study visits coincide with visits as per the South African National ART 
Guidelines, except for the follow-up visit, which is additional.  
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Visit Screen Random-
isation 
Base-
line 
Week 
16 
Week 
32 
Week 
48 
Follow-
up* 
Informed consent X       
Randomisation  X      
Commence new ART   X     
Dispense EAMD   X     
Adherence review by 
pharmacy refill and tablet 
counta 
   X X X  
Clinical reviewb X  X X X X  
Detail adverse events, 
concomitant medications 
  X X X X  
Viral load, CD4 countc,d X   X  X  
Record dosing time.    X X X  
Pharmacokinetic (PK) 
samplinge 
   X X X  
Sample for storagef    X X X  
CAGE score X   X  X  
Depression score x     x  
EAMD acceptability 
questionnaires 
   X  X  
Event monitoring and 
study feedback 
      X 
* The follow-up is the only additional visit required by the study in order to feedback on 
EAMD adherence assessment. There will be extra samples drawn at standard blood draw 
times for PK and plasma storage and an additional blood draw for a further PK sample if 
consent is given. 
a. Adherence review will be done as per standard of care, i.e. through tablet counts. 
Feedback from the EAMD device will only be given to those randomised to ARM TWO.  
b. A full clinical examination will be done at screen and month 12, otherwise a symptom-
driven targeted examination will be completed. 
c. CD4 counts are completed at baselineand 48 weeks at the HCTC according to the SA 
National Protocol and viral loads (VL) at week 16 and 48 only. [2] Baseline VL and week 16 
CD4 count will require donor funding. 
d If a viral load is >1000 copies at any visit, the test will be repeated within 6 weeks. Two 
consecutive viral loads > 1000 copies/ml within 6 weeks will constitute virological failure.  
e. Samples for PK will be drawn from all individuals who provide consent. Mid dosing interval 
levels will be collected for those on efavirenz. Trough levels (Cmin) will be collected for 
those on nevirapine, Individuals will act as their own controls. Dosing times will be recorded 
and confirmed by EAMD. Four ml of blood will be collected per draw in a lithium heparin 
tube.  
f. Plasma will be stored for all consenting individuals at every on treatment time point for 
future HIV genotype or pharmacogenetic analysis. (Two x 4ml EDTA tube). 
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2. Introduction: 
2.1 Background.  
Increasing numbers of HIV-positive individuals are receiving antiretroviral therapy (ART) in 
resource limited countries such as South Africa. South Africa has the highest number of 
people living with HIV (5.7 million), and in the seven years since the introduction of ART 1 
058 399 adults and 105 123 children (under age 15) have commenced first-line non-
nucleoside reverse transcriptase (NNRTI)–based ART in the public sector alone. [1,2] The 
numbers of patients failing first-line and commencing second-line ART are increasing with 
expanded access and time on treatment [3]. Second-line increases the cost of therapy 
markedly (by at least three times, as of January 2012). First line ART is also easier to take in 
terms of tablet burden and tolerability. Maintaining people on successful first line therapy is 
thus a priority.  
Adherence as measured by tablet returns and pharmacy refill is excellent in most adult 
cohorts across sub-Saharan Africa yet despite this failure continues [4-8]. More recently the 
impact of treatment persistence, examining the impact of duration on therapy and 
minimising treatment interruptions, on virological outcomes are being explored in these 
populations. [5,9,10]  
Patients taking ART at the Hannan Crusaid Treatment Centre (HCTC), a large public sector 
antiretroviral roll out site, in Cape Town, South Africa, have been monitored since 
September 2002. At the end of 2011, 3811 individuals are being treated at the site, with 397 
(10%) on second-line therapy. Ten percent of individuals who start first-line ART at the HCTC 
fail first line therapy by the end of three years. Adherence is monitored at each visit by 
counting tablet returns. A recent study by this investigator shows adherence is excellent 
among those who suppress virologically (median 97.8%). It is also excellent for those who 
fail (median 96.6%). [10] Some of those who fail do so through poor adherence (<80%), but 
a substantial subset (19%) fail despite adequate adherence [Table 1]. Some of this 
adherence-failure discordance may be explained by treatment interruptions. Our study also 
shows that, despite excellent adherence (>95%) when in possession of ART, a single 
treatment interruption increases the odds of failure by 5.65 (CI 1.40-22.85). [10] 
Overestimation of adherence may also be an explanatory factor when using tablet counts as 
a measure. In another study by our group exploring different adherence measures in the 
paediatric cohort of the HCTC, tablet/syrup returns overestimated adherence by 8% 
compared to MEMScaps data. [11] Poor timing of the twice daily doses was also noted in 
this study. Other factors that have not been thoroughly explored may also impact, such as 
drug bioavailability, which may differ in our population. It is already known that efavirenz 
metabolism differs in a sub-Saharan African population, due to genetic variants in the 
cytochrome p450 2B6 enyzme. [12] 
Table 1: proportion of patients with concordant or discordant adherence-virological 
outcomes at 48 weeks (n=211). 
At week 48 on first-line 
ART* 
Viral load ≤50 copies/ml Viral load >50 copies/ml 
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Cumulative adherence ≥ 
95% 
Expected viral suppression n=124 
(59%) 
Unexpected non-suppression 
n=41 (19%) 
Cumulative adherence 
<95% 
Unexpected viral suppression n=28 
(13%) 
Expected non-suppression n=18 
(7%) 
*Tablet count adherence data from HCTC cohort as described by Ncaca, Kranzer and Orrell. 
[13] 
Limited research has been conducted to determine virologic, immunologic and mortality 
outcomes in adolescents on ART in South Africa, and findings indicate significantly lower 
virological suppression and increased virological failure in adolescents compared to young 
adults in a peri-urban setting in Cape Town, the Hannan Crusaid Treatment Centre and the 
authors suggest poor adherence as a possible explanation for their finding.[14] A further 
study measuring both virological outcomes and adherence in adolescents compared to 
adults in a private sector disease management program in 9 countries in Southern Africa, 
(including South Africa), found significantly poorer adherence in adolescents compared to 
adults and a significant relationship between adherence and virological suppression.[15] 
The majority who fail first-line ART in resource poor settings have at least dual class 
resistance at first-line failure, usually including resistance to lamivudine and the chosen 
NNRTI, either efavirenz or nevirapine. [13,16,17] Much of this resistance is likely to occur 
due to prolonged time spent on the failing ART regimen where viral loads are a limited 
resource, due to their cost. In a cohort where viral load monitoring was more tightly 
monitored, these resistance patterns were similar though much less frequent and complex. 
[18] We have shown that an intensive adherence intervention results in 67% of those who 
have a first viral load >1000 copies/ml being re-suppressed at the subsequent viral load. [3, 
19] Tight control of adherence with early intervention thus is likely to reduce the time that 
virus is exposed to sub-therapeutic drug levels.  
The 2010 South African ART guidelines have reduced the number of viral loads available for 
the ART programme. Two are allowed in the first year (one at 4 months, the other at 12 
months) and thereafter a single viral load is permitted annually. [2] With such sparse 
monitoring there is a great need for an affordable, real time adherence-monitoring device 
that is acceptable to the ART-taking population. Use of such a device would allow 
exploration of adherence-failure-resistance relationships in more detail and allow real-time 
monitoring of adherence in those deemed to require such an intervention.  
2.2 Study hypotheses and goals: 
This study will explore the acceptability and impact of a locally produced, novel, wireless, 
electronic adherence monitoring device (EAMD), on adherence behaviour in ART-naïve 
individuals commencing ART at the HCTC. Other studies using a similar device have been 
completed in Kenya and Uganda. [20,21] We hypothesise that the use of real-time 
monitoring will reduce the overestimation of adherence seen with current methods. With 
the addition of a reminder sent by text message in the randomised arm should dosing be 
late, we hypothesise that the electronic adherence monitoring device will improve 
adherence, reduce treatment interruptions and subsequently reduce first-line ART failure 
rate (two consecutive viral loads >1000 copies/ml). In 2007, up to 92% of South Africans 
carried cell phones, so the use of reminder text messages should be feasible in our 
population [http://www.gapminder.org/]. Pharmacokinetic samples will be collected from 
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all individuals who give consent. If on efavirenz, two mid-dosing interval time points will be 
drawn an hour or more apart at each visit (this will allow description of elimination and an 
estimate the trough concentration). For those on nevirapine or lopinavir/r, a predose trough 
will be drawn. These samples allow for sparse population pharmacokinetic (PK) analysis as 
well as exploration of PK results in those with discordant adherence-failure outcomes i.e. 
those with good adherence (>95%) and viraemia (>50 copies RNA/mL) or poor adherence 
(<95%) and virological suppression. We will also qualitatively investigate the reasons for 
poor adherence e.g. personal life events, alcohol use (shown to impact on early poor 
adherence [Daniella Mark – personal communication]), disclosure of HIV status, evidence of 
depression or anxiety or poor tolerance of medication, as well as the relationship between 
complex adherence patterns and viral failure, in order to lay the foundation for an 
adherence intervention that might prevent viral failure after missed doses, but before viral 
rebound. Data will be available for cost-effectiveness analyses. 
Adherence research with this depth has not been completed before. In addition to the 
impact of an electronic adherence monitoring device (EAMD) on adherence, retention in 
care and virological outcomes, we will examine detailed pharmacokinetic results in the same 
cohort, while storing specimens for future pharmacogenetic and HIV genotyping studies.  
This study is entirely in line with the Desmond Tutu HIV Centre’s goals and strategies to 
impact policy and practice both nationally and internationally through research relevant to a 
country that remains the epicentre of HIV and TB epidemics; as well as in line with that of 
the host institution, UCT, to “address the health challenges facing South African and African 
society” by “undertaking research relevant to Africa's needs.” 
[http://www.health.uct.ac.za/about/mission/] 
2.3 Principal research questions 
1. Does a real-time electronic adherence monitoring device (EAMD) with text message 
feedback improve adherence, retention in care and virological outcomes among ART-naïve 
individuals receiving new antiretroviral therapy? 
2. Does population pharmacokinetic data explain discordance between adherence and 
virological response? 
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3. Study design and endpoints: 
3.1 Study methodology.  
 A randomised study over 48 weeks investigating the impact of a real-time electronic 
adherence monitoring device on adherence and persistence to ART therapy of ART-naive 
individuals on first-line ART. All individuals who consent to additional sampling will be 
enrolled in a voluntary pharmacokinetic substudy. 
3.2 Study design.   
The study is described in Table 2. ART-naïve participants at the HCTC will commence their 
new treatment as per the clinic routine, with the addition of study information at one 
treatment preparedness session and an informed consent process.  
Inclusion criteria: 
 ART-naïve individual (< 1 month prior ART) 12 years or older. Women who have 
completed pMTCT will be considered naïve. 
 Been prescribed new antiretroviral therapy by a Hannan clinician. 
 At least one medication of the regimen must be in tablet formulation. 
 Willing to sign the patient informed consent if 18 years of age or above, or assent if 17 
years old or below, to participate in the study. Parent or legal guardian must be willing 
to provide written consent for their child to participate in the study if 17 years or below. 
Exclusion criteria: 
 Active disease which, in the opinion of the study staff, would preclude the informed 
consent process.  
 Participant or carer not in possession of a cellular telephone. 
A log of those who do not meet inclusion/exclusion criteria will be kept. 
The EAMD will be dispensed at time of ART initiation. The chosen EAMD (Wisepill®) is a 
locally-produced, affordable electronic device the size of a mobile phone which can store up 
to a week of medication either as a blister pack or a seven compartment pill box (figure 1). 
On opening, a signal is sent via the mobile-phone network to a central computer, thus 
recording adherence behaviour in real time. There is an option to send a reminder by text 
message to the participant’s mobile phone.  
Table 2: study schematic. 
Screen (week -4 to 
0) 
Week 0. 
 
Weeks 16, 32 and 48 – randomised phase. All receive 
standard of care at the HCTC with the addition of the 
ARM 1 or 2 details. 
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Informed consent 
process. 
All receive standard 
of care treatment 
preparedness at 
HCTC.  
Randomise 
(dispense 
Wisepill® 
device) 
ARM 1(n=110): Use of EAMD without text message 
feedback.  
Visits occur according to standard of care at HCTC. 
ARM 2 (n=110): Use of EAMD with text message 
service when dosing late. Report of adherence 
behaviour given at each 4-monthly visit. 
Visits occur according to standard of care at HCTC. 
 
Figure 1: The electronic adherence monitoring device (Wisepill®). 
 
3.3 Randomisation.  
A minimum of 220 people will be randomised 1:1 (110:110) to one of the two treatment 
arms:  
ARM 1(n=110): Standard of care, using the EAMD to monitor adherence only i.e. without 
any feedback.  
ARM 2 (n=110): Arm one with the addition of the use of the EAMD text message service 
when dosing late, and EAMD dosing feedback at 4-monthly visits.  
3.4 Study visits. 
Screening visit: All patients at the study site are seen by a (non-study) clinician on first 
attendance. Demographic details are recorded at this visit, with WHO clinical staging. Blood 
will be drawn for baseline viral load after the informed consent process is complete. CD4 
count data will be extracted from the Hannan patient file. Screen questionnaires (CAGE, 
disclosure status and Hospital Anxiety and Depression Scale) will be completed. This data is 
transferred into the HCTC Access database on a weekly basis and will be collected for the 
purposes of this study directly from the data base. 
All potential ART patients return for 3 treatment-preparedness sessions managed by the 
counselling team. At the first visit, in additional to the treatment readiness session, a study 
counsellor will describe the study and invite patients to participate. If they agree to 
participate, they will be given an appointment to meet the investigator or study coordinator 
for a full informed consent process. The informed consent document is attached as 
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Appendix 1. If consent is given, each individual will be randomised on a 1:1 basis to ARM 1 
(EAMD with reminder) or ARM 2 (EAMD no reminder) prior to their planned ART start date.  
Week 0 (ART start date): At this visit the SCO will explain the use of the EAMD with or 
without details of reminders as per randomised arm. If randomised to reminders (ARM 1) 
the SCO will establish planned times of dosing and preferred time lag prior to reminder 
being sent. ART will be started by the HCTC (non-study) clinician as per standard practice. 
Details of the treatment regimen will be captured through the HCTC Access database. 
Baseline questionnaires on disclosure status, alcohol use and the Hospital Anxiety and 
Depression score (HADS) will be completed. 
Should the inclusion and exclusion criteria be met, then screen and week 0 may be 
completed on the same day. 
Weeks 16, 32 and 48 (on treatment visits): The participants will complete standard HCTC 
visits by non-study clinical and phlebotomy staff. Adherence will be monitored and 
responded to based on tablet count data and a clinical visit will be completed. For 
individuals on ARM 2, feedback from the EAMD data will be placed in their patient files for 
the clinicians to review at these visits. Cell phone numbers will be confirmed at every visit. 
Visit windows will stretch from 8 weeks before the scheduled date to 8 weeks after the 
scheduled date. 
Blood for CD4 cell count, viral load, first PK sample and plasma for storage will be drawn at 
weeks 16 and 48. At week 32, only blood for PK and plasma storage will be drawn. Time of 
blood draw will be recorded as will time of most recent ART dosing. A sample of hair for PK 
analysis will be taken should the patient permit. 
Should patients need additional counselling the study counsellors will be available to 
provide this. EAMD acceptability and the CAGE questionnaire will be completed by the study 
counsellors at weeks 16 and 48. The HADS will be completed again at week 48. 
Pharmacokinetic data: The study coordinator will complete the blood draw at each study 
visit. Blood will be taken for PK and for storage as per table 3 (schedule of events). 
Follow-up visit: At this visit, one month after week 48, all participants will be given feedback 
from their EAMD data. A questionnaire describing life events perceived to impact on 
adherence over the 48 weeks will be administered.  
 
Drug dispensing: Dispensing will be as per standard of care. Patients will be given one 
month of medication (in four patient-ready weekly EAMD pillboxes) per month for the first 
four months and resupplied two-monthly (with eight patient-ready weekly EAMD pillboxes) 
for the rest of the study.
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3.5 Study duration. 
Each individual would be followed until 52 weeks after start of new ART (48 weeks on study, 
with a follow-up visit 4 weeks later). Further care will be continued at the HCTC as per 
standard of care. 
3.6 Primary outcome. 
Primary outcome: proportion of patients with a cumulative adherence by EAMD >95% at 
week 48 by arm.  
3.7 Secondary outcomes. 
1. Virological outcome: Proportion of patients with a viral load of <50 copies/ml at week 48; 
as well as proportion of patients who failed (consecutive VL >1000 copies/ml) by week 48.  
2. Adherence: comparison of cumulative EAMD adherence data and tablet count adherence 
data at weeks 16, 32 and 48.  
3. Retention in care: proportion of patients still in care at 48 weeks (excluding those 
transferred to other ART sites); proportion with a treatment interruption of >72 hours.  
4. Pharmacokinetic: Mid-dosing efavirenz levels or trough nevirapine and lopinavir levels for 
discordant participants at weeks 16, 32 and 48. 
5. Exploratory endpoint: relationship of PK results to adherence and to virological outcome 
at week 16, 32 and 48. 
6. Qualitative endpoints: Acceptability of EAMD device; impact of qualitative issues on 
adherence (alcohol, disclosure, mental health status, ART tolerability, life events). 
3.8 Withdrawal of participants from the study. 
Participants will be withdrawn from the study only if they withdraw consent.  
Death and loss to follow-up will be recorded and analysed as part of the retention in care 
secondary outcome.  
Transfer out: a patient transferred to another clinic will be considered still in care.  
Patients who fail virologically will have reached an endpoint but will remain on the study 
with their new regimen. 
3.9 Standard of care at the Hannan Crusaid Treatment Centre. 
Care at the HCTC is provided according to the South African National ART Guidelines of 
2010. [2] Patients who meet the criteria for ART initiation (CD4<350cells/ml, WHO stage 4 
disease) usually initiate ART four weeks after their first/screening visit. In those four weeks 
they are encouraged to attend 3 group treatment preparedness sessions and will have pre-
treatment safety bloods drawn as part of their clinical assessment. 
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Preferred first-line ART includes tenofovir (TDF), 3TC and either efavirenz or nevirapine. 
Efavirenz is the non-nucleoside reverse transcriptase inhibitor (NNRTI) of choice, and only 
women who plan to conceive in the next few years will be offered nevirapine. Should 
tenofovir be inappropriate (age or renal insufficiency), then zidovudine (AZT) can be 
prescribed instead. 
Patients are seen monthly for the first four months, and after that they attend every 
second-month. Two months of medication is given at one time after month four. Viral loads 
are assessed at 4 months into treatment, at a year into treatment and then annually. Once a 
patient has a second viral load <50 copies/ml (usually at a year into ART) then they may be 
transferred to an adherence club or the green clinic where they have fewer visits and annual 
clinical assessments. 
Failure is defined at two consecutive viral loads >1000 copies/ml, after which second-line 
ART is offered. 
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4. Statistical methodology: 
4.1 Study site and population. 
The study will be conducted at the Hannan Crusaid Treatment Centre (HCTC) in Gugulethu, 
Cape Town. The HCTC is one of four public-sector antiretroviral delivery sites in the 
Klipfontein Health Sub-district of Cape Town. The clinic, which commenced delivery of ART 
in September 2002, is currently treating 3811 people. An average of 75 people commenced 
first-line ART every month over the last calendar year to 31 December 2011.  
The site is staffed by 7 clinicians (4 medical officers and 3 clinical nurse practitioners), a 
pharmacist and 30 therapeutic counsellors who provide treatment preparedness education 
(in the form of three group sessions), and on-treatment adherence support, including 
intensive individual adherence sessions as indicated by poor tablet returns or raised viral 
load (>50 copies/ml). CD4 cell counts are completed at baseline and month 4, then at month 
12 and annually thereafter. Viral load monitoring is completed at 4 months, 12 months and 
annually thereafter. [2] All demographic, clinical and laboratory data are recorded in an off-
site Access database and validated annually.  
4.2 Human participants. 
All ART-naïve individuals enrolling on new ART at the HCTC (adults and adolescents) will be 
invited to enrol in the study, until the study numbers have been achieved. Subjects will be 
informed about the study at one of the group education sessions and invited to approach 
the study counsellor at one of the scheduled visits during the 4 week pre-treatment ART-
preparedness period. Individual informed consent and/or assent will be signed with one of 
the study staff during a scheduled clinic visit before randomisation and commencing ART. 
4.3 Sample. 
Patients at the HCTC are representative of the typical South African population receiving 
ART, with a predominance of women accessing the service (67%) and a median CD4 of 104 
cells/mm3 at initiation of first line therapy. [22] Approximately 75 ART-naïve individuals 
commence treatment each month at the HCTC and all individuals attending the clinic for 
new ART will be approached to join the study over the recruitment period. Recruiting a 
sample size of 220, assuming 90% agree to join the study, should take 4 to 5 months.  
4.4 Sample size determination:  
An estimated 200 people will need to be randomised on a 1:1 basis to have >90% power to 
detect a 10% difference in virological suppression to a significance of 0.05. We intend to 
recruit 230 to account for loss of 10% of the population due to death or loss-to-follow up in 
the first year of therapy, [19] and an additional 10 people to account for transfers out to 
other clinics. 
4.5 Analysis including statistical methods: 
Baseline differences in randomisation groups will be described with simple proportions for 
categorical variables and means (+/- standard deviations) or median (+/- inter quartile 
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range) for numerical variables. The primary analysis will be an intention-to-treat analysis of 
any treatment failure with use of Cox proportional hazards regression. Differences in 
specific reasons for treatment failure (e.g. lost to follow-up, toxicity, death, etc) will be 
compared by treatment group with hazard ratios and 95% confidence intervals. Differences 
in time to failure will use Kaplan-Meier analyses. Group comparisons with the log-rank 
statistic will be regarded as significant if p values are less than 0.05. 
Data analysis will occur once all patients complete 48 weeks on study. 
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5. Study conduct: 
5.1 Ethics:  
The site has ethical approval for the ongoing collection of routine clinical and laboratory 
data. All patients at the HCTC have signed individual informed consent and/or assent to this 
end. This study will require additional informed consent to incorporate the use of the EAMD 
device and additional data collection including questionnaires. There will also be additional 
blood draws. The committee may enquire into the ethics of not using the EAMD feed back 
messages available in arm 1 as study staff may be able to identify participants with poor 
adherence while on study. We would argue that the study should not impact standard of 
care and clinic staff should identify those most at risk through tablet counts, as is currently 
the case.  
This study will also be submitted to the Western Cape Provincial Department of Health 
research committee for approval. 
5.2 Justification of use of questionnaires. 
We intend to avoid loading this cohort with questionnaires as we would prefer the EAMD to 
be the key intervention, rather than the presence and impact of the researchers. As such 
the data collected by questionnaire will be kept to a minimum. Alcohol, disclosure status, 
depression and anxiety all have reported impact on adherence to ART and this data will be 
collected at baseline. The CAGE questionnaire (appendix 2) is the simplest effective 
questionnaire to identify individuals with alcohol use issues and is a tool already available to 
clinic staff. Disclosure will be examined by two simple questions: “Have you disclosed your 
HIV status to anyone?” If yes, “to whom?” Mental health status will be assessed though the 
hospital anxiety and depression scale (HADS) which contains only 14 items and has been 
validated for adults and adolescents (appendix 3). 
Adverse event data is not routinely captured at this clinic, but will be collected for study 
purposes by asking a single open question (“Have you noted any problems you relate to use 
of your medication?”) and explored as necessary.  
A short questionnaire will be formulated to elicit acceptability of the EAMD device. Stigma 
related to HIV is still widespread in South African communities so the device needs to be 
discreet and the text messages subtle. At the end of the study adherence data from the 
EAMD device will be given to each participant and significant changes in pattern explored. 
Details of this questionnaire will be presented in a subsequent protocol. 
5.3 Patient informed consent. 
The patients will undergo an informed consent process as per the DTHC standard operating 
procedure (SOP). In short, the study may be explained in a group setting, in the patient’s 
home language, and the patient given a copy of the ICF to read. There will be ample time 
allowed for questions. The ICF will be signed with the study staff in an individual 
consultation with privacy for further questions thereafter. Those under 18 years will not be 
able to participate without both their assent and their parent/legal guardian’s consent. 
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5.4 Patient confidentiality. 
Data: No data containing patient identifiers (name or address) will leave the HCTC site.  
Staff: All DTHC staff sign a confidentiality statement on commencing employment with the 
Centre. They are made aware of the sensitivity of patient information and any breach of 
confidentiality is treated with the utmost severity. 
5.5 Patient compensation. 
Patients on this study will continue to receive ART as standard of care at their community 
clinic. They will receive R20 in financial compensation for being the extra time spent at the 
clinic due to completing the questionnaires and the extra blood which is drawn during the 
study. This compensation will be given at each of the 5 study scheduled visits only. These 
coincide with the scheduled ART visits. The patient will be reimbursed R150 for the final or 
post-study visit, which is an additional visit. 
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6. Study procedures and observations: 
The items listed in table 3 below will occur at the specified study visit. Antiretroviral therapy 
will be decided as per the HCTC standard of care, and clinical visits will also occur as per 
their protocol and are not considered study procedures. Adverse events and laboratory 
safety blood results will be managed as per standard of care by HCTC clinicians and are not 
study procedures, although adverse events will be recorded e.g. concomitant use of 
rifampicin for treatment of tuberculosis, due to their potential impact on ART dosing or drug 
levels. 
Table 3: Schedule of events: 
Visit Screen Random-
isation 
Base-
line 
Week 
16 
Week 
32 
Week 
48 
Follow-
up* 
Informed consent X       
Randomisation  X      
Commence new ART   X     
Dispense EAMD 
device 
  X     
Adherence review by 
pharmacy refill and 
tablet counta 
   X X X  
Clinical reviewb X  X X X X  
Detail adverse events, 
concomitant 
medications 
  X X X X  
CD4 countc X   X  X  
Viral loadc,d X   X  X  
Record dosing time.    X X X  
Pharmacokinetic (PK) 
sampling – serum and 
haire 
   X X X  
Sample for storagef    X X X  
Disclosure status X  X X X X  
HADS X     X  
CAGE X   X  X  
EAMD acceptability 
questionnaires 
   X  X  
Event monitoring and 
study feedback 
      X 
* The follow-up is the only additional visit required by the study in order to feedback on 
EAMD adherence assessment. There will be extra samples drawn at standard blood draw 
times for PK and plasma storage. a. Adherence review will be done as per standard of care, 
i.e. through tablet counts. In ARM 2 a report of adherence from the EAMD will be given to 
the clinician for discussion. No feedback from the EAMD device will be given until the 
follow-up visit (week 52) for those in ARM 1. 
b. Clinical procedures will occur as per standard of care at the HCTC. 
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c. CD4 counts are completed at baseline 48 weeks at the HCTC according to the SA National 
Protocol [2]. Viral loads (VL) are only completed at weeks 16 and 48 at the HCTC according 
to the SA National Protocol [2]. Baseline viral loads and week 16 CD4 counts will be added 
through donor funding for this study. 
d If a viral load is >1000 copies at any visit another will be repeated within 6 weeks. Two 
consecutive viral loads > 1000 copies/ml constitutes virological failure. Patients will remain 
on study despite reaching an endpoint. 
e. Samples for PK will be drawn from all individuals who provide consent. Mid dosing interval 
levels will be collected for those on efavirenz  and trough levels (Cmin) for those on 
nevirapine or lopinavir/r. Individuals will act as their own controls.  Four millilitres of blood 
will be collected per draw in a lithium heparin tube.  
Dosing times will be recorded and confirmed by EAMD. Hair samples (head or axillary) will 
also be collected. 
f. Plasma will be stored for all consenting individuals at every “on treatment” time point for 
future HIV genotype or pharmacogenetic analysis (2 x 4ml EDTA tubes). Plasma aliquots 
from EDTA tubes will be kept at -70oC until analysis. 
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7. Reports and study output: 
7.1. Plan for dissemination of study results. 
Outcomes from this study would include at least two peer-reviewed publications (one 
describing the primary outcome and another the pharmacokinetic data) as well as 
motivations to the Provincial Department of Health for continued use of the EAMD device 
should it prove to be beneficial in adherence and retention in care. Information on 
adherence patterns and PK issues leading to discordance will be incorporate into clinical 
practice through in-service training at local meetings. Should this not have the benefit we 
expect, we will incorporate all we learn about adherence behaviour into pre-and on-
treatment education sessions and if necessary design a new intervention to make best use 
of the results. Many clinical practice improvements from the HCTC have been incorporated 
into the Western Cape and South African Antiretroviral guidelines in the past 7 years. 
7.2. Project plan with timescale and milestones. 
Figure 1: Overall trial timeline. 
Time from 
funding 
approval (in 
months): 
0-3 4-6  7-9  10-12 13-15 16-18 19-21 22-24  25-27 28-30 
Protocol 
completion 
          
Ethics 
submission  
          
Staff training           
Participant 
recruitment* 
          
Study follow-up.           
Data analysis           
Report writing.           
* Funding approval was received on 29 February 2012, so this project aims to be completed 
by September 2014.  
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8. Study administration: 
8.1. Project management.  
The study coordinator on site at the Hannan Crusaid Treatment Centre will manage the 
project on a day-to-day basis. Three counsellors will be assigned to the project and will 
assist in managing bookings and completing questionnaires. Participants will be seen by 
staff of the HCTC as per standard of care and will follow the standard routine for treatment 
preparedness and on-treatment visits. HCTC counsellors routinely manage the 3 treatment 
preparedness sessions and count tablet returns at each visit. Both clinical nurse practitioner 
and doctors are available for clinical review. Standard blood draws will be drawn by the 
HCTC phlebotomy staff. The extra blood draw required for the PK samples will be completed 
by the study coordinator. Clinical, laboratory and adherence details necessary will be 
collected by the study coordinator after the visits and from the HCTC access database. 
8.2. Study staff roles.  
The investigator (Dr. Catherine Orrell): The investigator is responsible for the overall running 
of the study, including protocol development; staff and patient recruitment; ethics 
submissions; the informed consent process; maintaining study integrity; collection of data; 
data analysis and dissemination of results. 
Study coordinator: The SCO manages the study on a day to day basis; maintains and 
manages the booking diary; manages the counsellors on-site; identifies study participants in 
the clinic; identifies missing participants; completes the case report forms; draws the extra 
blood samples and prepares them for storage. 
Counsellors: The Sizophila counsellors are an established group of HIV-positive lay staff who 
are educated to support others living with HIV on ART. The HCTC employs 30 counsellors. 
This study will support five of these well-trained counsellors who will be seconded to the 
study for the duration of the work counsellors (one of whom will have received adolescent 
sensitivity training). These counsellors will provide pre and on-treatment counselling 
including treatment preparedness and additional adherence counselling; provide EAMD 
education; complete tablet counts at each visit; administer study questionnaires at each 
visit; do home visits as per standard protocols; and assist the SCO in managing patient 
bookings and visits.  
Data manager and statistician: Dr Carl Morrow (PhD) is an experienced data manager and 
has maintained DTHC research databases for three and a half years. He is skilled at 
extracting and analyzing relevant information that is translatable into published products. 
His expertise in working with, maintenance and development of the Gugulethu ARV 
database will provide support and insight into the data collection and subsequent analysis 
for this project. His experience in statistics gained during his PHD work will allow for 
rigorous analysis of the data from this project. He will be responsible for data management 
including data collation and entry, cleaning of the data and subsequent data analysis.  
Quality Management: Christie Heiberg is a qualified clinical trials monitor. The role of the 
quality manager is to ensure that adequate approvals are in place for the study to be 
page 209 
 
conducted; ensure that all subjects have signed an informed consent form; to monitor a 
random sample of subjects to ensure adherence to the protocol; to identify protocol 
deviations, report them accordingly, identify and implement corrective action to ensure that 
errors are not repeated; to ensure that all safety reporting is done according to the protocol 
and ethics committee requirements; to ensure that the principal investigator is provided 
with written and verbal feedback after each monitoring visit and, at the end of the study, 
ensure that all the documentation is in place and that the study is ready for archiving. 
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Appendix 1: Adult informed consent 
 
 
 
Adult information leaflet and consent form for the TAP study.  
A randomised controlled Trial to explore Adherence-failure relationships in a South African 
antiretroviral delivery site, using an electronic adherence device and sparse 
Pharmacokinetic sampling. 
Introduction: You have been asked to read this information as you are HIV-positive and 
about to commence new antiretroviral treatment (ART) at the Hannan Crusaid Treatment 
Centre (Hannan) in Gugulethu, Cape Town. You also have a cell phone. 
When you start ART you will be taking a number of tablets every day. In order for the ART to 
keep working for you for the rest of your life, you have to take this medication at the same 
time every day, as prescribed. Usually we check how well you are doing by seeing that you 
come regularly to the clinic and by counting the tablets that you bring back. At the moment 
there are thousands of people receiving ART from this clinic and it is becoming harder for 
the staff to make sure that everyone is doing well on their treatment all the time.  
Purpose of the study: We would like to ask you to be part of a research study that will help 
us to answer two research questions. 1. Will reminding people to take their ART every day 
by SMS help them to take their ART better than those who are not reminded? 2. What do 
the levels of ART in the blood look like in these groups of people? 
The TAP study details and duration: If you agree to be on the study, you will be given a small 
electronic pill box called the Wisepill when you start your ART. This device can fit in your 
pocket, and helps to monitor when you take your tablets. There is picture of this pill box 
below: 
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You would receive your treatment in plastic pillboxes (one per week) which slide into the 
Wisepill device as shown in the picture. You would open the device when you need to take 
your medication and take out the tablets you need. When you open and close the lid of this 
box, it sends a signal to a computer here at Hannan to let us know when you have taken 
your tablets. 
In total there will be 220 people on the study, all from Hannan. Those who agree to join this 
study will be given this pill box and taught how to refill it every week. There will be two arms 
to this study and you would be assigned to one of the arms randomly (like flipping a coin).   
In arm 1: you would continue to receive the same care at Hannan as everyone else, with the 
addition of using the electronic pill box.  
In arm 2: in addition to receiving usual care at Hannan and using the pill box, you would also 
get a reminder by SMS on your cell phone if you do not take your tablets within an hour of 
your usual dosing time. You would also be given a report showing when you took your 
tablets at your 4-monthly clinical visit. 
The study will continue for a year from your ART start date. 
Being on this study is your own decision (voluntary). You may choose NOT to participate in 
this study and you will then continue to receive good care at Hannan without any problems. 
Study procedures: At your clinic visits, in additional to the usual procedures we will ask you 
some questions about how easy or hard it is for you to use the pill box and a few short 
questions about whether you use any alcohol, have disclosed your HIV status to anyone or 
are feeling depressed or anxious. At the end of the study we will ask you if you can think of 
anything happening in your life over the time of the study that may have changed the way 
you took your ART. 
We will collect some information about you such as your age, gender, stage of HIV disease 
and assigned treatment. All this information will be kept completely confidential and 
accessed only by study staff using your clinic number e.g. XX 9876 and not your name. 
At most of the visits we will need to take extra tubes of blood. Before the study starts we 
would like to count the HIV in your blood (viral load) as well as look at the CD4 count that is 
usually taken. At each of the three visits we would like two or three extra tubes of blood 
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(10-15ml or 2-3 teaspoons) to study the levels of the ART in your blood and to store for later 
resistance testing, if needed. We would also like to collect a few strands of your hair (from 
your head / arm pit) at each visit, if you agree.  
There should be no reason for you to need extra clinic visits due to the use of the pill box or 
being on the study. Each time you come to the clinic we will replace the battery on the pill 
box (a battery lasts about 4 months).  
The study is voluntary: This means you can choose not to join the study or you can leave the 
study at any time without this causing a problem with you receiving ART at Hannan. 
Withdrawal from the study: You can withdraw from this study at any time without 
impacting your ART at Hannan. You may be withdrawn from the study by the study team 
only if the sponsor terminates the study. 
The table below describes what will happen at each visit during the TAP study (these are 
procedures that will happen in addition to your normal visit at Hannan). 
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Screen visit Base-line Week 16 Week 32 Week 48 Follow-up 
Sign 
informed 
consent
 
Given EAMD 
with 
explanation. 
 
   Review of 
EAMD results
 
Blood taken 
for viral load 
(5ml)&. 
 
 Blood taken 
for CD4 (5ml) 
drug levels 
(5ml) and to 
store for 
genotype 
(10ml)* 
 
Blood taken 
for drug 
levels (5ml) 
and to store 
for genotype 
(10ml)   
  
Blood taken 
for drug 
levels (5ml) 
and to store 
for genotype 
(10ml) $  
 
 
Disclosure, 
CAGE and 
depression 
questionnair
e  
 Disclosure, 
and CAGE 
questionnair
e  
 Disclosure, 
CAGE and 
depression 
questionnair
e  
 
  EAMD 
acceptability 
questionnair
e  
 EAMD 
acceptability 
questionnair
e  
Life events 
questionnair
e  
& In additional to CD4 count drawn at this visit 
* In addition the viral load drawn at this visit.  
$ In addition to the CD4 and viral load drawn at this visit. 
 
Please remember to come to the clinic before taking your morning dose of ART (if you have 
one) 
Participant responsibilities: You will be expected to take care of the device you are given 
and to make sure the battery is charged (either by charging it at home or coming to the 
clinic for a new battery) . Please bring the Wisepill device with you to every clinic visit. You 
will have to return the Wisepill after the study is complete. 
You will be expected to attend on your appointment date or to contact the study nurse and 
change the date if you cannot. 
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Risks and benefits: There is a small risk that people will identify you as HIV-positive through 
the use of the Wisepill, although previous studies have shown that this is rarely the case and 
that people using it quite like the look of the pill box.  
The risk of having extra blood draws is small, perhaps bruising or pain where the needle 
went in. Some people find having blood drawn very unpleasant. 
There may be benefits to you in that being on the study provides extra support to you in the 
first year of your treatment and so helps you to take your ART better. 
Reimbursement: You will be reimbursed R20 for the extra time you have to spend at the 
clinic (for the questionnaires) and the extra blood that has to be drawn. This reimbursement 
will occur only on the 5 scheduled study visits outlined above. You will be reimbursed R150 
for the final study visit, which is an extra visit. You should not incur any other expenses 
during the study as you would be attending Hannan for ART care in any case. 
Confidentiality: Your name and address will never leave Hannan. You will be identified only 
by a code and a number. All staff sign confidentiality agreements and will never reveal your 
status to any other person. 
At times someone from outside (e.g. the Ethics Committee) may want to review the files we 
use for the study. This will also be done in complete confidence. 
Contact details for the study team: 
Principal Investigator: Dr Catherine Orrell, Desmond Tutu HIV Centre, IIDMM, University of 
Cape Town, Faculty of Health Science. Phone 021 650 6958. 
Study coordinator: Sr. Heidi Freislich, Hannan Crusaid treatment Centre, NY 3, Gugulethu. 
Phone 021 633 5963. 
This study will be completed according to the International Declaration of Helsinki and meet 
Good Clinical Practice principles. This study has been approved by the University of Cape 
Town Research Ethics Committee. 
Complaints may be directed to the Chairperson of Faculty of Health Sciences, Human 
Research Ethics Committee, at the University of Cape Town, Prof Marc Blockman at 021 406 
6338. 
Thank you for taking the time to read this information. If you agree to participate, please 
sign below. If new information becomes available during the study we will update this form 
and give you a new one to sign. 
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I have read the information about the TAP study and I have had a chance to ask questions.  
I agree to participate in the study and know I may withdraw at any time. 
____________________________ _________________ _________ 
Patients’ full name and surname  Signature   Date 
 
____________________________ _________________ _________ 
Witness’s full name and surname  Signature   Date 
(If patient is illiterate)        or N/A □ 
 
____________________________ _________________ _________ 
Study staff’s full name and surname Signature   Date 
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Appendix 2: CAGE questionnaire  
Date:  dd - mmm - yyyy Patient number: ZZ 9999 
CAGE questionnaire. 
Ask the following questions: 
Have you ever felt you needed to Cut down on your drinking? Yes   □ No   □ 
Have people Annoyed you by criticizing your drinking?   Yes   □ No   □ 
Have you ever felt Guilty about drinking?     Yes   □ No   □ 
Have you ever felt you needed a drink first thing in the morning (Eye-opener) to steady your 
nerves or to get rid of a hangover?    Yes   □ No   □ 
 
Each YES = 1 point. Write SCORE (1-4) here and on questionnaire CRF:  SCORE: _______ 
 
[Two "yes" responses indicate that the possibility of alcoholism should be investigated 
further  place copy of this from in Hannan folder.] 
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Appendix 3: HADS questionnaire. 
 
Hospital Anxiety and Depression Scale: Scoring Sheet 
 Yes, 
definitely 
Yes, 
some-
times 
No, not 
much 
No, not 
at all 
1. I wake early and then sleep badly for the rest of 
the night. 
3 2 1 0 
2. I get very frightened or have panic feelings for 
apparently no reason at all. 
3 2 1 0 
3. I feel miserable and sad. 3 2 1 0 
4. I feel anxious when I go out of the house on my 
own. 
3 2 1 0 
5. I have lost interest in things. 3 2 1 0 
6. I get palpitations, or sensations of ‘butterflies’ in 
my stomach or chest. 
3 2 1 0 
7. I have a good appetite. 0 1 2 3 
8. I feel scared or frightened. 3 2 1 0 
9. I feel life is not worth living. 3 2 1 0 
10. I still enjoy the things I used to. 0 1 2 3 
11. I am restless and can’t keep still. 3 2 1 0 
12. I am more irritable than usual. 3 2 1 0 
13. I feel as if I have slowed down. 3 2 1 0 
14. Worrying thoughts constantly go through my 
mind. 
3 2 1 0 
 
Add the scores for anxiety and depression: 
Anxiety 2, 4, 6, 8, 11, 12, 14: Total _________________ 
Depression 1, 3, 5, 7, 9, 10, 13 Total _________________ 
GRADING: 0 - 7 = Non-case 8 – 10 = Borderline case 11+ = Case 
  
page 220 
 
Appendix 2: University of Cape Town Research Ethics Committee approval 
letters. 
1. Observational cohorts 
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2. Randomised controlled study (TAP study) – initial, annual renewals and closure 
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HUMAN RESEARCH 
OWN ETHICSCOMMITTEE 
,,.,,.,v,,.,~ ~,..,._.,. ... ,.,., , ,,.., • .,, . .. ~,,.,,, •• 
U N IVERSITY OF CAPE 
UL TY OF HEAL TH SCIENCES 
1 5 MAY 2013 Huml!n Research Ethics Committee 
FHS01 / Renewal 
This erves as notification of annual approval , Including any documentation described below. 
Annual progress report 
D Not approved See attached comments 
Sig nature Chairperson of the HREC 
Principal Investigator to complete t 
1. Protocol information 
Date form submitted 13 May 2013 
Approved untiUnext renewal date 
Date Signed 
HREC REF Number 158/2012 I Current Ethics Approval was granted until 130"' May 2013 
Protocol title 
A randomised controlled Trial to explore A dherence-failu re relationships in 
a South African antiretroviral delive ry site using an electronic adherence 
device and spa rse Pharmacokinetic sampling. (TAP study) 
Protocol number (if nla 
applicable) 
Principal Investigator Or Catherine Orrell 
Department I Office Desmond Tutu HIV Centre, Room N1.21.5 Werner-Seit Building North, IIDMM, 
Internal Mail Address UCT Faculty of Health Sciences. 
1.1 Does this protocol receive US Federal funding? D Yes 
1.2 Has sponsorship of this study changed? If yes, please attach a revised D Yes 
summary of the budget. 
2. List of documentation 
TAP protocol - 28Jan2013 (version 2.1). 
AOVL T information leaflet and consent form for the TAP study-28Jan 13 (version 1.2). 
PARENT information leaflet and consent form for the TAP stu(ly-28Jan13 (version 1.2). 
CHILD information leaflet and consent form for the TAP study-28Jan13 (version 1.2). 
Genetic testing consent for TAP study - 18May12 (version1 .0). 
Wisepill device-acceptability qu-16Jan13 (version 2.0) 
26 July2012 Pag8 1 of 4 
{N01e: Please complete the Q()Su,e form {FHS010) if the stvt!y i$ completed within the approv11 pe<lod} 
X No 
X No 
FHS-016 
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Appendix 3: Adherence Experts Consultation Summary Report. 
 
 
This summary document attached here is the initial version compiled by Dr Jessica Haberer 
and is NOT the final version, which is being commented on by other of the meeting 
attendees, before being drafted for publication.  
 
 
Adherence Experts Consultation Summary Report Regarding Consultation Presentations 
and Discussion: Vancouver, July 18, 2015 
 
Background 
 
In advance of the consultation, participants were asked to submit “one or two of the most 
significant abstracts or program descriptions in your area of expertise.” These materials 
were then compiled and disseminated by the Co-Chairs in advance of the consultation. In 
total, over 300 pages of materials were compiled, disseminated, and reviewed regarding the 
following categories of promising ART adherence interventions: (i) individual counseling 
interventions, (ii) peer and family support interventions, (iii) healthcare system/community 
interventions, (iv) electronic interventions, (v) behavioral economics/economic 
empowerment, and (vi) other/summary information.  These materials are available on 
request. 
 
Presenters were asked to make a brief presentation (5-10 minutes) describing evidence-
based interventions and their impact, focusing specifically on the relative scalability of the 
intervention – whether the intervention had been tested at scale, what were barriers to 
scale up, and what would be necessary to support broad scale-up. Following each 
presentation, the Co-Chairs facilitated open discussion. The last two hours of the 
consultation were devoted to developing consensus recommendations regarding those 
interventions that were, in the opinion of participants, materially and positively impactful on 
adherence and immediately scalable. 
 
Individual Counseling and Peer/Family Support Interventions (Discussion Led By Rivet 
Amico, Robert Remien, and Jean Nachega) 
 
Counseling for adherence is an exchange of information about medication and health, and is 
most effective when implemented simultaneously with other interventions – such as family 
engagement, cognitive education, or peer support. Counseling can take different forms. 
Cognitive behavioral therapy (CBT) focuses on the “think-feel-behave” cycle and requires 
several sessions (typically with a trained counselor). CBT helps influence adherence behavior 
through self-reflection and development of coping tools. Another form of counseling, 
motivational interviewing (MI), focuses on decision-making and motivation. Other forms of 
counseling include electronic dose monitoring-driven counseling, multi- media-supported 
counseling, narrative stories, music, and theater. Several attendees noted that counseling 
that utilizes storytelling helps address disclosure, bereavement, depression, social support, 
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and similar barriers to care. These engagement interventions, it was noted, are particularly 
effective with youth. 
 
There is strong evidence that counseling is highly influenced by the counselor and is most 
effective when done by peers. However, peer support based interventions are difficult to 
standardize, and some patients lack an existing support network to leverage. Given stigma 
and related issues, it is important that peers be selected by the patient and not provided or 
otherwise imposed on the patient. It was noted that a benefit of the use of multimedia and 
other supporting technologies is that it can standardize, streamline, and improve the overall 
quality of counseling. Finally, all such counseling is more effective if stigma is not an issue 
and if the patient’s family can be engaged and involved in such counseling and patient 
support. 
 
Although these forms of enhanced counseling and support have been proven to be 
effective, particularly when combined with additional interventions, they have not been 
scaled up to date. This is due in large part to the facts that (i) acceptability of enhanced 
counseling is based on the quality of counselor care and as yet counselor quality is often 
poor, and (ii) mechanisms to automate or scale the peer selection and peer counseling 
processes are embryonic at this point.  Importantly, virtually every clinic and every provider 
is doing some form of counseling – however modest, however ad hoc.  Thus, there is an 
immediate and existing opportunity to improve overall medication adherence by improving, 
standardizing, and automating this existing counseling and working toward incorporating 
therein some of these proven-effective enhanced and peer-based counseling techniques.   
 
Healthcare System/Community Interventions (Discussions Led by Elvin Geng and Sherri 
Weiser) 
 
Health systems are overburdened by a high patient load and limited resources, and the 
burden is continuously increasing. Healthcare systems have a direct effect on patient 
adherence and follow-up (e.g., long lines at clinics or extended travel to clinics can lead to 
delayed refill and resultant treatment interruptions), and patient interactions with health 
care workers can positively or negatively influence adherence and retention. Thus, 
improvements in these logistical and human interactions elements of health care delivery 
can be highly impactful on initiation, implementation, and persistence.   
 
Pilot programs have shown that approaches that streamline and reduce the patient burden 
with respect to medication refill are well received and impactful. Two approaches were 
discussed. In the first, patients perceived to have good adherence (e.g., per viral load 
suppression) are permitted to obtain their medications via an “adherence club.”  These 
clubs may provide some adherence counseling and peer support, as well as enable a “fast 
track” refill mechanisms. In the second, patients are placed in groups of approximately six 
patients and one member of the group (rotating each month) is permitted to obtain refills 
for all of the patients in his or her group. These approaches decrease the patient burden on 
health facilities, reduce transportation costs and waiting times for patients, help overcome 
structural barriers, reduce treatment fatigue and loss to follow up, increase disclosure and 
treatment education, and help patients develop necessary social ties.    
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Electronic Interventions (Discussion Led by Rich Lester and Catherine Orrel) 
 
Electronic interventions are an additional resource for patients to connect with their 
healthcare systems, and can help improve adherence in resource-limited settings. Electronic 
dose monitoring (EDM) provides critical data on adherence patterns (thus permitting the 
early and accurate identification of those struggling with adherence) and can be combined 
with social network–based interventions and delivery of counseling. Evidence suggests that 
counseling informed and enabled by detailed dosing histories is a highly effective adherence 
intervention. Moreover, it was noted that (i) adherence monitoring through electronic-
based interventions may be cost-effective because it reduces human workload and is 
generally well liked by patients (Wisepill in particular), and (ii) that EDM can also help 
identify which patients might need expensive HIV RNA testing, and identify virologic failure 
before it becomes clinically significant.  
 
Another electronic intervention worth noting is SMS, particularly the weekly SMS system 
developed by Wel-Tel.  Wel-Tel’s SMS intervention uses SMS to connect with and assess 
patient adherence via SMS-based self-reporting.  It uses SMS messages that ask patients 
“How are you?” (“Mambo?” in Swahili). These discrete messages serve as points of contact 
between providers and patients, as well as reminder messages for drug adherence. Because 
HIV and/or medications are not mentioned, accidental disclosure on shared devices is 
unlikely. Studies have found that this type of engagement and support benefit is more 
effective than simple reminders, and the program is cost- effective and scalable. Studies 
have also shown that message content has a limited effect on adherence, but timing and 
frequency of the message are crucial to success.  
 
There was also discussion of using SMS approaches, such as Wel-Tel, for adherence 
monitoring, both identifying poor adherers generally and compiling more detailed dosing 
histories.  However, self-reporting is not always reliable, and Wel-Tel does not address how 
best to reach patients who are unwilling to engage in care and report their health status. 
Effectiveness may also vary widely as follow-up care is diverse and program-based. 
Nevertheless, SMS reminders and approaches like Wel-Tel are inexpensive in relative terms 
and scalable, and represent an interesting and potentially important part of a 
comprehensive adherence program. 
 
Interventions Related to Behavioral Economics/Economic Empowerment (Discussion Led 
by Omar Gallaraga and Alex Tsai) 
 
Behavioral economics may help HIV research by determining and addressing economic 
barriers to health and by evaluating the impact of incentives on medication adherence. 
Social and economic factors are huge influences to care and are accurate indicators of 
attrition. Most of the current behavioral economic research focuses on the interface 
between poverty and stigma, because HIV-positive individuals are less able to contribute to 
their communities and are targeted for exclusion. Programs that promote contributions to 
society by HIV-positive individuals can help address the stigma-exclusion cycle. Microfinance 
and other economic programs can lead to social integration, increased food security, 
community reciprocity, and reduced stigma. Livelihood programs, such as lease-to-own and 
savings groups, help provide empowerment to persons living with HIV and their families. 
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Current incentive practices vary widely by type, amount, length of time, and whether 
incentives are conditional or not. Most economists prefer unconditional cash transfers, but 
“loan plus training” and “in-kind loan plus training” are also used as incentive models. 
Non-cash incentives have proven effective with youth (e.g., a can of tuna) in establishing 
behaviors that lead to engagement of care. Yet economists doubt whether these loan 
programs are sustainable without a steady influx of resources from investors, and whether 
they work in low-income environments. Incentives can also motivate patients to misreport 
their circumstances to qualify for studies and/or increase their cash incentive. Incentives 
may also shift the balance of power in a family environment and lead to peer and family 
pressures.  
 
Conclusions and Consensus Recommendations (Discussion Facilitated by Jessica Haberer 
and David Bangsberg)  
 
At the outset, it is important to note that the group was unanimous in its view that 
adherence is and remains a major obstacle to advancing toward the goal of ending AIDS.   
The group also agreed that statistics regarding “average adherence” are misleading, 
particularly when based on self-reporting, pill counts and other methods agreed to have 
strong positive bias. Additionally, a large number of non-adherent patients are ignored by 
adherence interventions because they are not identified in the first place. Most adherence 
interventions understandably focus on ongoing treatment. While it is key to establish 
positive adherence behaviors early, it is also necessary to engage patients in care to improve 
adherence long-term, as nearly all individuals will struggle with adherence at some point 
during their lifetimes. Most study designs, however, look at the short-term (i.e., one year or 
less) and miss important effects over time. It is equally important to track adherence before 
patients begin to miss clinic visits and before viral load changes become apparent. 
 
The group was strongly of the view that it is important to move toward differentiated care 
by separating the “doers from the non-doers,” to quote Linda Gail Bekker (Desmond Tutu 
HIV Foundation). The group acknowledged and agreed that, particularly as HIV treatment 
targets are expanded, it is increasingly important and positively impactful to identify those 
patients who need more help with adherence and to be able to allocate relatively more 
resources toward them. This assessment needs to take place on a continuing basis, given 
the length of ARV therapy and the fact that patterns of adherence and poor adherence 
change over time. There is a need for increased monitoring and support for high-risk 
populations (e.g., youth, elderly, pregnant/post-partum women, individuals with chronic 
health conditions, lifestyle risks); however, those criteria alone shouldn’t be used to identify 
people as “non-adherers”. While the group did not settle upon a particular methodology or 
technology to drive the identification of non-adherent patients, it was generally agreed that 
viral load testing alone is not the answer and that today’s best approaches (taking into 
consideration affordability, patient acceptance, and ability to generate detailed dosing 
histories) may well include interactive SMS and electronic dose monitoring. The group 
discussed both “funnel” and “menu” approaches. With a funnel approach, the largest 
possible number of individuals would be screened for non-adherence. Those identified as 
such (including those who never initiate care) would receive one standard intervention 
strategy. The intensity of interventions would then increase for the likely decreasing number 
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of individuals who continue to have adherence challenges. The first intervention should be 
the most appealing, so that patients do not stop adherence to gain benefits of later funnel 
steps (ex: personalized care, incentives, etc.). With the menu approach, a number of 
intervention options could be presented to individuals, allowing them to choose their 
intervention strategy. Menus could be altered for specific populations (e.g., adolescents 
engaging in mHealth, patients with depression in counseling, socioeconomic barriers in 
“adherence clubs”, etc.). 
 
There was also broad agreement that in recent years more has been done at the individual 
clinic level to address poor adherence – both avoiding poor adherence and intervening to 
correct poor adherence. At virtually every clinic, some form of counseling or educational 
support is provided to patients – explaining why adherence is important and offering   
encouragement as well as some basic techniques to use to remain adherent. However, 
current efforts are less effective and less efficient than they might otherwise be because 
these efforts (i) are applied on a “one size fits all” basis, (ii) are not informed or supported 
by accurate or detailed adherence data, and (iii) do not address or ameliorate the inherent 
challenges in the current clinic-based approach to patient management (e.g., long waiting 
times, travel, stigma).   
 
In terms of specific interventions, those that received the most support and/or favorable 
response from the group were as follows: 
 
 Tools to standardize, automate, or enhance individual patient counseling. These 
include laptop or tablet-based tools to provide more interactive education and 
counseling as well as some approaches that use picture books and similar education 
and counseling tools; 
 
 Interventions that address some of the clinic setting-specific issues that negatively 
affect adherence. Particularly interesting to the group were “adherence clubs” or 
other mechanisms to reduce the burden associated with medication refill. However, 
it was noted that it is essential that some reliable monitoring mechanism be used to 
ensure this “fast track” approach is used only with patients who are good adherers; 
 
 Interventions that involve peer and family support also were viewed as interesting 
and impactful. However, there was a belief that these interventions were most 
appropriate as a response to demonstrated poor adherence, as opposed to generally 
available for all patients upon treatment initiation; 
 
 Although it was not discussed at length, there was general acknowledgement that 
there is potential in creating, maintaining, and leveraging pharmacy refill data. In 
many clinics, refill data is fairly robust; however, refill data is rarely shared with 
clinicians or otherwise used to identify poor adherers or those at risk of becoming 
poor adherers; 
 
 There was strong interest in the potential of weekly SMS as a patient reminder and 
as a way to strengthen patient-clinic connection and related emotional and other 
support.  This approach is inexpensive and in several studies has been shown to 
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positively affect adherence. There was discussion but not agreement as to whether 
SMS is an effective way of identifying poor or potentially poor adherers as there 
were concerns about the accuracy of patient self-reporting and also about patient 
burden and fatigue over time. Nevertheless, SMS was broadly viewed as technology 
with potential and technology that is scalable today; 
 
 Finally, there was support for the use of electronic dose monitoring to both generate 
the sort of detailed dosing histories that allow the identification of poor adherers 
and also to inform and support other interventions such as peer or family support or 
more intensive counseling.  A number of attendees had positive experience with 
electronic dose monitoring and there was a general belief that at a lower per unit 
price point electronic dose monitor would be scalable. 
